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RÉSUMÉ 
Contexte - La variation interindividuelle de la réponse aux corticostéroïdes (CS) est un 
problème important chez les patients atteints de maladies inflammatoires d’intestin. Ce 
problème est bien plus accentué chez les enfants avec la prévalence de la 
corticodépendance extrêmement (~40 %) élevée. La maladie réfractaire au CS a des 
répercussions sur le développement et le bien-être physique et psychologique des patients 
et impose des coûts médicaux élevés, particulièrement avec la maladie active 
comparativement à la maladie en rémission, le coût étant 2-3 fois plus élevé en 
ambulatoire et 20 fois plus élevé en hôpital. Il est ainsi primordial de déterminer les 
marqueurs prédictifs de la réponse aux CS. Les efforts précédents de découvrir les 
marqueurs cliniques et démographiques ont été équivoques, ce qui souligne davantage le 
besoin de marqueurs moléculaires. L'action des CS se base sur des processus complexes 
déterminés génétiquement. Deux gènes, le ABCB1, appartenant à la famille des 
transporteurs transmembraneaux, et le NR3C1, encodant le récepteur glucocorticoïde, 
sont des éléments importants des voies métaboliques. Nous avons postulé que les 
variations dans ces gènes ont un rôle dans la variabilité observée de la réponse aux CS et 
pourraient servir en tant que les marqueurs prédictifs. 
Objectifs - Nous avons visé à: (1) examiner le fardeau de la maladie réfractaire aux CS 
chez les enfants avec la maladie de Crohn (MC) et le rôle des caractéristiques cliniques et 
démographiques potentiellement liés à la réponse; (2) étudier l'association entre les 
variantes d'ADN de gène ABCB1 et la réponse aux CS; (3) étudier les associations entre 
les variantes d'ADN de gène NR3C1 et la réponse aux CS. 
Méthodes - Afin d’atteindre ces objectifs, nous avons mené une étude de cohorte des 
patients recrutés dans deux cliniques pédiatriques tertiaires de gastroentérologie à 
l’Ottawa (CHEO) et à Montréal (HSJ). Les patients avec la MC ont été diagnostiqués 
avant l'âge de 18 ans selon les critères standard radiologiques, endoscopiques et 
histopathologiques. La corticorésistance et la corticodépendance ont été définies en 
adaptant les critères reconnus. L’ADN, acquise soit du sang ou de la salive, était 
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génotypée pour des variations à travers de gènes ABCB1 et NR3C1 sélectionnées à 
l’aide de la méthodologie de tag-SNP. La fréquence de la corticorésistance et la 
corticodépendance a été estimée assumant une distribution binomiale. Les associations 
entre les variables cliniques/démographiques et la réponse aux CS ont été examinées en 
utilisant la régression logistique en ajustant pour des variables potentielles de confusion. 
Les associations entre variantes génétiques de ABCB1 et NR3C1 et la réponse aux CS ont 
été examinées en utilisant la régression logistique assumant différents modèles de la 
transmission. Les associations multimarqueurs ont été examinées en utilisant l'analyse de 
haplotypes. Les variantes nongénotypées ont été imputées en utilisant les données de 
HAPMAP et les associations avec SNPs imputés ont été examinées en utilisant des 
méthodes standard. 
Résultats - Parmi 645 patients avec la MC, 364 (56.2%) ont reçu CS. La majorité de 
patients étaient des hommes (54.9 %); présentaient la maladie de l’iléocôlon (51.7%) ou 
la maladie inflammatoire (84.6%) au diagnostic et étaient les Caucasiens (95.6 %). Huit 
pourcents de patients étaient corticorésistants et 40.9% - corticodépendants. Le plus bas 
âge au diagnostic (OR=1.34, 95% CI: 1.03-3.01, p=0.040), la maladie cœxistante de la 
région digestive supérieure (OR=1.35, 95% CI: 95% CI: 1.06-3.07, p=0.031) et l’usage 
simultané des immunomodulateurs (OR=0.35, 95% CI: 0.16-0.75, p=0.007) ont été 
associés avec la corticodépendance. Un total de 27 marqueurs génotypés à travers de 
ABCB1 (n=14) et NR3C1 (n=13) ont été en l'Équilibre de Hardy-Weinberg, à l’exception 
d’un dans le gène NR3C1 (rs258751, exclu).  
Dans ABCB1, l'allèle rare de rs2032583 (OR=0.56, 95% CI: 0.34-0.95, p=0.029) et 
génotype hétérozygote (OR=0.52, 95% CI: 0.28-0.95 p=0.035) ont été négativement 
associes avec la dépendance de CS. Un haplotype à 3 marqueurs, comprenant le SNP 
fonctionnel rs1045642 a été associé avec la dépendance de CS (p empirique=0.004). 24 
SNPs imputés introniques et six haplotypes ont été significativement associés avec la 
dépendance de CS. Aucune de ces associations n'a cependant maintenu la signification 
après des corrections pour des comparaisons multiples. Dans NR3C1, trois SNPs: 
rs10482682 (OR=1.43, 95% CI: 0.99-2.08, p=0.047), rs6196 (OR=0.55, 95% CI: 0.31-
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0.95, p=0.024), et rs2963155 (OR=0.64, 95% CI: 0.42-0.98, p=0.039), ont été associés 
sous un modèle additif, tandis que rs4912911 (OR=0.37, 95% CI: 0.13-1.00, p=0.03) et 
rs2963156 (OR=0.32, 95% CI: 0.07-1.12, p=0.047) - sous un modèle récessif. Deux 
haplotypes incluant ces 5 SNPs (AAACA et GGGCG) ont été significativement (p=0.006 
et 0.01 empiriques) associés avec la corticodépendance. 19 SNPs imputés ont été associés 
avec la dépendance de CS. Deux haplotypes multimarqueurs (p=0.001), incluant les 
SNPs génotypés et imputés, ont été associés avec la dépendance de CS. 
Conclusion - Nos études suggèrent que le fardeau de la corticodépendance est élevé 
parmi les enfants avec le CD. Les enfants plus jeunes au diagnostic et ceux avec la 
maladie coexistante de la région supérieure ainsi que ceux avec des variations dans les 
gènes ABCB1 et NR3C1 étaient plus susceptibles de devenir corticodépendants.   
Mots-clés : Épidémiologie génétique, étude d’association génétique, gène candidat, 
maladie inflammatoire de l’intestin, maladie de Crohn, réponse aux médicaments,  
variations interindividuelles, ABCB1, NR3C1, polymorphismes d’un nucléotide simple 
(SNPs). 
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ABSTRACT 
Background - Inter-individual variation in response to treatment by corticosteroids (CS) 
is an important problem in the management of inflammatory bowel disease (IBD) 
patient’s. This problem is even more prominent in children, the prevalence of steroid 
dependence (~40%) in whom is extremely high. Steroid refractoriness has a considerable 
impact on the physical and psychological development of these children, also imposing 
high medical costs related to treatment. Active disease, as opposed to quiescent, 
increases medical costs 2-3 times in ambulatory patients and 20 times in hospitalized 
cases. Identifying markers that could predict steroid response is therefore a high clinical 
priority. Previous attempts to investigate potential clinical and demographic markers 
have been equivocal, highlighting the need for further investigations of other predictive 
markers. It is well known that the action of CS entails complex processes controlled by 
genetic factors. Two genes, the ABCB1 gene, which belongs to the family of trans-
membrane transporters, and the NR3C1 gene, coding for the glucocorticoid receptor, are 
major elements of the pathway. We postulated that inter-individual variations in these 
genes may play a role in the observed variability of the response to CS and could serve as 
potential predictors.  
Objectives - We aimed to: (1) examine the burden of steroid refractoriness in children 
diagnosed with CD and explore the potential clinical/demographic factors related to CS 
response; (2) study the association between DNA variants in the ABCB1 gene and CS 
response; (3) investigate the associations between DNA variants in the NR3C1 gene and 
CS response.  
Methods - We investigated these objectives in a cohort of CD patients recruited from two 
tertiary paediatric gastroenterology clinics from Ottawa (CHEO) and Montreal (HSJ). 
CD patients diagnosed prior to age 18 using standard clinical, radiological, endoscopic 
and histopathological criteria were included. Published criteria were adapted to define 
CS-resistance and dependence. DNA acquired from blood and/or saliva was genotyped 
for variations across the ABCB1 and NR3C1 genes selected using the tag-SNP 
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methodology. The frequencies of steroid resistance and dependence were estimated 
assuming a binomial distribution. Associations between clinical/demographic variables 
and steroid responses were examined using logistic regression modeling after accounting 
for potential confounding variables. Associations between ABCB1 and NR3C1 genes’ 
variants and steroid responses were examined using logistic regression assuming 
different models of inheritance. Multi-marker associations were examined via haplotype 
analysis. Un-genotyped variants in the genes were imputed using HAPMAP data as the 
reference panel and associations with imputed SNPs examined using standard methods.  
Results - Among 645 CD patients diagnosed at the study centers, 364 (56.2%) received 
corticosteroids during the first year since diagnosis. The majority of patients were male 
(54.9%), had inflammatory (84.6%), ileo-colonic (51.7%) disease phenotypes at 
diagnosis and were Caucasians (95.6%). Eight percent of patients developed CS-
resistance and 40.9% became CS-dependent. Younger age at diagnosis (OR=1.34, 95% 
CI: 1.03-3.01, p=0.040), coexisting upper digestive tract involvement (OR=1.35, 95% 
CI: 1.06-3.07, p=0.031) and concomitant immunomodulators use (OR=0.35, 95% CI: 
0.16-0.75, p=0.007) were significantly associated with CS-dependency in multivariate 
analysis. From among the 27 markers genotyped across the ABCB1 (n=14) and NR3C1 
genes (n=13), all except one in NR3C1 gene (rs258751, excluded) were in Hardy-
Weinberg Equilibrium. For ABCB1, the rare allele of rs2032583 (OR=0.56, 95% CI: 
0.34-0.95, p=0.029) and heterozygous genotype (OR=0.52, 95% CI: 0.28-0.95, p=0.035) 
conferred protection from CS dependency. A 3-marker haplotype including the 
functional SNP rs1045642 was associated with CS-dependence (empiric p-value=0.004). 
On imputation 24 intronic SNPs and six haplotypes were statistically significantly 
associated with CS dependence. None of these associations however maintained 
significance after corrections for multiple comparisons.  
For the NR3C1 gene 3 SNPs, rs10482682 (OR=1.43, 95% CI: 0.99-2.08, p=0.047), 
rs6196 (OR=0.55, 95% CI: 0.31-0.95, p=0.024), and rs2963155 (OR=0.64, 95% CI: 0.42-
0.98, p=0.039), showed associations under an additive model whereas rs4912911 
(OR=0.37, 95% CI: 0.13-1.00, p=0.03) and rs2963156 (OR=0.32, 95% CI: 0.07-1.12, 
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p=0.047) showed associations under a recessive model. Two haplotypes 
encompassing these 5 SNPs (AAACA and GGGCG) were significantly (empirical 
p=0.006 and 0.01 respectively) were associated with CS-dependence. On imputation 19 
SNPs were associated with CS-dependence. Two multi-marker haplotypes (p-
values=0.001 each) including genotyped and imputed SNPs conferred susceptibility for 
CS-dependency. Conclusions - Our studies suggest that the burden of steroid dependence 
is high among children with CD. Children diagnosed at a younger age, those with co-
existent upper tract disease and with variations in the ABCB1 and NR3C1 genes were 
more likely to become CS dependent.   
Keywords: Genetic epidemiology, genetic association study, gene candidate, 
inflammatory bowel disease, Crohn’s disease, drug response, inter-individual variations, 
ABCB1, NR3C1, single nucleotide polymorphisms (SNPs). 
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INTRODUCTION 
Crohn’s disease (CD), a type of inflammatory bowel disease (IBD), is a lifelong 
condition characterized by a chronic, extensive inflammation of the gastro-intestinal 
tract (GIT) with a relapsing and remitting clinical course. Its burden in Canada is one of 
the highest in the world. In particular, as in most western countries, the incidence of 
paediatric onset CD is increasing in Canada and Quebec [1-3]. Various lines of evidence 
suggest that CD’s complex aetiology is due to the interplay between genetic, 
environmental and immunological factors. It is now well recognized that CD represents 
a group of heterogeneous diseases showing phenotypic variation [4-6]. Presently, given 
the yet unknown and most likely complex aetiology of CD, primary preventive strategies 
are not available, making secondary and tertiary prevention essential. Since active, as 
opposed to quiescent disease is associated with a 2-3-fold increase in costs for non-
hospitalized cases and a 20-fold increase in costs for hospitalized cases [7], the 
achievement of clinical remission remains the main goal in disease management, well-
warranted from the patient’s and societal perspective.   
Corticosteroids (CS) are the mainstay of treatment in moderate to severe CD, 
effectively inducing clinical remission [8]. A major issue with CS treatment is the 
observed large inter-individual variation in efficacy and associated side effects. For 
example, about 8%-20% of patients receiving CS do not respond to treatment, and, are 
CS resistant. Furthermore, among those who initially respond, a larger percentage (30% 
to 45%) subsequently relapse during dose reduction thus impeding discontinuation of 
treatment, or relapse shortly after the end of treatment (CS dependent) requiring 
additional doses of steroids.[9-14]. CS are relatively inexpensive therapeutic agents, but 
they come with significant long-term complications, such as osteoporosis, impaired 
glucose tolerance, cataracts and poor wound healing, which entail high medical costs. 
For example, CS dependent patients are more likely to require surgical intervention [13, 
14] and additional CS requirement has been shown to be associated with disabling 
disease course [15]. Surgical intervention accounts for 40% of inpatient medical costs 
  
2 
[16-18]. The consequences of surgical intervention, aside from its high cost of 
hospitalization [17], greatly impair patients’ quality of life, preventing participation in 
daily activities and affecting patients’ self-image, particularly that of adolescents and 
young adults, affecting their psychosocial development and well-being. CS therapy itself 
can cause numerous side effects [19, 20], some of them severe, such as linear growth 
retardation and bone demineralization [21]. Children with osteopenia have higher risk of 
fractures in childhood as well as in adulthood. In addition, other side effects such as 
striae, acne, and “moon face” present clinical dilemma when administering CS to 
adolescents. Therefore, the identification of patients susceptible to CS refractoriness (CS 
resistance or dependence) early during the course of the disease is an important issue in 
CD therapeutic management. 
CS mediates anti-inflammatory responses by first binding to the intracellular 
glucocorticoid receptor (GR). Activated GR mediates transcriptional regulation of 
specific target genes when transported to the nucleus of the targeted cells.  
Consequently, appropriate activation and expression of the GR (NR3C1) gene is 
necessary for anti-inflammatory responses. Stevens et al. [22] have described a 
haplotype of the GR that is associated with dexamethasone resistance in normal 
individuals. These findings, in addition to the fact that the GR gene is located in a region 
of chromosome 5 previously linked to CD (known as the IBD5 region), suggests that 
variants in the GR may underlie susceptibility to steroid refractoriness and that GR may 
be an important candidate for determining this phenotype. 
The ABCB1 gene, also called the multidrug resistance gene 1 (MDR1), is another 
key gene. It codes for the P-glycoprotein 170 pump and is expressed in high 
concentrations on the apical surfaces of superficial columnar epithelial cells of the colon 
and distal small bowel and functions as an efflux pump, transporting steroids out of the 
cell, thus reducing their efficacy [22]. The gene is located on chromosome 7q21.1, a 
region linked to CD [23]. This gene is also involved in the metabolism of xenobiotics 
[24, 25]. The MDR1 gene therefore is also potentially a prime candidate gene associated 
with response to CS. 
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  CS are potent anti-inflammatory agents used to treat various inflammatory, 
autoimmune and proliferative diseases [26-28] and altered sensitivity to CS has been  
reported in a variety of medical conditions [29]. For instance, in pediatric asthma [30],  
an increased  heterogeneity in response to CS has been observed [31] wherein about 5 % 
of patients showing altered response with CS dependency as a major complication [32, 
33]. In acute lymphoblastic leukemia (ALL) [34, 35] and rheumatoid arthritis [36] the 
inter-individual variability in response to CS is a widespread phenomenon and shown to 
be related to GR and ABCB1(MDR1) genes [37, 38]. Various malignancies have been 
shown to have MDR1 resistant phenotype [39] including leukemia [40], suggesting the 
role of this gene in inter-individual variability of response to treatment. In asthma, 
similarly to IBD, several mechanisms have been proposed to account for a failure to 
respond to CS including a reduced number of GRs, altered affinity of the ligand for GR, 
reduced ability of the GR to bind to DNA or increased activation of transcription factors, 
such as AP-1, that compete for DNA binding. The observations that CS dependency is 
not related to the binding, distribution and clearance of prednisolone supports the notion 
that CS dependency in asthmatics could be related to defects in steroid receptor 
sensitivity that is mediated by variation in the GR gene. [41]. The latter is hypothesis is 
supported by findings by Leung et al (1997)  who demonstrated that in asthmatic 
patients insensitive to CS (or dependent) there were cytokine-induced abnormalities in 
the DNA binding capability of the GR implying that variability in the GR gene could be 
related to CS dependency. [42]. Other studies [31, 43] however have pointed that rather 
than primary structural defects of the GR gene per se, but an increase in pro-
inflammatory transcription factors such as AP1 may be related to altered CS response, in 
particular CS resistance.   
The mechanisms of CS resistance in RA are not fully understood, nevertheless 
existing evidence suggests that this could involve known molecular events related to the 
mechanisms of CS action. These include alterations in the functional status of GR [44], 
and perturbations of the cytokine and hormonal milieu [45]. Moreover, significantly 
elevated T-lymphocyte MDR1 expression has been shown in patients with RA who 
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require CS, supporting  the importance of MDR1 gene in response to CS [46]. It is 
therefore possible that variability in response to CS is a common phenomenon across 
multiple phenotypes and involved mechanisms could be related to variation in the  
ABCB1 and NR1C3 genes. 
Although possible mechanisms underlying the anti-inflammatory effects of CS 
are relatively well outlined, information on the biological pathways that determine 
steroid dependence and resistance is limited. Furthermore, there is currently limited 
information on potential markers that could predict the variability in response to CS. On 
the basis of the known molecular mechanisms underlying the anti-inflammatory effects 
of steroids, we have proposed that important proteins, the activities of which are partly 
under genetic control, could be important determinants of CS response. Modifications in 
these key proteins due to genetic variation could potentially determine an individual’s 
therapeutic response to corticosteroids. Identifying these stable markers would greatly 
facilitate the identification of potential subgroups of patients who would be 
corticosteroid-dependent or resistant and hence benefit from timely alternate treatment 
strategies. 
This study therefore aimed to examine the burden of CS refractoriness in 
children diagnosed with CD and to examine potential clinical/demographic factors 
related to response. The second objective was to study the association between DNA 
variants in the ABCB1 gene and CS response. The third objective was to investigate the 
associations between DNA variants in the NR3C1 gene and CS response. The thesis 
comprises four chapters. The first describes the knowledge surrounding the inter-
individual variation in response to CS in CD patients and other autoimmune 
inflammatory conditions as well its postulated mechanisms. The second chapter is 
dedicated to the description of methodology used for examining proposed hypotheses.  
The third chapter describes the results for the 3 studies that were carried out to 
investigate the outlined objectives. Finally, a general discussion of acquired results and 
future perspectives are, outlined in the fourth chapter.   
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The first article of this thesis characterizes the burden of corticosteroid-
refractoriness in paediatric patients and examines potential clinical or demographic 
predictors related with response to CS. In the second article, associations between 
variants in the ABCB1/MDR1 gene and CS-dependence are reported and in the third 
article, those between the NR3C1/GR gene and CS-dependence are described.  
    
 
 
 
 
 
 
 
 
CHAPTER 1  
LITERATURE REVIEW AND STUDY 
RATIONALE 
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1.1 Crohn’s disease (CD) 
Crohn’s disease (CD) along with ulcerative colitis (UC) comprises inflammatory 
bowel diseases (IBD) a chronic, relapsing, inflammatory intestinal disorder postulated to 
result from abnormal host - microbe interactions and involving a complex interaction 
between genetic and environmental components [47-52]. CD is characterised by transmural 
inflammation leading to various complications such as fistulae, strictures and the narrowing 
of inflamed sections of digestive tract. The natural course of CD is characterised by 
numerous relapses and progression towards more complicated disease [53]. CD can occur 
at any age but the peak incidence is between the teens and early twenties. 
1.1.1 Epidemiology of CD 
Burden of pediatric CD is increasing worldwide, particularly in Canada where over 
the last two decades the highest incidence and prevalence have been reported. According to 
a province-wide study carried out in Manitoba, the incidence and prevalence of CD among 
individuals below 20 years of age were 12.7/105 and 56/105 respectively, suggesting that the 
incidence among children has approached that of adults, which ranges from 13.5/105 to 
16.5/105 [1]. Benchimol et al. [54] has reported an increasing trend in CD incidence from 
9.5 (in 1994) to 11.4 (in 2005) in Ontario. According to more recent nation-wide study 
conducted by Bernstein et al. in five Canadian provinces, the average incidence rate of CD 
for children less than 20 years of age during 1998-2000 was 8.3/105 [3]. This study also 
revealed a geographic variation with the lowest CD incidence in the western provinces 
(British Columbia) and highest CD incidence in the eastern provinces (Nova Scotia). 
Recently, a Quebec based study reported even higher incidence and prevalence of CD [2]. 
According to this study, the age- and sex-standardized average prevalence for 1993-2002 
was 189.7/105 and age- and sex-standardized CD’s incidence was 20.2/105 person-years for 
the 1998-2000 period. The average incidence in those <20 years at diagnosis was 13.9/105. 
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The female/male ratio among incident cases was 0.74 for the 0-14-year-old group which is 
in contrast with adult onset of CD (1.77). 
Over the past two decades (1983-2003) IBD hospitalization rates remained stable 
despite of a steady decline in the overall rate of hospitalization in Canada [55]. The 
percentage of all hospitalizations attributable to IBD has risen as a result. The stability of 
IBD hospitalization rates reflects a high proportion of readmissions due to chronic and 
complicated clinical course of the disease. It was shown that hospitalizations due to CD 
accounted for more than half of direct medical costs in the USA [56]. Kappelman et al. 
when estimating the direct health care costs of children and adults with CD or UC in the 
USA [57] reported that the annual health costs attributed to the management of pediatric 
IBD were higher as compared to adults (9800 $ versus 8000 $). 
1.1.2 Clinical features of paediatric CD 
CD is characterised by chronic clinical course with many disease flares and 
increasing occurrence of complications leading to surgeries. Numerous studies have 
emphasised the particularities of CD in children versus that in adults [58-67]. In 
comparison to adult patients, children with CD differ in disease phenotype and are more 
likely to have severe disease course and greater number of complications. More 
importantly, children are at risk of growth retardation and pubertal delay [68-71] and suffer 
more from psychological consequences. 
1.1.2.1 Disease localization and behaviour 
There are suggestions that paediatric CD may be phenotypically different from adult 
onset CD, implying potential differences in pathogenesis [66]. Disease localization is the 
most consistent among the reported phenotypic differences. Compared to adults, children, 
especially those diagnosed in first decade of life, more often tend to have colonic disease 
presentation [59, 62, 64, 72] and less of ileitis. Children diagnosed at an age prior to 8 years 
are of special interest, as they tend to have a more isolated colonic localisation of disease 
[59, 60]. The uncomplicated disease behaviour at diagnosis (80-90 %) can change with 
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time to stricturing and/or penetrating disease. These rates are much higher in children than 
in adults (66%). The occurrence of complications such as abscesses, fistulas and strictures 
often leads to major surgical interventions. In a Scottish [66] study, childhood-onset IBD 
was characterized by more “pan-enteric” (extensive) CD (L3-L4; 43.2% vs. 3.2%; 
OR=23.36; 95% CI: 13.45–40.59) than adult-onset CD. According to this study, 24% of 
children developed stricturing or penetrating complications within 4 years (vs. 9% at 
diagnosis). A subsequent study in a French [65] paediatric CD cohort reported similar rates, 
confirming distinctions with adult CD. Clinical management and treatment of CD 
The two focuses of CD management are the induction and maintenance of 
remission. Various treatment strategies are employed to achieve these goals [73].  
Treatment of paediatric CD patients is largely, based on experience gained from 
adult populations. There are however, particular aspects of CD that need distinct 
management strategies. Since it is widely accepted that CD has an effect on nutritional 
status and growth in children, the main goals of therapy in paediatric IBD are: to (1) 
maximize efficacy; (2) maximize adherence; (3) minimize toxicity; (4) maximize quality of 
life; (5) maintain physical and psychosocial growth; and (6) prevent disease complications 
[74] . 
Depending on presenting symptoms, severity of illness, and individual patient's 
disease course, treatment can involve multiple medications with varying regimens, dietary 
changes, and surgery. Historically CD treatment paradigms were changing with the 
advances in development of pharmacologic agents. Initially a conventional so called “step-
up” treatment approach was predominant when patient’s treatment was usually started with 
5-Acetyl salicylic acid analogs (ASA-5), and if not successful was followed by 
corticosteroids, immunosupressors, biologic agents and finally by surgical intervention. 
Azathioprine and its metabolite 6-mercaptopurine (6-MP) belong to the class of thiopurine 
immunomodulators. They are prescribed for steroid-refractory patients enabling the 
tapering of corticosteroids and are useful in the maintenance of remission in moderate to 
severe CD [75, 76]. These drugs have a slow onset and take about 3 to 6 months to generate 
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an effect [77]. Methotrexate is also used as an immunosupressor administered in patients 
with side effects or those failing to respond to azathioprine and 6-MP [78]. One of 
recognised drawbacks of the “step-up” approach is that patients are often treated with a 
non-effective agent for prolonged periods without achievement of mucosal healing, thus 
unnecessarily subjecting them to the potential side effects of these drugs [79]. The presently 
emerging trend of “top-down” therapy is based on the premise that early use of biological 
agents can heal mucosa and perhaps change the course of disease [58]. The anti-TNFα is 
commonly used biological treatment in paediatric CD. The most common is Infliximab, a 
chimeric monoclonal antibody (IgG1) directed against TNF-α that neutralizes circulating 
TNF-α and binds to cell-bound TNF-α causing apoptosis. Two other biological agents - 
adalimumab and certolizumab have also shown efficacy in controlled clinical trials. 
Infliximab administration however is associated with the development of antibodies to the 
medication in a large proportion of patients [80, 81].  
1.2 Corticosteroids (CS) 
CS are a class of steroid hormones that are produced from cholesterol in the cortex 
of the adrenal gland. Glucocorticoids and mineralcorticoids are two subclasses of these 
hormones. Glucocorticoids are a class of steroid hormones that binds to the GR receptor. 
The name “glucocorticoid” derives from their role in the regulation of the metabolism of 
glucose, their synthesis in the adrenal cortex, and their steroidal structure. In technical 
terms, “corticosteroid” refers to both glucocorticoids and mineralocorticoids (as both are 
produced by the adrenal cortex), but is often used as a synonym for glucocorticoid (GC). In 
this document, the term “corticosteroids” is used interchangeably with “glucocorticoids”. 
Some common natural glucocorticoid hormones are corticosterone and cortisol. CS 
exert known immunosuppressive effect and are used widely in the treatment of chronic 
inflammatory disease such as IBD. They have been used in the treatment of active IBD for 
several decades and are effective in inducing remission in moderate to severe CD with 
success rates of about 70% [9, 12]. However, CS are not appropriate for maintenance 
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therapy because of lack of efficacy [82] and side effects associated with prolonged use. 
Commonly used systemic CS are available in parenteral hydrocortisone and 
methylprednisolone formulations and oral prednisone, prednisolone, and budesonide 
formulations [83]. Hydrocortisone is the active liver metabolite of cortisol. 
Methylprednisolone, prednisone and prednisolone are the synthetic analogs of cortisol [84]. 
Budesonide (EntocortTM, Astra Pharmaceuticals) is a corticosteroid with low systemic 
bioavailability owing to a 90% first-pass liver metabolism.  
1.2.1 Anti-inflammatory action of CS 
Chronic inflammation is characterised by the increased expression of multiple 
inflammatory genes regulated by proinflammatory transcription factors, such as nuclear 
factor-kappa B (NF- B) and activator protein-1 (AP-1). CS mediate their anti-inflammatory 
action in cells via binding to glucocorticoid receptor (GR) protein – a member of the 
nuclear receptor subfamily [85]. Subsequently the GR-substrate complex passes into the 
nucleus where it acts via other genes participating in inflammatory pathways. CS action is 
dependent on GR-mediated transcriptional regulation of specific target genes as a result of 
sequence-specific deoxyribonucleic acid (DNA) binding, which in turn inhibits the 
promoter regions of genes such as NF- B and AP-1 [26, 86-88] the potent transcription 
factors for many pro-inflammatory cytokines and adhesion genes (Figure 1 on page 12). 
Important to the anti-inflammatory action of CS is the induction of inhibitor kappa B alpha 
(IκBα) which binds to and inhibits NF- B by sequestering it in the cytoplasm [89, 90] and 
thus regulates the inflammatory process.   
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Figure 1. Glucocorticoid suppression of activated inflammatory genes 
Legend: Inflammatory stimuli activate inhibitor of nuclear factor κB (NFκB) kinase 
(IKKβ), which therefore activates NFκB. A dimer of p50 and p65 NFκB proteins 
translocates to the nucleus and binds to specific κB recognition sites on the promoter 
regions of inflammatory genes and also to coactivators, such as cyclic AMP response 
element binding protein (CBP). The co-activators cause acetylation of core histones, 
activating gene expression of inflammatory proteins. Activated glucocorticoid receptors 
(GRs) bind to co-activators in the nucleus to inhibit histone acetyltransferase (HAT) 
activity directly. GRs also recruit histone deacetylase 2 (HDAC2), leading to suppression of 
the activated inflammatory genes. TNFα=tumour necrosis factor α. 
(From Barnes PJ, Adcock IM. “Glucocorticoid resistance in inflammatory diseases”. 
Lancet 2009; 373:1905-1917). With permission from Elsevier, Copyright © 2009 Elsevier 
Ltd All rights reserved. 
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The exact mechanism of action of budesonide in the treatment of CD is not fully 
understood. However, being a glucocorticosteroid, budesonide has a high local anti-
inflammatory effect. 
1.2.1.1 Disease activity assessment and CS dosing  
Given that treatment decisions are based on disease severity and disease localization 
[91], it is important to evaluate disease activity in CD at the beginning of treatment. The 
assessment of therapeutic efficacy is also based on disease activity. Several measures have 
been proposed to assess disease activity. The Crohn’s disease activity index (CDAI) is 
widely used for the assessment of disease activity in adult patients. This index is based on a 
7-day assessment of variables including laboratory values, objective examination and 
history. After minor modifications CDAI was validated and considered appropriate for use 
in children [92]. The Pediatric Crohn's Disease Activity Index (PCDAI) is thus a well-
validated tool in paediatric patients with CD [93]. The scale is scored 0 - 100 based on 
subjective criteria (e.g., pain), objective criteria, laboratory findings, and growth 
parameters. Scores <15, indicate inactive disease; 15-30, mild to moderate disease; and 
>30, severe disease activity. In comparison to CDAI, the PCDAI index is better able to 
discriminate between levels of disease activity. Nevertheless, this index incorporates 
parameters related to growth, which tend to change slowly over relatively short periods of 
clinical studies, and hence the index is less responsive measure for assessing disease 
activity in such context. To overcome these limitations, the modified Harvey-Bradshaw 
index (HBI) [94] was created and has been successfully used to measure disease activity in 
paediatric patients [76]. This index is less cumbersome, easier to calculate and shown to be 
highly correlated with CDAI [95] and Physician Global Assessment Index [93].  
Usual dose of oral CS is 1 mg per kg of body weight up to 40 mg/day, beyond 
which additional benefits have not been observed [96]. Budesonide is used in patients with 
ileal disease. Similar to conventional CS, budesonide is well absorbed from the proximal 
and distal intestine, relying on rapid hepatic metabolism to reduce systemic impact. 
Budesonide, administered as 9 mg/day, has been shown to be efficacious for active ileal 
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and ileocecal Crohn’s disease [97-99]. Patients with fulminant inflammatory CD are treated 
with intravenous corticosteroids, such as methylprednisolone. 
1.2.1.2 CS withdrawal schemes 
After an achievement of clinical remission, CS cannot be stopped abruptly because 
of CS withdrawal symptoms. The suppression of Hypothalamic-pituitary-adrenal (HPA) 
axis occurs early when supraphysiologic doses of CS are used (which is the case in the 
treatment of CD) and may result in a secondary adrenal insufficiency. Patients undergoing 
CS dose tapering may experience lethargy, malaise, anorexia, myalgias, headache, and 
fever. Withdrawal plans are based on a dual goal to complete therapy and at the same time 
to avoid the potential consequences of adrenal insufficiency. Given that there is insufficient 
evidence to recommend any particular CS withdrawal regimen [100], various dose tapering 
schemes are used in clinical practice for prednisone and its analogs. These diverse CS 
withdrawal schemes however, according to Yang et al. do not appear to influence the long-
term outcomes of CS therapy [101]. Traditionally withdrawal schemes begin by 
incrementally reducing the CS from supraphysiologic to physiologic doses. The 
physiologic dose is approximately 15-20 mg of hydrocortisone per day or its equivalent.  
Once patient is on a replacement (physiologic) dose of CS, various strategies may be taken 
subsequently. To allow the recovery of HPA some authors recommend switching to 
alternate day therapy [102]. The most common scheme consists of gradual decrease of CS 
daily dose (by 5 mg per week). Consequently, if at the beginning of therapy an average 
daily dose is 40 mg, the weaning from CS period takes about 7-8 weeks. For budesonide 
the dose tapering scheme usually consist of dose decrease by 3 mg/day/month, thus starting 
from 9 mg/day it takes about 8 weeks to wean of CS. 
1.2.1.3 CS sparing medication 
CS are rarely administered alone. In order to avoid disease reactivation and to 
facilitate dose-tapering process, immunomodulators or 5-ASA are introduced. Recently the 
early use of immunomodulators has become standard of care in IBD and has decreased 
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corticosteroid dependence. In patients with newly diagnosed moderate to severe CD a 
multicenter trial of 6-mercaptopurine and prednisone has revealed that an addition of 6-
mercaptopurine significantly improves treatment outcome in comparison to the addition of 
placebo [76]. 
1.2.2 Inter-individual variation of response to CS in CD patients 
Despite successful use of CS in treatment of CD, some patients fail to respond to the 
standard steroid therapy employed to induce remission and control acute disease flares, thus 
transforming the status of the disease into corticosteroid-dependent or corticosteroid-
resistant [103, 104]. CS dependency in CD is characterized by frequent relapses and a 
requirement for chronic corticosteroid use. It is important to recognize those patients 
predisposed to develop an impaired response to CS, since it may allow the timely 
establishment of alternative or additive treatments, thus avoiding unnecessary exposure to 
CS side effects. The extent of inter-individual variation of response to CS in adults patients 
has been well described initially by Munkholm et al. in a population based study carried out 
in Denmark [13], and subsequently by others [14, 105-109]. The Danish study reported CS 
resistance in 20 % and CS dependence in 36 % of 109 CD patients (Table I on page 16). 
Similar results were shown by a USA population-based study from Olmstead County, 
Minnesota [14] carried out on 74 CD patients (28 % CS dependent and 16 % CS resistant). 
Three other hospital-based retrospective studies in adults carried out in UK, Italy and China 
reported CS dependence frequencies of 24%, 35 % and 38 % respectively. CS resistance 
frequencies in these studies were comparable to the Danish and USA studies, with the 
exception of the Chinese study that reported lower rates (6%).  
In paediatric patients, four studies [65, 76, 77, 110] have described rates of CS-
dependence and CS-resistance. A population-based study describing the natural history of 
CD from France included 404 CD patients and reported that 25 % of patients became CS 
dependent [65]. Another population-based study conducted by Thung et al. in Olmstead 
County, Minnesota, USA, examined a small number of patients (N=26) and observed CS 
dependency in 31% of patients [110]. Similarly in a study from a multicenter North 
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American observational registry, among 109 newly diagnosed children with moderate-
severe CD treated with corticosteroids, 31% had become CS dependent [77]. A North 
American multicenter clinical trial reported the highest frequency (50%) of CS-dependence 
in the placebo study arm [76]. Barring the later study, rates of CS dependence in paediatric 
CD were similar to that reported among adults. Rates of CS resistance were by-and-large 
similar across the paediatric studies [77, 110] and are slightly lower than in adults.  
 
Table I: Studies examining the response to CS therapy in CD patients.  
Outcomes, % Study 
CS Resistance CS Dependence  
Munkholm et al., (1994) 20 36 
Faubion et al., (2001) 16 28 
Ho et al., (2006) 20 24 
Papi et al., (2007) 14 35 
Chow et al., (2009) 6 38 
Adult 
Weiss et al., (2009) 1 21 
Thung et al.,  (2006) 12 31 
Markowitz et al, (2000) NA ≈ 50 
Markowitz et al, (2006) 17 31 
Children 
Vernier-Massouille et al, (2008) 5 25 
NA, Not a study’s objective.  
 
1.2.2.1 Side effects of prolonged CS therapy 
CS can induce side-effects even after short-term treatment of 2-3 weeks [111]. 
Prolonged use of CS may cause multiple systemic side effects. The toxicity of CS increases 
with higher doses and prolonged use. Side effects of CS range from reversible short-term 
effects (moon face, skin striae, weight gain, acne, sleep disturbances, mood swings and 
psychoses) to serious consequences, such as bone loss, growth retardation and pubertal 
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delay. Exogenous Cushing’s syndrome can occur as a result of prolonged use of CS [112]. 
Exogenous Cushing’s syndrome usually presents with the same signs as spontaneous 
(endogenous) Cushing’s syndrome (Figure 2 below). However because some patients 
receive high doses of CS during prolonged period, the onset of the exogenous syndrome 
may be more striking than in the case of spontaneous Cushing syndrome. 
 
 
 
 
Figure 2. Symptoms of Cushing’s syndrome.   
 
© 2004 by the Cushing’s Support and Research Foundation. The Cushing’s Support and 
Research Foundation grants permission for the duplication and distribution of this brochure, 
URL: http://www.lohmann-birkner.de/ercusyn/wEnglish/cushings/uk.php 
The traditional stigmata of Cushing’s syndrome include weight gain usually 
presenting as central obesity (Figure 3 on page 18 and Figure 4 on page 19) with 
redistribution of body fat to truncal and dorsocervical areas and appearance of classical 
moon face.   
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Figure 3. Typical clinical signs of Cushing syndrome including obesity, moon-face and 
hirsutism.   
(From Therdpong Tempark et al, “Exogenous Cushing’s syndrome due to topical 
corticosteroid application: case report and review literature”. Endocr., 2010, 38:328–334, 
with kind permission of Springer Science and Business Media). 
 
Weak muscles, thin skin, striae, easy bruising and hypertrichosis also can be present 
(Figure 4 on page 19). Patients became susceptible to poor wound healing and infections 
[113]. Some manifestations of CS excess appear early in treatment course. For example, 
psychiatric disturbances, increased appetite and insomnia can occur within hours. In a 
double blind multicenter clinical trial comparing budesonide to prednisone [114] 55% of 
patients receiving prednisone experienced one or more side effects associated with CS 
therapy (p=0.01).  
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A    B    C 
Figure 4. Side effects of corticosteroids 
(A) central obesity; (B) skin striae 
(From Edwin K Joe MD, “Cushing syndrome secondary to topical glucocorticoids”. 
Dermatology Online Journal 9(4): 16, © 2003 Dermatology Online Journal, with the 
permission of NYU Langone Medical Center, The Ronald O. Perelman Department of 
Dermatology). 
(C) Hypertrichosis of the back caused by excessive intranasal steroid use. 
(From Perry R J et al. “Cushing's syndrome, growth impairment, and occult adrenal 
suppression associated with intranasal steroids”. Arch Dis Child 2002;87:45-48, ©2002 by 
BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health). 
 
As mentioned above, among possible side effects of particular concern are the 
potential for bone loss [21, 115-119] and deleterious effects on linear growth [120, 121]. 
Osteopenia and osteoporosis are common and severe adverse effects that can lead to 
increased risk for bone fractures. The relationship between long-term use of CS and risk for 
bone fractures is well-established [122-124]. In healthy subjects the life-long risk of bone 
fractures is related to peak bone mass which is achieved in puberty [125]. It is also known 
that CS have negative impact on calcium homeostasis [126]. Moreover it is suggested that 
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inhibition of osteoblast function by CS [127, 128] results in decrease of bone formation. 
The prevalence of osteopenia in paediatric patients is as high as 70% according to some 
reports [129, 130]. These studies have shown that CS use contributes to decrease of bone 
density resulting from other factors such as hipoalbuminemia, parenteral nutrition and use 
of immunomodulators. According to these studies, a cumulative dose of 5g of CS and 12 
months exposure was associated with the maximum loss in bone density. Related to losses 
in bone density, growth impairment and associated pubertal delay [131, 132] are common 
in paediatric patients with IBD and in particularly with CD. Growth failure is reported to 
occur in 15 - 40% of children with CD [68]. Although growth failure and significant bone 
decrease can be present before treatment with corticosteroids [121, 133], exposure to CS 
can further hinder the achievement of peak bone mass and maintain the growth delay.  
Children treated with prednisolone [19, 20] may develop ocular complications.  
When carrying out ocular examinations of 58 CS-treated paediatric patients with 
inflammatory bowel disease (IBD) and 58 age-matched controls, Tripathi et al. observed 
the presence of subcapsular posterior cataract in 20% of cases [19]. An increased 
intraocular pressure was noted in a case-control study among patients with nephrosis who 
were receiving CS [134]. Observation that ocular complications can follow CS therapy was 
further substantiated by findings that steroid cataract and glaucoma occurred in patients on 
long term (>2 years) treatment with prednisone at doses higher than 15 mg. None of these 
patients had a history of eye disease prior to CS treatment [135].  
CS treatment can also lead to opportunistic infections. Toruner et al. [136] reported 
strong risks (OR=3.4; 95% CI: 1.8-6.2) of infections associated with CS use in IBD 
patients. A variety of opportunistic infections, ranging from viral, fungal, bacterial, and 
mycobacterial organisms were associated with use of CS, according to this study. The 
severity of infections varied considerably, ranging from mucosal herpes to life-threatening 
systemic fungal infections. Compared with other immunosuppressant agents CS have also 
been found to increase the risk of C. difficile infections (RR=3.4; 95% CI: 1.9-6.1) [137].  
A meta-analysis [138] that examined the risk associated with CS use has also shown that 
patents with intestinal diseases who were administered CS were more prone to infections 
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(RR=1.4; 95% CI: 1.1-1.7). Moreover, CS increase the risk of wound infections by 
hampering wound healing both by their anti-inflammatory action and by inhibiting collagen 
synthesis [139].  
Regarding central nervous system function, CS have been shown to influence mood, 
memory and neuronal integrity [140]. A major concern related to CS use has been the 
resulting psychological health consequences, in particular in children with IBD [141-146]. 
This is particularly challenging as in spite of recovery from reversible side effects, 
children’s psychological problems persist and contribute to low self esteem. Some studies 
have suggested that CS may be causally related to depression in children [147, 148]. 
Psychological side effects from CS therapy can occur early during the course of CS therapy 
and during CS withdrawal as well. The effects range from minor to moderate mood, 
behavioural and cognitive effects to acute psychological symptoms. In children with IBD 
exposed to CS, depressive symptoms were likely to be more prominent than in non exposed 
patients [149]. In this study subjects receiving CS were more likely to have Children 
Depression Inventory (CDI) scores > or =12, and those with such scores were on higher 
doses of CS than were subjects without clinically significant depressive symptoms (both p 
values < 0.05). The frequency of acute psychological reactions is not negligible with 
reports that they can occur in about 1.3% of patients receiving 40 mg of oral prednisolone 
per day [150].  
1.2.2.2 Clinical and demographic markers of variability in response to CS 
As outlined above, CS treatment although effective in CD, is associated with 
numerous side effects and shows high variability in response. Identification of 
immunological, biochemical, and/or clinical parameters that may predict refractoriness to 
treatment has therefore been an important research priority. Table II on page 23 
summarizes the findings of the major studies undertaken. In the Munkholm et al. study no 
correlations between initial symptoms such as diarrhoea, abdominal pain, weight loss, 
associations with fever, age, sex, duration, extent, and localization of disease, or laboratory 
values (haemoglobin, white blood cells count, erythrocyte sedimentation rate, serum 
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albumin) and response to CS treatment were evident [13]. Younger age of diagnosis as a 
predictor of CS dependence was reported by Franchimont’s et al. in a retrospective study 
carried out in an adult population comparing 20 corticosteroid dependent and 248 non-
corticosteroid dependent CD patients [106]. Corticosteroid-dependent patients were 
younger (p < 0.05), more frequently smokers (p <0.05), and suffered more often from 
colonic (p < 0.05) or inflammatory type of CD. Colonic disease localization was negatively 
associated (HR= 0.3, 95% CI: 0.10-0.80) in a Chinese study [105] and positively (OR=3.2, 
p=0.009) associated with CS dependency in an Israeli study [109]. Laboratory parameters 
such as trombocytosis was positively associated with CS dependence (HR=3.0, 95% CI: 
1.40-6.40) and only stricturing disease (HR=4.5; 95% CI: 1.80-10.9) was predictive for CS 
dependence in a Chinese study. An Italian study [108] examining 77 CD patients reported 
increased C reactive protein (CRP) levels (OR=5.57, 95% CI: 1.20-25.91) during steroid 
weaning despite clinical remission. This study also noted that penetrating complications 
(OR=4.20, 95% CI: 1.76-10.04) might predict further steroid requirement in already steroid 
responsive patients. A North American multicenter paediatric study examined whether 
clinical or laboratory parameters were associated with CS therapy outcomes [77] and found 
that growth delay at diagnosis was associated with CS dependence. In this study, amongst 
both the corticosteroid-dependent and surgical patients, 67% presented with growth 
impairment, compared with only 18% among those who had a prolonged 1-year response 
(p=0.001). A paediatric study conducted by Markowitz et al. further confirmed that growth 
delay at diagnosis could influence the occurrence of CS dependency [77]. In a prospective 
multicenter study Gelbmann et al. evaluated 30 clinical and 24 laboratory parameters in 239 
adult CD patients, but found that prior bowel resection (OR=3.63, 95% CI: 1.79-7.36) and 
perianal disease (OR=2.28, 95% CI: 1.12-4.66) were associated with CS resistance. In this 
study, however, none of the studied parameters was associated with CS dependence [151]. 
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Table II: Studies examining potential predictors of response to CS in CD patients.  
 
Study Markers 
examined 
  
Association with CS 
dependence 
Association 
with CS 
resistance 
Munkholm et al., (1994) C, D, LAB None None 
Franchimont et al., (1998) C, D Younger age at 
diagnosis, L2 
NA 
Faubion et al., (2001) C, D None None 
Gelbman et al.(2002) C, D, LAB None Prior 
surgery 
Ho et al., (2006) C, D, smoking None None 
Papi et al., (2007) C, LAB Increased CRP, B3 None 
Chow et al., (2009) C, D, LAB L2, trombocytosis B2 B3 
A
du
lt 
po
pu
la
tio
n 
Weiss et al., (2009) C, D L2 NA 
Thung et al., (2006) C, D,  None None 
Markowitz et al, (2000) Growth No  NA 
C
hi
ld
re
n 
Markowitz et al, (2006) 
 
C, D, LAB, 
growth 
Growth delay None 
C, Clinical variables; D, Demographic variables ; LAB, Laboratory parameters;  
B2, Stricturing disease; B3, Penetrating disease; CRP, C-reactive protein; L2, Colonic 
disease; NA, Not applicable. 
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1.3 Proposed mechanisms for the variability in response to CS 
therapy 
1.3.1 Inter-individual variability of response to CS in autoimmune diseases 
CS are used to treat a variety of different immune-mediated diseases [27]. As 
glucocorticoids they affect a variety of vital functions in the body, such as glucose and fat 
metabolism, immune response, cell differentiation and response to stress. GC act through 
the cytoplasmic glucocorticoid receptor (GR) and negatively or positively regulate 
approximately 20% of genes expressed in leucocytes.  
Inter-individual variability in response to CS is encountered in healthy subjects 
[152-154] as well in those with various medical conditions [45, 155-158] such as 
rheumatoid arthritis (RA), asthma, leukemia and IBD. Based on clinical and laboratory 
evidence, subjects can be divided into, “steroid-sensitive” and “steroid-resistant” groups. In 
this context, it is important to separate the rare familial condition of primary CS resistance 
from the more common phenomenon of poor response to therapeutic doses of CS. Primary 
hereditary resistance to glucocorticoids is a rare disorder due to mutations in NR3C1 gene 
[159, 160]. In this syndrome, feedback inhibition of the hypothalamo-pituitary-adrenal axis 
is set at a higher level with slightly elevated plasma adrenocorticotropic hormone (ACTH) 
and increased circulating cortical concentrations. Generalised cortisol resistance is 
characterised by hypercortisolism without Cushingoid features. The Cushingoid features 
are absent because of the lack of receptors in all target organs. Symptoms of resistance to 
glucocorticoids arise primarily from ACTH-induced adrenocortical overstimulation which 
results in increased serum concentrations of androgens and mineral-corticoids [161]. 
Because of the elevated ACTH levels, adrenal androgen levels are also increased, causing - 
particularly in females - acne, hirsutism and virilisation, male pattern baldness, menstrual 
irregularity, and infertility. Only a part of resistance to beneficial effects of glucocorticoids 
in patients with RA and asthma is attributed to generalised (hereditary) form, with the 
majority of patients experiencing the acquired (local) form due to the high cytokine 
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production [161]. The local form of glucocorticoid resistance is supposed to be somehow 
compartmentalised by T-lymphocytes or other forms of inflammatory cells. This 
assumption is supported by studies of correlation between T-lymphocytes proliferation and 
drug response in inflammatory conditions such as asthma [162], RA [163] and renal 
allograft rejection [164].   
In CD, Franchimont et al. studied sensitivity to GC by comparing the response to 
exogenous dexametahsone between quiescent CD patients and healthy controls in blood 
cells [165]. This study reported a decrease in sensitivity to GC in CD patients compared to 
healthy controls, suggesting a predominant role for genetic/constitutional predisposition 
over acquired factors. Nevertheless, no significant difference in sensitivity to GC was 
observed between CS-dependent and CS non-dependent patients and both subgroups of 
patients had similar degrees of dexamethasone-mediated cytokine inhibition. The absence 
of any differences in sensitivity between CS dependent and CS non-dependent patients may 
be due to: (1) CS dependence not related to sensitivity to CS and (2) improvement of 
response to CS under the influence of concomitant administration of immunosuppressive 
drugs. 
1.3.2 Mechanisms of inter-individual variability of response to CS in IBD 
There is some knowledge of the mechanisms underlying steroid refractoriness in 
other inflammatory conditions such as asthma and RA (viz. a post-receptor mechanism) 
[166] and reduced peripheral T-lymphocyte binding affinity [167] as well as an increased 
expression of β isoform of GR receptor [45, 168]. However, the pathophysiology of steroid 
refractoriness in CD has not been as well studied. Based on the available evidence, three 
potential mechanisms have been proposed [156]:  
1. Decreased cytoplasmic steroid concentration secondary to increased P-glycoprotein-
mediated efflux of steroid from target cells due to over-expression of the ABCB1 
gene; 
2. Impaired steroid signalling due to dysfunction at the level of the NR3C1 gene; 
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3. Constitutive epithelial activation of proinflammatory mediators, including NF- B 
and resulting in the inhibition of GR transcriptional activity. 
 
The proposed mechanisms underlying steroid refractoriness are depicted in Figure 
5 below. 
Figure 5. Proposed mechanisms of variation in response to CS 
1.4 The ABCB1 gene  
ABCB1 belongs to the family of adenosine triphosphate (ATP) cassette binding 
transporters and also known as MDR1. This gene, located on chromosome 7, spans 200 kb 
comprising 28 exons and codes a P-glycoprotein-170 efflux pump (P-gp). Many drugs, 
including therapeutic CS, are substrates of this transporter. Cortisol, dexamethasone and 
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methylprednisolone have been shown to be the substrates of P-gp. Given the large spectrum 
of substrates and widespread expression in tissues, ABCB1, along with other genes coding 
for transporters, is thought to play a major role in cell protection from environmental and 
endogenous harmful substances. 
1.4.1 Role of the ABCB1 gene in modulating response to CS 
1.4.1.1 P-glycoprotein’s function and substrates 
P-gp is a known drug transporter, which eliminates exogenous and endogenous 
substances from cells. According to currently accepted model, P-gp functions as a 
transmembrane efflux pump [169], transferring substrates from intracellular to extracellular 
compartments (Figure 6 on page 28). It can also remove drug molecules trapped in the 
cellular membrane. ATP hydrolysis provides energy, allowing the active transport of 
substrates against steep concentration gradients. The “vacuum cleaner” metaphor is often 
used to describe this mechanism. A wide spectrum of substrates [24, 170, 171], including a 
variety of structurally divergent drugs, makes this protein interesting to study in relation to 
steroid drug metabolism. Several studies have shown that P-gp can bind to and transport 
different steroids [172-177]. Natural corticosteroids – cortisol, and the CS used in IBD 
treatments (dexamethasone and methylprednisolone) are shown to be substrates of this 
protein [173, 176]. More recently, two other steroid drugs, budesonide and prednisone, 
were also identified as a substrates of the intestinal drug efflux pump [177].  
Human P-gp is a complex phosphorylated and glycosylated transmembrane protein 
that has 1280 amino acids long and is composed of 2 homologous and symmetric 
sequences, each of which contains 6 transmembrane domains and an ATP-binding motif 
[178].   
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Figure 6. P-glycoprotein (P-gp) function.  
Legend: This model shows that P-gp–mediated efflux transport of drug substrates can occur 
at the level of the plasma membrane or from the intracellular compartment. ATP, 
Adenosine triphosphate; ADP, adenosine diphosphate; Pi, inorganic phosphate.   
(Reprinted by permission from Macmillan Publishers Ltd: From Marzolini C, Paus E, Buclin T, 
Kim RB. “Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical 
relevance”. Clin Pharmacol Ther 2004; 75:13-33.  Copyright © 2004, Nature Publishing Group). 
1.4.1.2 Expression in tissues 
Several studies have found the products of ABCB1 gene being expressed in many 
human tissues including the digestive tract. The highest concentrations of P-gp are present 
in epithelial cells of the colon [179] followed by the ileum, jejunum and stomach [179, 
180]. This protein can limit oral drug availability, acting in the small bowel [181] and 
actively transporting various substrates, including drugs, out of the target cells, thereby 
reducing their efficacy [182]. Consequently, variability in P-gp expression or function can 
alter the extent of absorption, distribution in tissues, and excretion of substrate drugs. The 
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function and the anatomic localization of P-gp suggest that this transporter acts as a 
protective barrier to keep toxins out of the body by excreting these compounds into bile, 
urine, and the intestinal lumen.   
Variability in drug response is widely observed for several of P-gp substrates. One 
potential mechanism for this variability is inter-individual differences in P-gp activity that 
result in altered pharmacokinetics. The number of P-gp transporters on the cell membrane 
and the level of P-gp transport function are the two most important factors that control the 
apparent activity of P-gp. Farrel et al. demonstrated that peripheral blood lymphocytes from 
IBD patients with previous bowel resection due to failed medical therapy had a higher P-gp 
expression compared with patients with inactive disease [183]. In a follow-up study, the 
same authors further demonstrated that inhibition of the MDR1 pump using specific 
inhibitors could significantly increase intracellular human intestinal epithelial and T-
lymphocyte levels of CS [184]. These findings were in line with results from animal 
studies, which have revealed that mdr1-deficient mice had an increase of dexamethasone 
levels in the small and large bowel as compared to wild type mice [185-187]. Some other 
studies have suggested that ABCB1/MDR1 may be a potential target for 
immunosuppressive therapy in various medical conditions [46, 188-191]. For instance, 
patients with rheumatoid arthritis who required CS [46] had significantly elevated MDR1 
expression in T-lymphocytes. The relevance of genetic ABCB1 polymorphisms to altered 
function of P-gp is also supported by the phenotype of mdr1 knockout mice spontaneously 
developing colitis [192]. Moreover, the ABCB1 gene is a very polymorphic site comprising 
more than 50 coding SNPS 3 insertion/deletion polymorphisms [193]. The consistency of 
this feature with the very complex structure of P-gp and the wide spectrum of substrates 
and the results of expression studies allows us to conjecture about the role of genetic 
variations in response to CS. Therefore, the genetic variations of the ABCB1 gene in 
relation to the function of this transporter are of high interest due to its potential to explain 
the variation in drug response.  
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1.4.2 Characterization of ABCB1 genetic variants 
The ABCB1 gene is characterised by multiple variations across the gene. Many 
synonymous and non-synonymous variations have been described, most of which result in 
changes to the intracellular protein domain [194] suggesting that they could impact the 
function of the protein (Figure 7, below).  
 
 
 
Figure 7. Polymorphisms in ABCB1 with a minor allele frequency >5%, as confirmed by 
genotyping in Ensembl, as of January 2006.  
(Reprinted with permission from Macmillan Publishers Ltd : from Leschziner GD, Andrew 
T, Pirmohamed M, Johnson MR. “ABCB1 genotype and PGP expression, function and 
therapeutic drug response: a critical review and recommendations for future research.” 
Pharmacogenomics J 2007; 7:154-179. Copyright © 2007, Nature Publishing Group).  
1.4.2.1 Common variants and haplotypes of ABCB1 
The ABCB1 gene is located in a genomic region with strong linkage disequilibrium 
(LD). Kroetz et al [195] described the sequence diversity and haplotype structure of this 
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gene in several populations, including Caucasians. This USA-based study found two 
common haplotypes that represent 36% of all haplotypes observed. The haplotype 
ABCB1*13, containing three SNPs (C1236T, G2677T/A, and C3435T), was most common 
in the Caucasian population. This study provided evidence that the C3435T site is in tight 
LD with other regions including G2677T and that multiple haplotypes contain SNP 
C3435T. The common synonymous variants C1236T and C3435T are evolutionary 
conserved SNPs whereas SNP G2677T is a tri-allelic non-synonymous SNP.  
1.4.2.2 Expression studies in relation to genetic variants of ABCB1 
Specific variants in the ABCB1 gene influence glycoprotein expression. According 
to the SNP database maintained by the National Center for Biotechnology Information 
(NCBI), there are more than 50 SNPs in the human ABCB1 coding region. Among these 
polymorphisms, two SNPs: SNP C3435T in exon 26 and SNP G2677T/A in exon 21 have 
been most commonly studied (Figure 8 on page 32). Both these variants are thought to 
influence the level, activity and function of P-glycoprotein and thus to influence the 
transport and uptake of various substrates [196-200]. However, there is a considerable level 
of controversy about the functional significance of ABCB1 polymorphisms. Both increased 
and decreased functions have been associated with in particular the C3435T variation 
[195]. In one study, Hoffmeyer et al. showed a borderline-significant (p=0.056) association 
of C3435T polymorphism with expression and function of the protein [196]. In this study, 
individuals homozygous for the rare allele (TT) of this polymorphism had significantly 
lower duodenal MDR-1 expression and the highest digoxin plasma levels. Similarly, in 
healthy individuals, the rare allele and the rare homozygous genotype of this SNP was 
significantly correlated with decreased levels of expression of the MDR1 pump [201, 202]. 
Consistently, Hiltz et al. have found that healthy individuals homozygous for this 
polymorphism (CC) have significantly higher MDR1 expression in natural killer peripheral 
blood cells and as compared to the TT genotype [203]. More recently, Hitzl et al. 
demonstrated no association between placental Pgp expression and C3435T in mothers or 
foetuses, but described a positive association between protein expression and genotype 
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when wild type homozygous mothers and foetuses were compared with variant 
homozygous mothers and foetuses [204]. Likewise, allele T was also shown to be 
associated with better response to anti-depressive drugs in Taiwanese patients [205]. Other 
studies, however, have failed to replicate these results [199, 206, 207]. Interestingly, 
Markova et al. when examining in vitro the expression and function of ABCB1 in human 
peripheral blood mononuclear cells subjected to experimental acute inflammation, reported 
that CS therapy might be more effective in carriers of the allele C of the C3435T SNP 
[208]. For the G2677T/A SNP, most of the studies have not showed any influence on 
protein expression [206, 207, 209, 210], barring one study that observed an association 
between the GG genotype and reduced mRNA expression [211]. 
Given these inconsistencies, some studies have suggested that the functional 
properties of ABCB1 polymorphisms may reside in the haplotype structure rather than in 
single SNP. Reasons for the inconsistent results may be related to the fact that the substrate 
spectrum of MDR1 is quite wide and may overlap with that of other transporters such as 
ABCG2 [212] and CYP3A4 [213, 214]. Moreover, given the substantial differences in the 
frequency of the C3435T variant between racial groups, the assessment of its functional 
significance is further complicated. The frequency of CC genotype of the C3435T SNP 
ranges from 21% to 42% in Caucasians according to different studies [196, 215-218]. 
However, recently, Kimshi-Sarfaty et al., have shown that despite an absence in any 
changes to the amino-acid sequences polymorphisms such as C3435T can influence protein 
activity and substrate specificity [219]. 
 
 
 
Figure 8. Most commonly studied ABCB1 gene variants. 
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Therefore, despite the inconsistent evidence, polymorphisms in the C3435T 
genotype may potentially play an important role in determining the corticosteroid refractory 
phenotype. 
1.4.3 ABCB1 gene variants and susceptibility for CS refractoriness 
1.4.3.1 Epidemiological studies of CS response in IBD 
In spite of the known biological role of the MDR1 gene in CS metabolism, very few 
studies have investigated associations between DNA variants in the MDR1 gene and 
response to CS. In one study, Potocnik et al. [220] studied whether ABCB1 gene 
polymorphisms were associated with corticosteroid refractoriness in a Slovenian 
population. CD cases with moderately to severely active disease, who failed conventional 
treatment using 5-ASA, antibiotics, corticosteroids and azathioprine and those patients who 
developed fistulising disease were considered as corticosteroid refractory. Twenty-four 
steroid-refractory cases were studied and frequencies of 10 exonic and intronic variants, 
including one SNP from the promoter region were contrasted with those among healthy 
blood donors. Significant associations with two intronic SNPs were observed: one in intron 
13 (rs2235035) and one in intron 16 (rs1922242) with p-values of 0.014 and 0.024 
respectively. These two SNPs were in LD one with another. The frequencies of the rare 
alleles of these two SNPs were lower among CD-refractory cases in comparison with 
controls (0.23/0.29 and 0.41/0.47 respectively). A SNP in exon 21 (A893S) (rs2032582) 
was marginally significantly associated with refractory CD (0.54 versus 0.40, p=0.064). 
Haplotype analysis using individually associated SNPs did not reveal associations with 
steroid refractoriness. A common 3-marker haplotype (TTT) comprising SNPs rs2032582, 
rs1128503 (C1236T exon 12) and rs1045642 (C3435T, exon 26) variants was however 
associated with a higher risk of refractory CD (OR=3.1, p=0.044).  
In a more recent Italian study [221] Palmieri et al. examined the association of two 
ABCB1 variants rs2032582 and rs1045642 (examined previously by Potocnik et al. above), 
with steroid-refractory CD. A responder to CS was defined as a patient who achieved 
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clinical remission after at least one course of systemic CS and CS-dependent as a patient 
who continued CS therapy at the end of one year due to relapse after discontinuation of 
treatment or due to relapse at dose reduction. This study did not detect any associations 
between either of the two SNPs and CS response in their population. In another study, De 
Iudicibus et al. examined the C3435T and G2677T variants in 117 Italian IBD patients, but 
did not find any associations with CS dependence [222]. The T allele of C3435T SNP was 
associated with significant or complete CS tapering in a cohort studied from Leuven [223]. 
In the only paediatric association study carried out so far, in an Italian population, the 
authors [224] did not observe any association between the C3435T SNP and CS response. 
Various reasons may underlie observed differences between studies carried out in 
seemingly heterogeneous populations. For one, most of the studies used different 
classifications of steroid-refractoriness. The significant results described by Potocnik were 
based on only 24 steroid-refractory cases and potentially susceptible to false-positivity, 
considering that no adjustments for multiple testing were made. Although Palmieri et al. 
studied a larger population [221], the phenotype definition was narrower than that in the 
Potocnik study. Besides, the Italian study examined haplotypes composed only of two 
markers. 
A meta-analysis [225] that included seven studies [220, 225-230] examined 
associations between the two commonly studied SNPs (C3435T and G2677T/A) in relation 
CS response in a large sample of IBD patients. This meta-analysis included the Slovenian 
study [220] but not the two Italian studies [222, 224] that were published subsequently. No 
associations between the two SNPs and CS response were observed in CD patients. 
However, both the SNPs appeared to be associated with CS response in UC patients. The 
meta-analyses however included only adult studies. Given that paediatric CD differs 
extensively from adult CD, it is however likely that the associations between the ABCB1 
gene and steroid response may differ as well.  
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1.4.3.2 ABCB1 variants and CS refractoriness in other inflammatory diseases 
Refractoriness to the anti-inflammatory action of CS has been observed in many 
medical conditions, including cancers [231] and immunity-related inflammatory diseases, 
further supporting the relevance of studying the variations of this gene in relation to CS-
refractory IBD. About 30% of patients with acute lymphoblastic lymphoma (ALL) [35] and 
RA [232] are resistant to CS. In patients with ALL, a worse clinical response to CS was 
associated with the CC genotype of SNP C3435T (0.62 vs. 0.87; p=0.007) [231]. The 
C3435T variant has been found to be associated with response to CS in RA [233]. In this 
study, the probability of remission of RA symptoms after therapy with methotrexate and 
CS was 2.9 times greater in patients with the 3435TT genotype compared to patients with 
the genotypes 3435CC and 3435CT. Similarly, in children with heart transplants the TT 
genotype predicted weaning from CS [234]. Thus, patients with the CC genotype were 
significantly (p=0.04) more likely to be still on steroids 1 year after transplantation.  
1.5  NR3C1/GR gene and response to CS 
NR3C1/GR belongs to large family of nuclear receptors and the gene is located at 
chromosome 5q31-32 corresponding to the IBD-5 susceptibility locus. It extends 157,5 kb 
and contains 10 exons. The encoded protein has a three-domain structure: an amino-
terminal trans-activating domain (TAD), which directs trans-activation of target genes, a 
DNA-binding domain, interacting with glucocorticoid response elements (GRE) in the 
DNA and a carboxy-terminal ligand-binding domain, which contains specific steroid and 
heat shock protein binding sites [235]. The biological role of this gene is well studied. 
Glucocorticoid receptor (GR) is derived from a single gene, and since its cloning, the 
prevailing assumption has been that a single receptor protein is responsible for the diverse 
actions of glucocorticoids. This “one gene-one receptor” paradigm has been challenged by 
recent studies revealing a large group of functionally distinct GR subtypes that arise from 
alternative processing of the gene. These receptor isoforms, in turn, are subject to various 
post-translational modifications that can further modulate their activity. The large variety of 
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GR isoforms probably explains the large spectrum of physiological functions regulated by 
NR3C1. 
1.5.1 GR receptor 
The protein encoded by NR3C1 resides in the cytoplasm until it binds to a substrate, 
which induces transport into the nucleus. Variations in this gene are known to cause a 
glucocorticoid resistance (or cortisol resistance). Multiple isoforms of GR: GRα, GRβ and 
GRγ, arise from alternative splicing, the use of at least three different promoters and from 
translational events [236-238]. The GRα isoform is the full-length receptor, consisting of 
777 amino acids, which binds to a ligand and mediates glucocorticoid action. Two 
truncated isoforms, GR (742 aa) and GR (676 aa), are unable to bind to a ligand and have 
been shown to mediate GR activity. The physiological and pathophysiological role of GRβ 
actually is controversial, as it has been shown to have a dominant-negative effect on GR 
activity [239] and as well a synergistic effect with GRα via transcriptional repression of 
cytokine genes IL5 and IL13 [240].  
A GR-related variable phenotype encompasses a sensitivity and resistance to the 
suppressive action of GC on the hypothalamic-pituitary-adrenal axis (HPA). Several forms 
of resistance to GC were described, including familial resistance. Primary glucocorticoid 
resistance has been described as a rare familial or sporadic syndrome [241] mostly due to 
inactivating mutations of the GR gene, while several autoimmune-inflammatory diseases, 
such as rheumatoid arthritis, osteoarthritis, CD, ulcerative colitis and asthma, are often 
associated with resistance of the inflamed tissues to CS [242-244].  
1.5.2 Role of the NR3C1 gene in modulating response to CS 
The anti-inflammatory actions of CS are directly mediated via their contact with the 
GR in the cell. Therefore, any modifications in the density and function of the GR are likely 
to mediate resistance to CS. Inside cells, CS bind to an intracellular receptor, so the 
sensitivity to CS may depend on the number of receptors and their affinity to ligand [245].  
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Several studies have shown reduced peripheral T-lymphocyte GR binding affinity 
[167] and abnormalities of GR-AP-1 binding [166]. Flood et al. studied GR receptor 
density in relation to response to CS in IBD patients, but did not observe a relation between 
GR density or GR mRNA levels and CS resistance [246].   
The identification of several isoforms of the protein coded by NR3C1 has led to the 
hypothesis that variations in the gene may influence the function or expression of GR. 
Particularly, increased expression of GRβ - a truncated splice variant of the normal isoform 
GRα that does not bind glucocorticoid ligands, and is unable to transactivate 
glucocorticoid-responsive genes, has been suggested to exert a dominant-negative 
inhibition of CS action [247]. Observations of increased expression of the GRβ isoform in 
some CS resistant states lend support of this hypothesis [248-250]. Nevertheless, studies 
comparing the differences in expression of the GRβ and GRα isoforms in IBD are not 
conclusive. For example, Honda et al. examined the expression of GRβ isoform in 
peripheral blood mononuclear cells of IBD patients and showed that the receptor was 
significantly more frequently expressed in glucocorticoid-resistant UC patients than in 
glucocorticoid-responsive patients and healthy volunteers [251]. The authors concluded that 
differential expression of GR isoforms might have a predictive value for response to CS. 
No differences in GRβ expression in patients with active CD and healthy subjects were 
however observed. In contrast, Towers et al. reported higher levels of GRβ-mRNA among 
steroid resistant CD patients in comparison to responsive patients [252]. In a more recent 
prospective study Hausmann et al. did not observe differences in the expression of GR 
isoforms in 35 IBD patients compared to healthy controls and CS-naïve patients [253]. 
Separate findings for CD were not presented. Most of these studies were however based on 
small sample sizes and using different controls, probably resulting in the discrepant 
findings.  
1.5.3 Variants in NR3C1/GR gene 
From among the known polymorphisms in the NR3C1 gene, some such as the 
ER22/23EK (rs6189/6190), N363S (rs6195), BclI (41423247) and GR-9β are considered 
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functionally relevant (Figure 9 below). These polymorphisms have been shown mediate 
changes in glucocorticoid sensitivity or altered cortisol levels [254-258].  
 
 
Figure 9. Structure of NR3C1 gene and location of the most commonly studied 
polymorphisms. 
For example, SNPs rs41423247 and rs6195 (A>G) appear to increase sensitivity to 
dexamethasone [255, 259-261]. On the other hand, SNP, rs6190 (G>A) has been reported 
to decrease response to dexamethasone, indicating relative resistance to CS [254].  
1.5.3.1 NR3C1/GR variants and susceptibility to CS refractory CD  
Given the important role of GR in mediating the actions of CS and the influence of 
genetic variants to influence GR expression, some studies have examined the association 
between GR gene variants and response to CS in IBD.  
Three Italian studies [222, 262, 263] have assessed whether the BclI polymorphism 
(located in intron 2) was associated with CS response in IBD patients. In one study, De 
Iudicibus et al. investigated 64 young patients with CD and 100 healthy blood donors 
[222]. In this retrospective study rare homozygote genotype was more frequent in 
responders to CS than in CS-dependent patients (OR=0.15, 95% CI: 0.03-0.68). These 
results were subsequently confirmed by the same author [263] in 84 CD and 72 UC 
patients. However, Maltese et al. when studying 70 healthy blood donors and 40 CD 
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patients [262] did not find the associations between this variant and response to CS. A 
recent Swiss study conducted by Mwinyi et al. analyzed 13 SNPs, mostly from the coding 
parts of the NR3C1 gene, in a cohort of 181 (84 CD) IBD patients, but did not observe any 
association either with single SNPs or haplotypes with response to CS therapy [264]. This 
study included coding SNPs rs6190 (G>A) (exon 2) and rs6196 (A>G) (exon 9). A separate 
analysis for CD was however not carried out.  
1.5.3.2 NR3C1/GR variants and response to CS in other diseases 
Numerous associations between variants in the NR3C1 gene and the corticosteroid 
resistance syndrome due to disturbances in the metabolism of endogenous steroids have 
been reported [265]. There are some reports that certain variants in the exon 9β of the gene 
(that determines the GRβ isoform) that are associated with a greater GRβ stability may be 
related to rheumatoid arthritis, [266] but there are no reports on CS response is such 
patients. Some variants in this gene have been reported to be associated with resistance to 
CS treatment in asthma [42, 249], leukemia and multiple myeloma [267-269]. More 
recently, Stevens et al. identified a 3-marker haplotype (GAT) consisting of rs41423247 
(BclI), rs33389 and rs33388, associated with low post-dexamethasone cortisol administered 
in a combined group of healthy individuals and patients with psoriasis, suggesting that 
markers within the gene could determine population variability in response to exogenously 
administered steroids [261].  
1.6 Summary of the literature and study rationale  
CD burden has increased over the past two decades with rising incidence in children 
leading to major impact on health care costs. CD in children is characterized by a severe, 
extensive phenotype, the predominance of colonic localization and a greater risk of disease 
extension in localization and risk of surgery, suggesting the existence of a distinct CD 
phenotype and of differences in response to drugs. 
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CS are the mainstay of therapy in CD and are very effective in induction of disease 
remission. However, one of the drawbacks of this therapy is the occurrence of inter-
individual variability in response. Rates of CS resistance and CS dependence in particular 
are very high in children and the effects of prolonged use can be deleterious in this 
population because of many side effects. Therefore, it is of high clinical importance to 
predict patient’s atypical treatment response in order to personalise the treatment and to 
avoid unnecessary exposure to CS.  
The search for predictive markers, however, has resulted in inconsistent findings, 
most acquired from studies in adults. Among putative predictors, younger age at diagnosis, 
colonic disease localization and penetrating disease behaviour, trombocytosis and CRP 
levels have been reported to be associated with CS-dependence. The association with 
younger age at diagnosis may indicate potential differences in mechanisms involved in CS 
response in children versus adults. In the few paediatric studies that have been carried out 
so far, only associations with growth retardation at diagnosis and CS dependence appear to 
be consistent.  
The exact mechanism underlying CS response is presently unknown. Not 
surprisingly, the information on markers that could potentially predict CS response is also 
limited and inconsistent. Given our understanding of the actions of CS, targeting genes 
involved therein may help better understand reasons for variability in response. In this 
context, the ABCB1/MDR1 and NR3C1/GR genes are of key interest as they are intimately 
involved in the CS action pathway and thus can mediate responses to CS treatment.  
Despite the known mechanisms of CS action and the important role of the MDR1 
and GR genes, evidence for association between variants in these genes and CS response is 
both limited and inconsistent. Some of the inconsistencies are mostly related to the 
discrepancy in target coding variants to influence the expression of the relevant protein. 
This is in particular true for the MDR1 gene wherein rather than nonsynonymous variants, 
synonymous coding variants appear to influence protein expression. Concerning the 
synonymous coding variants, furthermore, evidence appears to be conflicting with studies 
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showing both increases and decreases in protein expression. These seemingly dual effects 
limit the interpretability of studies examining the influence of these variants in CS 
responses in CD, in particular when such studies are carried out in prevalent versus new-
onset cases and in adults. In both instances, the larger possibility of potential influence of 
environmental factors including therapy may alter expression of the relevant protein 
leading to inconsistent genetic associations. Unfortunately, most previous studies have been 
carried out in adults and in patients with long-standing disease. Studies to examine the 
potential influence of the MDR1 thus need to be carried out in children and within a short 
time window since disease onset or diagnosis. A further limitation of previous studies has 
been the use of small number of markers and small sample sizes. In addition, different 
reference or control groups have been used, potentially leading to either false-positive or 
false-negative results. Many studies combined both CD and UC populations without 
separate analysis. Although CD and UC share some pathogenesis mechanisms it is now 
clear that the genetic predisposition to disease susceptibility varies extensively. Although 
this does not necessarily presuppose that susceptibility for treatment responses will also 
vary, given the distinct phenotypes and clinical courses of both these disease, and the 
differential expression of the MDR1 and GR genes in different parts of the intestines, it 
would be nonetheless expected. Thus, separately studying the influence of potential 
predictors/markers in CD that is by-and-large more common in Canadian children (vis-à-
vis UC) is required.  
In summary, it is quite clear that CS refractoriness is a major clinical challenge in 
particular in children. Efforts to identify markers to identify children most likely to become 
refractory are urgently required. The principle aims of our proposed studies were to thus, 
comprehensively investigate, the hypothesized associations in a large cohort of children.  
1.7 Study hypotheses and objectives 
It is clear that administration of CS to children with CD although of high clinical 
benefit, present major challenges. A high proportion of children become either dependent 
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or are resistant to steroid medication. There is currently very limited information on why 
some children become refractory to CS while others do not. Some clinical and/or 
demographic characteristics have been implicated, but evidence is inconsistent. Based on 
known mechanisms underlying CS metabolism, we have hypothesized that genetic 
variability in the ability to metabolize steroids may underline susceptibility for inadequate 
response to CS. Specifically, we have proposed that DNA variations in the MDR1 and GR 
gene may be important. Based on this hypothesis, the specific objectives of the study were:  
 
o To describe the burden of the variability in response to CS and examine its clinical 
and/or demographic predictors in paediatric Crohn’s disease patients. 
 
o Examine if a variants in ABCB1/MDR1 gene were associated with corticosteroid 
dependency. 
 
o Examine if the variants in NR3C1/GR gene were associated with corticosteroid 
dependency. 
    
 
 
 
 
 
 
 
 
CHAPTER 2  
METHODOLOGY 
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2.1 Study design 
Aiming to address our study objectives, we implemented a retrospective cohort 
study at two Canadian tertiary paediatric gastroenterology centers: Ste. Justine’s 
Hospital (SJH) in Montreal, and the Children’s Hospital of Eastern Ontario (CHEO) in 
Ottawa. The study cohort comprised of CD patients diagnosed prior to age 18 and 
treated with CS between 1980 and 2008 at SJH and between 2000 and 2008 at CHEO.  
In order to establish the study cohort, all patients diagnosed with CD at the two 
centers for the requisite time periods were identified. The medical charts of these 
patients were consulted to identify those subjects who were administered steroids during 
the first year since diagnosis. For these patients, the medical records at each visit were 
scanned to determine the response of the patient to steroid medication. Published criteria 
were adapted to classify patients as either steroid resistant or steroid dependent, the two 
main outcomes of the study. The cohort members were contacted to acquire consent to 
participate in the study and to provide samples for DNA analysis. Acquired samples 
were then genotyped for variants in the study genes. The distribution of gene variants 
according to outcome status was then evaluated to examine associations between study 
genes and steroid response. Further details on the study population, recruitment and 
genotyping are presented in the next section.  
2.2 Study population, selection of participants 
As mentioned above, patients less than 18 years of age at diagnosis were 
identified and recruited from two Canadian tertiary paediatric gastroenterology centers. 
In order to define the population for the study (i.e. patients diagnosed with CD), we used 
multiple sources. One source was a list of patients treated for CD at the Montreal and 
Ottawa study centers. The gastroenterology clinics at both these centers maintain a 
comprehensive list of all patients who are treated for IBD at their clinics. The medical 
files of these patients were scanned to first confirm the diagnosis of CD and identify 
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those patients who were administered CS during the first year following diagnosis. In 
order to account for potential subjects not part of the lists and to establish a more 
comprehensive repository of patients, for the Montreal study center, we consulted the 
database maintained at the medical archives. The patient record database includes all 
clinic visits and hospitalization since 1980. Patient diagnoses are classified according to 
the International Classification of Diseases Ninth revision (ICD9) codes. Diagnosis 
codes that corresponded to CD (555.0, 555.1 and 555.2) were retrieved. The patient 
charts corresponding to the retrieved codes were then consulted to confirm the diagnosis 
of CD. Patients with CD and those who were administered steroids were included for 
study. Patients’ inclusion and exclusion criteria are enumerated below: 
1. Inclusion 
o Confirmed diagnosis of Crohn’s disease using standard criteria 
o Administration of systemic CS 
o Administration of CS within 1 year since  CD diagnosis  
2. Exclusion 
o Patient age >18 years at diagnosis 
o Patients that  received CS prior to CD diagnosis 
o Presence of serious co-morbidities (such as congenital disorders, 
neuromuscular degenerative disorders) with several additional medications 
prescribed 
 
The process of data abstraction was established after preliminary consultations 
with the study gastroenterologists at the two study centers. At the Ottawa study center, 
data was abstracted jointly by the study gastroenterologist and the IBD research nurse. 
For the Montreal study site, the majority of the data was abstracted by the lead author 
(AK). At this site, important aspects of data abstraction that included deciphering 
medical synonyms & abbreviations specific to the center were first discussed & clarified 
by the team. In order to limit inter-observer bias, at the Montreal study center, data for 
key study variables (disease severity, CS dependence and resistance) was abstracted by 
  
46 
two independent observers (AK and DKA). Discordance if any was resolved by 
discussion with the study gastroenterologist(s).  
2.2.1 Diagnosis of CD 
The diagnosis of CD was established according to standard clinical, endoscopic, 
histopathologic and radiologic criteria [270, 271]. These criteria included: (1) the 
presence of characteristic small bowel involvement, (2) deep linear ulcers, (3) distinctive 
cobblestone aspect and discontinuing character of inflammation at endoscopy, or (4) 
patchy transmucosal inflammation with granulomas in histological samples. 
2.2.2 Administration of CS 
Patients treated with systemic CS administered within 1 year after diagnosis were 
considered in order to have a population of patients with limited exposure to 
concomitant multiple therapeutic agents. Patients who were administered steroids prior 
to diagnosis with CD were excluded. CS therapy included oral prednisone, intravenous 
methylprednisolone (administered to patients with very severe, usually fulminant 
disease) for 1 week and substituted with oral CS subsequently, and budesonide 
(administered to some patients with pure ileal disease). 
CS doses determined empirically by the treating physician were abstracted. The 
dosage system was standard and corresponded to 1 mg/kg/day, with dosage no higher 
than 40 mg/day for children whose weight exceeded 40 kg.  
All the different dosage decrease regimens were abstracted. The most common 
consisted of a decrease by 5 mg weekly until 0 was reached. Another recommended 
regimen was to decrease the dose by 5 mg /week, but when a dose of 20 mg was 
reached, the current dose would be alternated with one decreased by 5 mg over a week. 
The following week, both doses would be decreased by 5 mg. For example : if a patient 
was started on 40 mg - then weaned by 5 mg /week until prednisone reaches 20 mg/day, 
they would be administered a dose of 15 mg on alternate days each week alternating 
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with 20 mg. The following week the doses would change to 20 mg and 15 mg; the week 
after it would be 20 mg and 10 mg. The weeks after the alternate-day dosage would 
reach zero, the 20 mg dose would be decreased by 5 mg and alternated with zero. (thus 
20-15-20-15-20-15-20-10-20-10-20-10-20-5-20-5-20-5-20-5-20-0-20-0-20-0-20-0-20-0-
15-0-15-0-15-0-15-0-10-0-10-0-10-0-10-0-5-0-5-0-5-0-5-0). This last regimen was most 
frequently used at the CHEO study center. 
2.3 Study variables  
The main study variables are described in Table III-A on page 48 and Table III-
B on page 51. Study outcomes were CS dependence and CS resistance. The main 
independent variables were the tag-SNPs in ABCB1 and NR3C1 genes with the addition 
of functionally relevant variants. Other co-variates included socio-demographic and 
clinical factors, some as predictors of the outcome and others as potential confounders.  
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Table III-A: Main study outcomes and independent variables. 
 
 Name Description  Related 
concept 
Data 
source 
Scale of 
measurement 
Reference 
CS 
resistance 
Absence of 
response to CS 
assessed on 30th 
day after the start 
of treatment 
Steroid 
refractoriness 
Medical 
charts 
Dichotomous: 
CS-resistant, 
responders 
Munkholm, 
1994 
O
ut
co
m
e 
(d
ep
en
de
nt
) v
ar
ia
bl
es
 
CS 
dependence 
Restarted CS due 
to relapse after 
the end of 
treatment, or 
inability to wean 
due to relapse at 
dose reduction. 
Steroid 
refractoriness 
Medical 
charts 
Dichotomous: 
CS-
dependent/  
responders 
Munkholm, 
1994 
 
Faubion, 
2001 
Tag-SNPs 
and 
haplotype in  
ABCB1 
Genetic 
variation  
Dichotomous: 
Presence or 
absence of the 
allele, 
haplotype 
Categorical* 
In
de
pe
nd
en
t v
ar
ia
bl
es
  
Tag-SNPs 
and 
haplotype in 
NR3C1 
 
Identified using 
publicly 
available 
database as 
reference 
Genetic 
variation 
Blood or 
saliva 
(DNA 
samples) 
samples) 
Dichotomous: 
Presence or 
absence of the 
allele, 
haplotype 
Categorical* 
Carlson, 
2004 
CS, Corticosteroids; DNA, Deoxyribonucleic acid; Tag-SNPs, Tagging single nucleotide 
polymorphisms. 
*For genotype analysis the categorical variables (0-1-2) were used.  
  
2.3.1 Definition of outcomes 
The main study outcome variables were corticosteroid resistance and 
corticosteroid dependence. The corticosteroid dependent phenotype was assessed based 
on adaptation of previously recommended criteria [13, 76, 107].  
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2.3.1.1 CS-dependence  
CS-dependence was defined as the reoccurrence of clinical symptoms during the 
weaning period (1) or clinical relapse occurring during 180 days following the end of 
treatment, requiring the reintroduction of CS (2) (Figure 10 on page 50). Comparison 
groups consisted of responders to CS, i.e. patients that maintained partial or complete 
remission since the end of corticosteroid therapy.   
Patients who had surgeries, who did not meet classification’s criteria because of 
lack of inscription in medical files or who had super-infections such as C. difficile, 
which could mask symptoms of disease reactivation, were classified as “others”. 
2.3.1.2 CS-resistance  
CS-resistance was defined, based on clinical symptoms, as the absence of 
response to CS treatment 30 days from the start of therapy. The following clinical 
symptoms were considered: (1) the number of abnormal stools per day, (2) the presence 
of mucus, blood or pus in the stool, (3) abdominal pain, (4) fever, weight loss and other 
extra-intestinal manifestations. Thirty days after the start of CS therapy, patients were 
classified into three categories: 
Complete remission - total regression of clinical symptoms, with 2 bowel 
movements a day and no pain; no blood, pus or mucus in stool; no fever, weight loss or 
extra-intestinal manifestations. 
Partial remission - regression of symptoms, with ≤ 4 bowel movements a day, 
less abdominal pain and no fever, weight loss or extra-intestinal manifestations. 
Non-response - no improvement within 30 days.  
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Figure 10. Study outcomes assessment criteria and timeline. 
2.3.2 Information on covariates 
Socio-demographic and clinical variables were used as potential predictors of the 
main study outcomes or as potential confounders in genetic association studies. The 
variables (1) age at diagnosis, (2) gender, (3) disease localization (4) disease behaviour, 
(5) disease severity, (6) extra-intestinal manifestations, (7) family history of IBD, (8) 
ancestry and (9) concomitant medication were postulated as clinical and socio-
demographic predictors (independent variables) of CS-dependence and CS-resistance. 
The rationale for their selection, either as predictors or as potential confounders, is 
provided below. 
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Table III-B: Main study variables, covariates. 
 Name Description  Related 
concept 
Data 
source 
Scale of 
measurement 
Reference 
Age at onset 
of CD* 
Patients’ age in 
years  
Categorical:1st 
versus 2-4 
quartile 
- 
Gender* Female /male Binary (1/0) - 
Ancestry European/non-
European 
Binary (1/0)  
Disease 
severity* 
HBI Categorical: 
Mild-
moderate/severe 
Markowitz, 
2000 
Disease 
behaviour* 
Presence of 
complications 
Binary:B1 versus 
B2 &B3 
Satsangi, 
2006 
Concomitant 
Medication 
Given with CS Categorical: 
3 categories 
As 
prescribed 
Disease 
localization* 
Location in 
gastrointestinal 
tract 
3 categories 
L1±L4;L2±L4 
L3±L4 
Satsangi, 
2006 
Family history 
of IBD* 
First or second 
degree relatives 
with IBD 
Binary (1/0)  
C
ov
ar
ia
te
s 
EIM   
Po
te
nt
ia
l c
on
fo
un
de
r 
M
ed
ic
al
 c
ha
rts
 
Binary (1/0) Su, 2002 
*These variables were used as covariates for genetic studies. 
B1, Inflammatory disease; B2, Stricturing disease; B3, Penetrating disease; CD, Crohn’s 
disease; EIM, Extraintestinal manifestations, HBI, Harvey Bradshaw Index; L1, Ileal; 
L2, Colonic; L3, Ileocolon; L4,Upper digestive tract involvement. 
 
 
2.3.2.1 Age at diagnosis 
Age at diagnosis is known to influence the occurrence of CD phenotypes. 
Although limited, some studies have shown that patients diagnosed at a younger age 
were more likely to be become steroid refractory [106]. It was thus included as a 
potential predictor of CS response. Although given the short age range of the study 
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population (5-18 years), the gene variants under study were unlikely to be differentially 
distributed within age-groups, based on reports that GR polymorphisms may differ 
according to age, age was considered a covariate in the genetic association studies [272]. 
For the purpose of the present studies, age at diagnosis was based on the date at which 
the endoscopy was carried out to confirm the diagnosis of CD.  
2.3.2.2 Gender 
Gender was considered a potential predictor of CS response. At the same time 
given observations that gender could be associated with complicated disease course [64, 
273], it was also considered to be a potential confounder for other predictors of CS 
response.  
2.3.2.3 Disease localization 
Disease localization was classified according to the Montreal classification of 
Crohn’s disease [274]. Disease localisation is an important characteristic of CD. Based 
on proposed CD classification (Table IV on page 53), disease localization was defined 
as ileal involvement - L1, colonic - L2 or ileocolonic involvement - L3. Upper digestive 
involvement - L4 was added to each of abovementioned categories, if applicable. 
Disease localisation was defined according to endoscopic, radiological and/or 
histological findings abstracted from the medical charts. It was considered as a potential 
predictor of CS response. Given that many genes are associated with specific disease 
localizations, it was also considered a potential covariate in the genetic association 
studies. 
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Table IV: Montreal classification of Crohn’s disease.  
 
2.3.2.4 Disease behaviour 
Disease behaviour was also determined according to the Montreal classification. 
Based on this classification, behaviour was classified as stricturing disease (B2) if 
endoscopic, and/or radiological examinations demonstrated the presence of strictures 
and/or bowel obstruction. It was classified as penetrating (B3) if investigations 
demonstrated the presence of internal fistulas or abscesses. Patients without structuring 
or penetrating disease were classified as having inflammatory disease behaviour (B1). 
The presence of perianal disease was included as a modifier to the three behaviour 
categories. 
2.3.2.5 Disease severity 
Disease severity is known to influence the clinical course of CD. It was 
considered an independent predictor of CS response. Disease severity at the start of 
Characteristics 
A1 below 16 y 
A2 between 17 and 40 y 
Age at diagnosis 
A3 above 40 y 
L1 ileal 
L2 colonic 
L3 ileo-colonic 
Localization 
L4 isolated upper disease* 
B1 inflammatory  
B2 stricturing  
B3 penetrating  
Behaviour 
p perianal disease modifier† 
*L4 is a modifier that can be added to L1–L3 when upper gastrointestinal disease is 
present. 
† ‘‘ p’’ is added to B1–B3 when concomitant perianal disease is present.  
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corticosteroid therapy was assessed using a modified Harvey Bradshaw Index (HBI) at 
SJH and the Physician Global assessment at CHEO. Both these criteria are highly 
correlated [93]. Other indices such as the Crohn’s disease activity index (CDAI) and the 
Pediatric CDAI (PCDAI) are widely used. These however require prospective data 
collection that includes maintenance of a 7-day patient diary of subjective symptoms. 
For retrospective studies, HBI and PGA are thus preferred and the HBI has been shown 
to be strongly correlated with the CDAI a well. The criteria used to calculate HBI are 
presented in Table V. The information required for estimating the index was abstracted 
from the patients’ medical charts. A binary variable was created by categorizing the 
scores as <5 and >= 5.  
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Table V: Harvey Bradshaw Index. 
2.3.2.6 Extra-intestinal manifestations 
CD is known to present with various extra-intestinal manifestations (EIM). 
Information on manifestations such as presence of skin, eye, joint, mouth and other 
symptoms [62, 275] was abstracted (Table VI). EIM were considered as independent 
predictors of CS response. A binary variable corresponding to the absence or presence of 
any EIM was created.  
 
Symptoms Subscore  Score 
1. General well-being  -- 
Very well 0  
Slightly below par 1  
Poor 2   
Very poor 3  
Terrible 4  
2. Abdominal pain  -- 
None  0  
Mild  1  
Moderate  2  
Severe 3  
3. Number of liquid stools  -- 
0 0  
1-2 1  
3-4 2  
5-6 3  
7-8 4  
>8 5  
4. Abdominal mass   -- 
None  0  
Dubious  1  
Definite  2  
Definite and tender 3  
5. Complications* 1 for each item -- 
Total score Sum of subscores 
 * Arthralgia, uveitis, E. nodosum, aphthous ulcers, pyoderma gangrenosum, draining 
fistula, abscess, temperature > 38 °, cutaneous vasculitis 
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Table VI: Extra-intestinal manifestations.  
Group Symptoms 
Skin Erythema nodosum 
 Pyoderma gangrenosum 
Mouth Cheilitis 
 Stomatitis 
 Aphtae 
Liver Primary sclerosing cholangitis 
 Hepatitis 
 Cholelithiasis 
Eye Uveitis 
 Episcleritis 
 Conjunctivitis 
Joints Arthralgia 
 Arthritis 
 Ankylosing spondylitis 
General Fever 
 Weight loss 
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2.3.2.7 Family history of IBD  
Associations between some CD susceptibility genes and a family history of IBD 
have been reported. It has been reported, for instance, that the CARD15 gene is 
associated with a family history of IBD [276]. We considered having a family history of 
IBD as a potential predictor of response to CS and included it as a co-variate in the 
multivariate genetic association analyses as it has been shown to increase the power of 
association studies [277]. Family history of IBD was defined as the presence (or 
absence) of family history of IBD (including its both IBD forms: CD and UC) in a first-
degree relatives of the patient.   
2.3.2.8 Ancestry 
Ethnicity is known to be related to susceptibility to diseases, including 
susceptibility to IBD, and therefore could also influence the response to CS. Genetic 
population structure is known to influence findings of genetic disease susceptibility 
association studies [278, 279]. Population structure could have resulted in the noted 
discrepancies in associations between the ABCB1 gene and susceptibility to IBD in 
ethnically similar populations [221, 280]. Such confounding also may have potentially 
resulted in lack of replication of susceptibility genes and response to CS [221]. Thus, 
accounting for potential structure may be important. We considered ethnicity as a 
potential predictor of response to CS. Based on findings of a lack of association between 
ethnicity and both response to CS and variation in the study genes, ethnicity was not 
included as a covariate in the genetic association analyses.  
Patients were classified into two ancestry categories: European and not European 
basing on self-reported information about ethnic origin. Self-reported ancestry has been 
shown to be highly correlated with ancient geographic ancestry [281]. Information on 
ancestry was acquired by administering a socio-demographic questionnaire (see 
Appendix 1) to the patient.  
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2.3.2.9 Concomitant medication 
Medication given concurrently (at the time of administration of CS) was 
considered as concomitant. As immunomodulators are frequently prescribed for the 
management of CS dependent CD, this definition included medication given only prior 
to disease relapse. Concomitant medication comprised of ASA-5 analogs or 
immunosuppressive agents [azathioprine (AZA), 6-mercaptopurine (6-MP), and 
methotrexate (MTX)] and antibiotics. The following categories were created:  
Reference category-Patients who either did not receive any concomitant medication or 
received only antibiotics. 
Category 1- Patients receiving immunomodulators. 
Category 2 - Patients receiving ASA-5 analogs. 
2.3.3 Genetic information  
Patients were concurrently contacted to solicit participation, acquire ethical 
consent and DNA samples (blood and/or saliva). In order to extract DNA, either 
peripheral blood or saliva samples were acquired from study participants. Peripheral 
blood (PB) samples were collected during the patients’ regular follow-up visit. Saliva 
was collected using ORAGENE KITS (DNA Genotek Inc., Ottawa, Canada) if blood 
samples were not being collected. Instructions for the appropriate collection of the saliva 
samples were given to each patient. For the subjects for whom a follow-up visit was not 
scheduled, the ORAGENE kits were mailed to them. Detailed instructions explaining the 
procedure for collecting saliva samples were sent to patients’ (families) and they were 
contacted by phone to re-enforce the process and offer assistance. By-and-large, the 
ORAGENE kits are very user-friendly and provide large quantity of high quality DNA. 
In addition to its effectiveness, and non-invasiveness, this method encourages subjects to 
consent and is an efficient alternative to collecting DNA from blood samples. Upon 
receipt, the saliva kits were stored at 4ºC. Subsequently DNA extraction was carried out 
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according to the extraction methods provided by the manufacturer. For PB samples, 
DNA extraction was performed using the commercially available PUREGENE DNA 
isolation kit. 
2.3.3.1 The variants selected for genotyping 
The main genetic variables of interest were single nucleotide polymorphisms (SNPs) in 
the NR3C1 (13 tag-SNPs and 1 functionally relevant SNP) and ABCB1 (14 tag-SNPs) 
genes. “Tagging” refers to methods used to select a minimal number of SNPs that retain 
as much as possible of the genetic variation of the full SNP set. Since many of the SNPs 
are in LD with others, information acquired from few typed SNPs may serve as proxies 
for neighbouring SNPs. There are several approaches for selecting tagging variations, but 
tagging results are highly concordant between different tagging methods, despite the fact 
that they often involve different sets of tagging SNPs [282]. The tag-SNPs were selected 
using the LDSELECT program (http://pga.gs.washington.edu), from a publicly available 
data base of genotyped SNPs of a population of European descent (Seattle SNP public 
database, which employs an LD-based SNP selection algorithm proposed by Carlson et 
al. [283]. The regions of 2000 bp from the 5’ and 3’ends of the genes were included in 
the selection process. Based on the Carlson algorithm, using a defined threshold for LD 
(r2) and specifying a minimum allele frequency (MAF), SNPs in LD each with other are 
grouped in subsets called bins. SNPs with the highest LD with others SNPs are selected 
(tagged) using an iterative algorithm. Accordingly selected tagging SNPs are 
representative of the un-assayed SNPs. Using this approach, 80% of haplotypes in 
population could be resolved. The selected tag-SNPs are described in Appendices 2 and 
3. 
2.3.3.2 Genotyping  
Genotyping was done using the GenomeLab Sequenom technology which is 
based on a newly developed genotyping assay termed iPLEX for use with the Mass 
ARRAY platform. Genotyping was performed using high-throughput facilities at the 
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McGill University Genome Quebec Innovation Center in Montreal 
(http://www.genomequebecplatforms.com/mcgill/home/index.aspx). The multiplexed 
genotyping assays rely on the molecular weight differences of DNA bases. Analyzing 
primer composition complementary to the target or by the addition of one or more non-
complementary 5' bases to the genotyping primers, mass spectra of interleaved 
genotyping products can be generated with no ambiguity in allele assignment [284]. 
2.4 Data management 
Clinical and demographic information was abstracted from patients’ charts and 
entered in a structured database. Each patient was provided an alternate ID to maintain 
confidentiality. The database was constructed such that non-corresponding entries could 
be easily identified at the time of data entry. Specific algorithms were incorporated in 
the database that used the raw information to create the appropriate variable definitions.  
For example, specific algorithms based on the HB index enabled the classification of 
disease activity based on the raw clinical information required for the definition. 
Similarly, algorithms were used to classify individuals into CS resistant or dependent. 
The algorithms were pilot tested to establish their accuracy in a sample of patients 
(n=40). 
The clinical database was linked to a genetic database that kept track of the DNA 
collection, extraction and analysis process.  
2.5 Quality control 
Quality control was ensured at each stage of date collection when possible.  
Clinical data were collected according to data entry forms and entered into the 
computerised data base. Data entry monitoring was performed regularly in order to 
identify the problems and errors that occurred, and these were discussed with project 
team. Data validation mechanisms were implemented in the data base itself, allowing 
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error detection by various means, such as refusal of incompatible values. The algorithms 
for study outcome definitions were implemented in the data base in order to diminish the 
future possibility of errors (Table VII-A below and Table VII-B below). In addition, to 
enhance accuracy, information on some key variables such as disease severity and the 
use of concomitant medication, was abstracted by two independent team members. In 
situations wherein abstracted clinical information did not enable adequate classification 
of certain patients, discussions were held with the team gastroenterologists to adopt the 
best available strategy (such as patient exclusion, use of alternative definitions and use 
of physician global assessment). 
Table VII-A: Algorithms used to assess study short term outcomes. 
Response Symptoms 
Complete Partial Absent 
(CS resistance) 
Bowel movement <=2 3 or 4 <=2 <=2 >4 
Pus, mucus 0 0 Or 1 1 not daily  
Blood 0 0 Or 1 1 not daily NA 
Abdominal pain 0 0 Or 1 1 not daily  
Fever 0  0  Or 1 
Weight loss 0  0  Or 1 
EIM 0  0  Or 1 
 
 
Table VII-B: Algorithms used to assess study long-term outcomes.  
Prolonged response CS dependence Other 
Relapse date < CS course end  Surgery No relapse  
Or relapse later than 180 
days from CS end 
Relapse date < = (CS course end+ 180 
days) 
Additional 
infection 
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In order to ensure the quality and quantity of DNA, genetic material was stored at 
-80 C and processed for DNA extraction according to standard protocols.  
The genotyping process involved a stringent protocol for maintaining the quality 
of the results acquired. The GenomeLab Sequenom Genotyping System offers multiple 
advantages including: flexible and efficient assay design (96% success rate), improved 
call rates (85%) and accuracy (error rate ≤ 0.5%) and, significantly reduced cost per 
genotype. After a reception in the laboratory, samples were re-quantified, the quality of 
the assays for a particular SNP were validated in a sample of DNA. If the SNP assay 
performed well in the validation step, then the rest of the samples were genotyped. To 
assess the reproducibility of the genotyping techniques, 5% of the samples were 
randomly re-genotyped for all the SNPs. Genotyping results of SNPs showing >95% 
concordances on the duplicated samples were retained. Those samples that did not show 
concordance for a particular SNP were excluded from the analysis for that SNP. Samples 
that did not show concordance for at least 90% of the SNPs were entirely excluded from 
the analysis. Similarly, SNPs with <90% call rates were excluded from analysis.  
Prior to statistical analysis, additional quality control measures were applied. 
Evaluation of genotyping errors was carried out by testing for HWE using exact test 
[285] as implemented in the software PLINK [286]. Departures from HWE may indicate 
genotypic errors in addition to indicating other phenomena such as (1) changing 
population structure due to non-random mating, (2) mutations and (3) chance. Testing 
for HWE is commonly used for quality control and is one of the few ways to identify 
systematic genotyping errors in unrelated individuals [287, 288]. SNPs not meeting 
HWE equilibrium (p<0.05) were excluded.  In order to avoid observer bias, genotyping 
personnel were blind to the phenotype of the patient.  
2.6 Study power 
In order to estimate the study power required to detect significant associations, 
the following parameters were considered: the available sample size, the proportion of 
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patients expected to be CS resistant (and CS dependent); the expected magnitude of the 
associations (Odds ratios); the frequencies of clinical predictors and allele frequencies of 
the genes variants in the population; and the expected alpha level of significance. We 
thus estimated the power of the study based on a fixed sample size.  
Based on the preliminary screening of patients diagnosed with CD at the two 
study centers for the considered time periods (1980-2007 at HSJ and 2000-2008 at 
CHEO) a maximum of ~750 CD patients were expected to be available. From among 
these ~60 - 70% (n=450) were expected to have been administered CS during the first 
year since diagnosis. From among these patients, based on prior experience, ~20 % 
(n=90) attrition was expected due to either missing clinical data, a lack of participation 
in the genetic study, inadequate DNA samples, genotyping errors or incomplete call 
rates. Rates of CS resistance and CS dependence were expected to be respectively ~ 15 
(n=54) and 40 % (n=150) in paediatric CD patients’ population based on previous 
literature [76, 110]. An approximate total of 300-360 patients were expected to be 
available for the analysis of the genetic and clinical associations.   
Population frequencies of the study markers ranged from 10 to 50 %, according 
to publicly accessible databases. According to paediatric studies [59, 66], at the time of 
diagnosis with CD, 51% of patients have ileo-colonic disease (L3), 36% have pure 
colonic (L2) disease and 6% have pure ileal (L1) disease. Concomitant upper tract 
disease involvement is found in approximately 50 % of patients and complicated disease 
behaviour (stricturing and/or penetrating) is present in about 10-20% of patients. EIM at 
diagnosis may be present in up to 35 % of patients depending on definitions used [289, 
290]. 
Basing on the above parameters, the power of the study to detect significant 
associations was determined. Appendices 4 and 5 present these calculations. As shown, 
the study was adequately powered (power ≥80%) to detect the effects (OR) ranging from 
1.8 and higher for the majority of clinical and demographical predictors with frequencies 
ranging from 25% to 50 % (Appendix 4). For genetic associations, the study was 
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estimated to have adequate power to detect the ORs of about 1.6 and 1.7 for the markers 
with minor frequency of 0.50 to 0.30, and to detect the ORs higher than 1.8 and 2.0 for 
the markers with MAF of 0.30 to 0.10 (Appendix 5). Power estimations were made 
using the software QUANTO (freely available from http://hydra.usc.edu/gxe).  
2.7 Statistical analyses 
2.7.1 Statistical methods, article 1 
To estimate the frequency of main study outcomes CS resistance and CS 
dependence a binomial distribution was assumed and 95% confidence intervals (95% 
CI) were estimated. To examine the role of potential clinical and demographic predictors 
of CS resistance and CS dependence, univariate and multivariate logistic regression 
analyses were carried out. Chi square (χ2) tests were used to estimate the differences in 
proportions of clinical and demographical variables between CS-resistant and CS-
responsive patients in the univariate analysis. In the multivariate analysis, variables such 
as concomitant medication, year of diagnosis, study center were considered as potential 
confounders. Considering that CS dependency is not a rare outcome, the odds ratios 
(OR) were corrected using method described by Zhang et al. [291]. The following 
formula was used to correct ORs in order to better represent the true relative risk: 
 
 
 
P0 indicates the incidence of the outcome of interest in the non-exposed group; OR, odds 
ratio; and RR, risk ratio. 
Statistical analyses were performed using  STATA, version 10.0 
(http://www.stata.com/).   
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2.7.2 Statistical methods, article 2 
The aim of this article was to examine the potential contribution of the variations 
of ABCB1 gene to CS dependent phenotype. Single-marker association, using various 
models of inheritance and haplotype analysis using tag-SNPs, was employed to explore 
possible associations between corticosteroid dependent phenotype and genetic variations 
in ABCB1/MDR1 gene. For single-marker analysis, logistic regression analysis was 
implemented to estimate the effect of tag-SNPs on risk of CS dependency. The minor 
allele of each SNP was considered to be the “risk-conferring allele”. Given that mode of 
inheritance of CS dependent phenotype is unknown and likely to be complex, various 
models (additive, genotypic, recessive and dominant) were investigated [292]. Odds 
ratios and 95% confidence intervals were estimated. Power to detect associations may be 
enhanced using haplotypes as the unit of analysis, as opposed to single alleles. There is 
strong evidence to indicate that several mutation within a gene can act as a “super-
allele” that can have an effect on phenotype [293, 294]. Haplotypes that are not 
functional can provide a greater power than single marker analyses due to ancestral 
structure captured in haplotype distribution [295]. The power advantage for haplotype-
based methods is expected to be greatest when the marker alleles are not in strong LD 
with each other, but in strong LD with the causative alleles [296]. Haplotype analysis is 
therefore appropriate for the tagging SNPs, as based on a priori selection criteria they are 
not in high LD with each other. Haplotype analysis was carried out using methods 
described by Barrett et al. [297] and implemented in the HAPLOVIEW software 
(www.broad.mit.edu/mpg/haploview). Associations were evaluated by comparing the 
frequency of each haplotype among the cases and controls. Counts for the haplotype 
association test were obtained by summing the fractional likelihoods of each individual 
for each haplotype.   
Multiple testing is a common problem in genetic association studies leading to 
increased probability of false positive results given that numerous markers are studied.  
For single-marker associations, the Bonferroni correction was applied. The Bonferroni 
adjustment assumes that the hypothesis tests are not correlated, thus it is considered to 
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be overly conservative in the context of genetic association studies. In case of our study 
where markers are tag-SNP, this approach is appropriate as tag-SNPs by definition are 
not supposed to be in high LD, thus a test’s independence requirements holds. In order 
to obtain a measure of significance corrected for multiple testing bias, haplotype 
association results were permuted (n=1000) using HAPLOVIEW. The permutations 
approach allows for the independent correction of each p-value. In this approach, after p-
values are calculated for the original data set, a pseudo-data set is created by randomly 
dividing the data into response and non-response groups and the analysis is then 
repeated to compute p-values using the new data set. This process is repeated multiple 
times, and the minimum p-value from the original data is compared to the distribution of 
minimum p-values obtained from the permuted data. The proportion of permuted p-
values that are less than the minimum p-value from the original data is the adjusted p-
value. 
2.7.3 Statistical methods, article 3 
The statistical methods utilized for this article were similar to those implemented 
for article 2 above. Single-marker and haplotype association analyses using tag-SNPs 
were carried out. General genotype, additive, dominant and recessive models were 
examined [292] using logistic regression method implemented in STATA software. 
Haplotype analysis was carried out using on the maximum likelihood based method 
implemented in HAPLOVIEW [297].  
2.7.4 Imputation of un-genotyped markers, articles 2 and 3 
The imputation procedure implemented in the MACH software [298] 
(http://www.sph.umich.edu/csg/abecasis/MACH/) was used to examine potential 
associations between CS dependence and the un-genotyped SNPs. The term “genotype 
imputation” refers to the procedure of predicting or imputing SNPs that are not directly 
assayed in the samples. The genotypes are imputed with uncertainty and a probability 
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distribution over all three possible genotypes is produced. The use of the “in silico” 
genotypes helps to boost the number of studied SNPs. This technique was shown to be 
more powerful than the original analysis of directly genotyped markers in genome wide 
association studies (GWAS). Another advantage is that the imputation of un-typed 
variants can help to identify rare causal variants [299]. The HapMap haplotypes are 
widely used to carry out imputation in samples that have close ancestry to those in the 
HapMap panels. We used HapMap CEU population panel (Release 22) as the most 
corresponding to our population’s background. SNPs located within1000 bp around gene 
boundaries (putative transcription start sites) were included. There are several 
imputation methods based on different algorithms, yet all methods attempt to identify 
sharing between the underlying haplotypes of the study individuals and the haplotypes in 
the reference set and use this sharing to impute the missing alleles in study individuals. 
We used the Markov Chain Haplotyping (MACH) technique implemented in MACH as 
this method outperforms other available methods [300]. Additionally, in order to 
validate the results we used the BEAGLE [301] software which uses the hidden Markov 
model (HMM) algorithm (available at http://www.stat.auckland.ac.nz/~bbrowning/ 
beagle/). In order to access the quality of imputed genotypes at SNPs, MACH uses r2 
which is the ratio of the empirically observed variance of the allele dosage to the 
expected binomial variance at Hardy–Weinberg equilibrium. We applied the 
recommended threshold of r2 = 0.30 to filter out the SNPs with better quality of 
imputation that we have used for subsequent analyses. 
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The results described in this chapter represent those described in the three articles 
that are part of this thesis. First article of this thesis describes rates of corticosteroid 
dependency in our study cohort and explores potential clinical predictors of this 
condition. The second and third articles examined the associations between variants in 
two genes ABCB1 and NR3C1 and the CS-dependent phenotype. The first author has 
made an essential contribution at fundamental stages of study design, implementation, 
data analysis, interpretation and dissemination of results. In addition, she participated in 
identifying and recruiting patients at the Ste-Justine study site. She has also coordinated 
the implementation of a data collection tool on a web-based database. Clinical data at 
Ste-Justine Hospital, used for CD’s phenotype definition and study outcomes 
assessment, was abstracted and input into the database by the first author, who also has 
reviewed the medical charts. The data extraction from the clinical data base, as well as 
data management, cleaning and analysis of clinical and genetic data was also done by 
the first author. The first author has written the manuscripts presented here. Considering 
the nature of the field, the ultimate successful conduct of the thesis led by the first 
author, was based on a team effort where the collaborating authors provided guidance 
and suggestions on the appropriateness of the study design, coordination of its 
implementation, the conduct of the statistical analyses and interpretation of the results. 
The results were presented (oral and/or poster presentations) at numerous congresses and 
conferences† 
                                               
† The Ste-Justine Hospital students’ conference, 2007, the 75th ACFAS Congress, 7- 11 mai 2007, 
Université du Québec, Trois-Rivières, the 77th ACFAS Congress, May11-15, 2009 in Ottawa, the 
Canadian Society of Epidemiology and Biostatistics National Student Conference held on May 23-24, 
2009 in Ottawa, the international congress of gastroenterology, Digestive Diseases Week, May 19-24, 
2007, Washington, USA, Digestive Diseases Week, May 30-June 4, 2009, Chicago, USA, Digestive 
Disease Week, May 1-5, 2010, New Orleans, USA, 1st Bruce Kaufman/McGill Symposium on 
Immunoregulation and Inflammatory Bowel Disease, September 24, 2010, Montreal. 
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3.1.1 Abstract  
Background 
Although a mainstay of treatment of moderate to severe Crohn’s disease (CD), 
corticosteroids use presents significant challenges because of large inter-individual 
variability in response. Corticosteroid-dependence is of particular concern in children 
wherein high rates have been reported.  
Aims 
We examined the burden of corticosteroid-resistance and dependence in a well-
characterized cohort of paediatric CD patients and investigated potential predictors of 
response. 
Methods 
Children diagnosed with CD (<18 yr), were recruited from two Canadian 
pediatric gastroenterology clinics. Immediate and long-term responses to corticosteroid 
therapy were retrospectively ascertained. Response rates (resistance & dependence) 
were estimated and potential predictors assessed using logistic regression analysis. 
Results 
Of the 645 CD patients, 364 (56.2%) received corticosteroids. The frequency of 
corticosteroid-resistance was (8.0%) (95% CI: 5.0 % - 11%) and 40.9% (95% CI: 39.0% 
- 46.0%) became dependent. In univariate analysis female gender (OR = 2.49, 95% CI: 
1.1-5.5, p = 0.025), disease severity (OR=2.43, 95% CI: 1.10-5.38, p=0.029) and 
complicated disease (OR = 2.75, 95 % CI: 1.18-6.41, p = 0.019) were associated with 
resistance. In multivariate analysis lower age at diagnosis (OR = 1.34, 95% CI: 1.03-
3.01, p = 0.040), coexisting upper digestive tract involvement (OR=1.35, 95% CI: 1.06-
3.07, p =0.031) and concomitant immunomodulators use (OR=0.35, 95% CI: 0.16 - 
0.75, p=0.007) were significantly associated with steroid dependency. 
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Conclusions 
Our results demonstrate that steroid dependency is a frequent complication in 
children with CD. Children with an earlier age at diagnosis and coexisting upper 
digestive tract involvement could be potentially targeted for steroid-sparing therapy.  
 
Keywords: Crohn’s disease, paediatrics, corticosteroids, corticosteroid-
dependence, outcomes, predictors 
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3.1.2 Introduction  
Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) 
characterized by chronic inflammation of the digestive tract, with frequent flares and a 
progressive clinical course with many complications. During the past decades the 
incidence and prevalence of CD have increased in most western countries including 
Canada.1-5 Of relevance, it has become apparent that the incidence of CD in children and 
young adults is on the rise, with rates approaching that in adults.2,5 The latter is of 
particular concern as CD in children can severely impact physical and psychological 
wellbeing and can be associated with frequent surgery and growth delay.   
Corticosteroids are the mainstay of CD therapy effectively used to induce 
remission which is an important goal in therapeutic management of CD. However, large 
inter-individual variability in response to corticosteroid treatment has been noted that 
presents significant clinical challenges. Some patients do not respond to the initial 
treatment (resistant) and others require corticosteroids for long periods (dependent). 
Resistance and dependence to corticosteroids therapy can contribute to inadequate 
disease control and prolonged drug exposure potentially increasing the risk for steroid 
associated side-effects.6-12 Indeed, corticosteroid resistance and dependence are 
considered markers of treatment failure.13 Corticosteroid response is of particular 
importance in children diagnosed with CD as the consequences of failed or long-
standing therapy can be severe.14,15 
Epidemiological studies in adult populations indicate that the rates of resistance 
to corticosteroids (20%) and dependence (28-38%) are quite high. Some studies focused 
on paediatric population 16,17 suggest that rates are similarly high and in some instances 
higher than those among adults. It is unclear what factors contribute to varying 
responses to corticosteroids in children. Previous studies were mainly retrospective 
evaluations based on small cohorts of patients and thus were insufficiently powered to 
investigate actual rates of steroid responsiveness and factors that could influence these 
rates. In an attempt to further clarify the clinical variation of response to corticosteroids 
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and to investigate potential markers we studied a large population of well-characterized 
Canadian children diagnosed with CD and administered corticosteroids for therapy.  
3.1.3 Methods 
3.1.3.1 Study design, population and data collection 
A retrospective cohort study was carried out at two tertiary Canadian 
gastroenterology clinics: Ste-Justine Hospital (SJH), Montreal and Children's Hospital of 
Eastern Ontario (CHEO), Ottawa. Patients were children < 18 years of age diagnosed 
with CD using standard clinical, histological, radiological and endoscopic criteria.18,19 
For the Montreal site, all patients diagnosed between 1980 and 2008 and for the Ottawa 
site, patients newly diagnosed with CD between 2000 and 2008 were included. The 
medical records of these children were retrospectively reviewed to identify patients who 
received corticosteroids for the first time within one year since diagnosis. Clinical details 
such as disease characteristics (localization and behaviour) at diagnosis, corticosteroids 
therapy, concomitant medication, extra-intestinal manifestations (EIM), surgeries, 
family history of IBD and growth retardation (Montreal cohort only) were abstracted. 
Information on racial and ethnic background was acquired by administering a 
supplementary questionnaire. Data abstraction at the Montreal site was carried out by 1 
investigator (AK) with information on key variables such as disease activity, 
concomitant medication and steroid dependence validated by a second investigator 
(DKA). Discrepancies, if any, were resolved by consensus with the site 
gastroenterologist (CD). For the Ottawa center, data abstraction was carried out by a 
trained research nurse under the supervision of the gastroenterologist (DRM). 
CD was classified according to the World Gastroenterology Organization’s 
Montreal classification.20 To evaluate response to corticosteroid therapy, we assessed the 
immediate and long-term outcomes of corticosteroid therapy, based on adaptation of 
previously reported criteria.21,22 
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Immediate response  
Complete remission - total regression of clinical symptoms within 30 days, with 
2 bowel movements a day and no pain, no blood, pus or mucus in stool, fever, weight 
loss or extra-intestinal manifestations. 
Partial remission - regression of symptoms within 30 days, with 4 bowel 
movements a day, less abdominal pain and no fever, weight loss or extra-intestinal 
manifestations. 
Non-response - no improvement within 30 days.  
Long-term response 
Corticosteroid dependence - reoccurrence of clinical symptoms during the 
weaning period or clinical relapse occurring during 180 days following the end of 
treatment, requiring the reintroduction of corticosteroids. 
Prolonged response - maintenance of complete or partial remission after 
treatment had finished. 
Other - clinical relapse occurring later than 180 days since discontinuation of 
corticosteroids and management with alternatives. Also included in this category were 
patients who had moderate to severe relapse complicated by infections such as cl. 
difficile, Epstein-Bar virus (EBV)23 and some patients who had undergone surgery.   
Concomitant medication for the purpose of this study was considered if it was 
introduced during initial corticosteroid therapy before the start of corticosteroid tapering 
and not if it was given in response to disease relapse.  
Disease severity was assessed using a modified Harvey Bradshaw Index (HBI)24 
at the Montreal site and using Physician Global Assessment Index at the Ottawa site. 
Both these indices have been shown to be strongly correlated 25 enabling the 
combination of data across the two sites.  
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The institutional ethical boards of the two study centers approved the study and 
consent was acquired from the patients.  
Statistical analyses 
The frequencies (proportions) of corticosteroid response (resistance & 
dependence) were estimated along with their 95% confidence intervals (95% CI) 
assuming a binomial distribution. Univariate logistic regression analyses were carried 
out to examine the influence of potential predictors such as gender, age at diagnosis 
(categorized as ≤ 10.7 yr and > 10.7 yr based on the distribution in the cohort), family 
history of IBD (yes/no), EIM (yes/no), use of concomitant medication (categorized 
according to type of medication), clinical phenotypes of CD (disease localization and 
behaviour) on response (resistant versus non-resistant and dependent versus non-
dependent). In addition, for corticosteroid dependence, a multivariate logistic regression 
was applied to the data to jointly explore the influence of potential predictors. The latter 
was not implemented for corticosteroid resistance due to the limited number of subjects. 
Odds ratios (OR) and respective 95% CI were estimated. Potential temporal and clinic-
specific differences in CD management were accounted for by incorporating 
representative variables in the multivariate logistic model. As for a cohort study, when 
the frequency of the outcome (corticosteroid response in the present study) is greater 
than 10%, the estimated odds ratio can overestimate the relative risk, we corrected the 
ORs’ (and corresponding 95% CI) using methods described by Zhang et al.26 All 
analyses were carried out using STATA (Stata Statistical Software: Release 10. College 
Station, TX: StataCorp LP.) 
3.1.4 Results 
Of the 645 patients diagnosed with CD during the study period, 364 (56.2%) 
were administered corticosteroids during the first year following diagnosis. The mean 
age (±SD) at diagnosis was 12.5 (±3.2) (Table I on page 90). The majority of patients 
were male (54.9 %), had inflammatory disease phenotype (84.6%) and ileo-colonic 
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disease (51.7%) at diagnosis. Most patients (95.6%) were of European ancestry. 
Corticosteroid treatment included intravenous or oral prednisone with a starting dose of 
1 mg/kg per day for 2 to 4 weeks. In patients requiring intravenous treatment, the 
duration of the corticosteroid treatment was about one week with conversion to oral 
corticosteroids subsequently. Medication dose was tapered within 8 to 12 weeks using 
various regimens, but the most frequently used scheme consisted of a decrease of the 
prednisone dose by 5 mg per week. Budesonide was used in 11.8 % of patients with a 
starting dose of 9 mg per day and tapered off in decrements of 3 mg over three 4-week 
time intervals. 
The mean (±SD) duration of corticosteroid treatment was 148.2 (±82.4) days. 
Following treatment initiation, 94 patients (25.8%) (Figure 1 on page 98) were 
continuously using corticosteroids for 6 months and 22 patients (6.0%) were on therapy 
until the end of one year. On the 30th day after the initiation of corticosteroids 29 (8.0%) 
(95 % CI: 5.0% - 11%) patients did not respond (resistant), 135 (37.0%) (95% CI: 32.0% 
- 42.0%) patients had achieved partial response and 200 (55.0%) (95% CI: 50.0% - 
60.0%) had completely responded (Figure 2 on page 99).  
From among those who initially responded, 148 (44.2%) (95% CI: 39.0% - 
50.0%) became dependent (long-term outcome). One patient, initially nonresponsive on 
the 30th day, later became dependent. From among the patients who initially responded 
to corticosteroids, 9 (2.7%) had a subsequent course of corticosteroid therapy but did not 
meet the definition of dependency as they had a clinical relapse occurring later than 180 
days following the end of first treatment. Four (1.2%) initially responsive patients had a 
moderate to severe relapse due to concomitant infections (such as cl. difficile or EBV), 7 
(2.1%) had a surgery, 3 (0.9%) had a moderate to severe relapse but were not 
administered additional corticosteroids and treated with other medications. Overall, 17 
(4.7%) patients had surgery at some point during 1 year. Patients non-responsive to 
corticosteroids were more likely to undergo surgery in comparison to those who initially 
responded (17.2% versus 3.6%). 
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The overall frequency of corticosteroid dependence (Figure 2 on page 99), 
(including responders and non-responders) was 40.9% (95% CI: 0.39 - 0.46). The 
frequencies of corticosteroid dependency between the two study centers (Montreal & 
Ottawa) were comparable (38.4% versus 41.7%, p = 0.58). Similarly, no temporal 
differences in the rates of corticosteroid dependency were noted (43.9% prior to 2000 
and 39.4% in subsequent years, p = 0.411). The frequencies of corticosteroid-
dependency were significantly different (p-value = 0.003) between the patients’ 
receiving different types of concomitant medication (none, immunomodulators and 
ASA-5).  
Univariate analysis showed that non-response (resistance) to corticosteroids was 
more common in females (OR = 2.49, 95% CI: 1.10 - 5.50, p = 0.025) as compared to 
males (Table II on page 92). Similarly, children with complicated disease behaviour 
(stricturing and/or penetrating) were significantly (OR = 2.75, 95% CI: 1.18 - 6.41, p = 
0.019) less likely to respond to corticosteroids. Children who did not respond to therapy 
were more likely to have surgery (OR = 5.6, 95% CI: 1.82 - 17.2, p = 0.003). Similarly, 
children with severe disease at the commencement of steroid therapy were more likely to 
become resistant (OR=2.43, 95% CI: 1.10-5.38, p=0.029). For long-term response 
(Table III on page 94), in univariate analysis, children with coexisting upper digestive 
tract involvement (L4) (OR = 1.72, 95% CI: 1.05 - 2.83, p = 0.031) and those less than 
10.7 years of age at diagnosis (OR = 1.82, 95% CI: 1.10 - 3.03, p = 0.022) were more 
likely to become corticosteroid-dependent. Concurrent use of immunomodulators was 
negatively associated with occurrence of corticosteroid-dependency (OR = 0.38, 95% 
CI: 0.19 - 0.77, p = 0.007). These associations persisted when other potential predictors 
were adjusted for in the logistic regression model (Table III on page 94). Growth 
retardation was not associated with either steroid resistance or dependence in the 
Montreal cohort (data not acquired for the Ottawa cohort). 
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3.1.5 Discussion 
In a large cohort of paediatric CD patients administered corticosteroids, we 
observed that the frequencies of corticosteroid resistance and dependence were 8% and 
40.9% respectively. Girls, patients with complications at diagnosis and with severe 
disease activity were more likely to be resistant to corticosteroids. Children diagnosed 
with CD at a younger age (≤ 10.7 yr), and having coexisting upper digestive tract 
involvement were more likely to become corticosteroid dependent. Concomitant use of 
immunomodulators was associated with significantly lower risks for steroid dependence. 
Importantly, more than 25% of the patients were continuously using corticosteroids for 
at least 6 months.  
Corticosteroids are an important and effective form of therapy in IBD. Knowing 
who is best suited for therapy is an important clinical question as known side effects 
such as moon facies, acne and psychological disturbances can occur even after short 
term treatment. For example, 55% of patients in the prednisone arm of a randomized 
controlled trial developed side effects such as moon facies, acne, swollen ankles, easy 
bruising and insomnia after only 10-weeks of treatment.27 Other side effects of 
corticosteroids after more than 12 weeks treatment28 include striae, cataract, myopathy, 
susceptibility to infections, and growth retardation. Although the greatest decrease in 
bone density occurs in the first few months of therapy 29 prolonged corticosteroid 
therapy may contribute to further decrease.30 In paediatric patients with CD it is 
suggested that steroid therapy can explain up to 20% of variation in bone mineral 
density of the lumbar spine.8 Thus, minimizing adverse effects and maximizing benefit 
of corticosteroid therapy is an important clinical challenge. 
Our observed frequencies of corticosteroid resistance (8%) are within the range 
reported in earlier paediatric-CD studies carried out worldwide.17, 31,32 For example, in a 
study carried out in France31 the authors reported corticosteroid resistant rates to be 
≈5%, whereas in a study carried out in the Olmsted County in USA, ≈12% of the 
children were resistant to corticosteroids.32 Higher rates of resistance (17%) were 
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reported by Markowitz et al17 probably due to the use of different criteria (assessment of 
response after 3 months after therapy initiation) for assessing non-response. 
Corticosteroid dependence rates in previous paediatric studies 17,31,32 that used criteria 
similar to that utilized in our study, range from 25% to 31%. These rates are lower than 
what we observed (40.9%). In two studies17, 31 the frequency of concomitant use of 
immunomodulators (61% and 81%) was higher than that in our cohort (37.9%), 
probably explaining the differences in rates observed. The study by Tung et al32, was 
based on a small cohort (n = 26). In the North American multi-centered randomized trial 
in paediatric CD (6-mercaptopurine versus corticosteroids alone in the placebo arm)16 
noted rates of dependency were expectedly higher (50%). Most of the patients in our 
cohort were diagnosed prior to the introduction of anti-TNF and thus notably the rate of 
anti-TNF therapy was low in our patient population (≈6%). In previous adult population- 
and hospital-based studies 13,21,22,33,34 using similar definitions of response to 
corticosteroids, rates of resistance and dependency ranged from 16-20% and 20-38% 
respectively. It is interesting to note that overall slightly higher rates of resistance have 
been reported in adults than in paediatric studies, with the exception of a Chinese study 
in adult-CD that reported low rates of non-response (6%).33 Potential differences in rates 
of resistance between paediatric and adult-onset CD may be related to the age-dependent 
expression of the glucocorticoid receptor as shown in a recent experimental study by 
Kiela et al.35  
In contrast to rates of resistance, rates of dependency appear to be higher in 
paediatric-CD in comparison to adult-CD. These differences may not be related to 
differences in use of concomitant therapy as even among those children who do not 
receive concomitant immunomodulators, rates of dependence are higher (50%)16 in 
comparison with adults who likewise are treated only with corticosteroids (36%)21. 
Other biological mechanisms need to be examined to dissect these potential differences 
in rates.  
As identification of potential predictors of corticosteroid response would be 
important, we examined whether specific clinical and/or demographic characteristics 
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could be related to the various outcomes of corticosteroid treatment. Consistent with 
previous studies 33,36 we observed that female gender and complicated disease were 
associated with non-response to corticosteroids. Similarly our observations of the 
association between early age at diagnosis and corticosteroid dependency have been 
reported earlier.37 Furthermore, the protective effects of concomitant immunomodulator 
use on steroid dependency reported previously16,38 was confirmed in our cohort. Our 
finding of association between concomitant upper tract involvement and corticosteroid 
dependence is however novel. Other potential predictors for dependence, such as growth 
delay 17 and thrombocytosis 33 have been suggested. In a subset of the data, we did not 
observe any associations between growth retardation and steroid response. Variability in 
classification of growth impairment/retardation (height <3 percentile in our cohort) 
between studies may have resulted in varying findings. Taken together, the strongest risk 
factors for dependency appear to be early-age of diagnosis and coexisting upper 
digestive disease localization. Further studies are required to examine potential reasons 
for these associations and to explore whether alternatives to corticosteroids could be 
considered in these children. 
Our study was hospital-based and our observed higher rates of dependence may 
have resulted from an overall higher clinical severity of the patient population. However, 
we did not observe any association between the presence of complications at diagnosis 
and corticosteroid dependence. We were unable to take into account various 
corticosteroid-tapering regimens when examining responses to therapy. Although, this 
may have affected our estimation of rates of non-response, as shown previously, rates of 
dependency are unlikely to be influenced by the choice of weaning scheme 
implemented.39,40 It is likely that despite the large cohort, the retrospective nature of the 
study may have introduced bias in the determination of response predictors. By-and-
large we were successfully able to implement reported criteria for defining corticosteroid 
responses. A small number of patients (n=7) were however assigned to the partial 
response category, as sufficient information to classify them as complete responders was 
not available. Such potential misclassification could have influenced the rates for 
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immediate response but unlikely to have influenced the examination of predictors, given 
that the information on predictors (at diagnosis) was abstracted prior to knowledge on 
the responses.  
In conclusion, in a cohort of paediatric-onset CD, we observed that corticosteroid 
dependence is a significant clinical problem, in particular in younger patients, leading to 
prolonged exposure to corticosteroids. These findings highlight the need for the 
determination of reliable markers (biologic and/or genetic), that will enable the early 
identification of patients, susceptible for corticosteroid dependency. 
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3.1.7 Tables 
Table I: Demographic and clinical characteristics of the CD patients. 
Patient’s characteristic 
 
All 
N = 364 
Montreal 
N = 278  
Ottawa 
N = 86  
Age at diagnosis, years, Mean 12.5 (±3.2) 12.4 (±3.3) 12.5 (±2.9) 
Age at diagnosis, years, by quartiles     
1st Q 10.7 10.7 11.0   
2nd Q 12.8 12.8 12.6 
3rd Q 14.9 14.9 14.6 
Year of diagnosis (%)    
1980-1990 123 (33.8) 123 (44.24) 0 
1991-2000 82 (22.5) 73 (26.26) 9 (10.47) 
>2000 159 (43.7) 82 (29.50) 77 (89.53) 
Gender (%)    
Females 164 (45.1) 132 ( 47.5) 32 (37.2)   
Males 200 (54.9) 146 (52.5) 54 (62.8) 
European ancestry (%)    
Yes 348 (95.6) 262 (94.2) 86 (100.0) 
No 16 (4.4) 16 (5.8) 0 
Duration of corticosteroid therapy  148.2 (±82.15) 145.58 
(±87.04) 
153.39(±63.96) 
(days), mean (±SD)    
Disease localization (%)*     
L1±L4 70 (19.2) 40 (14.4) 30 (34.9) 
L2±L4 106 (29.1) 73 (26.3) 33 (38.4) 
L3±L4 188 (51.7) 165 (59.3) 23 (26.7) 
Co-existing L4 (%)    
Yes 101 (27.8) 68 (24.5) 33 (38.4) 
No 263 (72.2) 210 (75.5) 53 (61.6) 
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Table I. (Continued) 
Patient’s characteristic 
 
All 
N = 364 
Montreal 
N = 278  
Ottawa 
N = 86  
Disease behaviour (%)*    
B1±p 308 (84.6) 245 (88.1) 63 (73.3) 
B2±p 32 (8.8) 21 (7.6) 11 (12.8) 
B3±p 24 (6.6) 12 (4.3) 12 (13.9) 
EIM (%)†    
Yes 88 (24.2) 70 (25.2) 18 (20.9)  
No 276 (75.8) 208 (74.8) 68 (79.1) 
Family history of IBD‡ (%)    
Yes 43 (11.8) 32 (11.5) 11 (12.8) 
No 321 (88.2) 246 (88.5) 75 (87.2) 
Concomitant medication (%)    
None  56 (15.4) 33 (11.9) 23 (26.8) 
Immunomodulators 138 (37.9) 93 (33.4) 45 (52.3) 
ASA 170 (46.7) 152 (54.7) 18 (20.9) 
Use of anti-TNF§ (%)    
Yes 21 (5.8) 14 (5.0) 7 ( 8.1) 
No 343 (94.2) 264 (95.0) 79 (91.9) 
Surgery (%)    
No 347 (95.3) 265 (95.3) 82 (95.3) 
Yes 17 (4.7) 13 (4.7)   4 (4.7) 
Disease severity††    
Mild-moderate 198 (54.4) 154 (55.4) 44 (51.2) 
Severe 166 (45.60) 124 (44.6) 42 (48.8) 
Growth retardation‡‡ (%)    
Yes - 72 (25.9) - 
No - 206 (74.1)  - 
 
  
91 
 
Table I (Continued) 
*Disease localization and behaviour classified according to World Gastroenterology 
Organisation’s Montreal classification.  
† Extra intestinal manifestations. 
‡ IBD in first-degree relatives.  
§ Anti-TNF administered in response to corticosteroid dependency, resistance, side 
effects or failure of immunomodulators. 
†† HBI for Montreal and Physician General assessment for Ottawa patients. 
‡‡ Data available for Montreal cohort only. 
L1 - Ileal 
L2 - Colonic 
L3 - Ileo-colonic 
L4 - Upper digestive tract 
B1 - Inflammatory disease 
B2 - Stricturing disease 
B3 - Penetrating disease 
p - Perianal disease 
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Table II: Univariate analysis of short term response to corticosteroids in CD patients. 
 
Patient’s characteristics N = 364 
 Non response 
N = 29 
Response  
N = 335 
OR (CI 95%) P value 
Age at diagnosis, (%)     
1st Q  4 (13.8)  87 (26.0) 0.46 (0.15 - 1.35) 0.156 
2nd 3rd and 4t h Q 25 (86.2) 248 (74.0)   
Year of diagnosis (%)     
<2000 10 (34.5) 113 (33.7)   
>2000 19 (65.5) 222 (66.3) 0.96 (0.44 - 2.1) 0.935 
Study centre (%)     
Montreal 24 (82.8) 254 (75.8)  1.53 (0.56 - 4.14) 0.402 
Ottawa 5 (17.2) 81 (24.2)   
Gender (%)     
Females 19 (65.0) 145 (43.3) 2.49 (1.10 - 5.50) 0.025 
Males 10 (35.0) 190 (56.7)   
European ancestry (%)     
Yes 29 (100.0) 319 (95.2) -  
No - 16 (4.8) - 0.229 
Duration of corticosteroid 
therapy (days), mean (±SD) 
109.8 (15.8) 151.6 (4.5)  0.004 
Disease localization (%)     
L1±L4  3 (10.3)  67 (20.0) Reference  
L2±L4  11 (37.9) 95 (28.4) 2.58 (0.69 - 9.62) 0.157 
L3±L4  15 (51.7) 173 (51.6) 1.94 (0.54 - 6.90) 0.308 
Coexisting L4 (%)     
Yes 5 (17.2) 96 (28.7) 0.52 (0.19 - 1.40) 0.195 
No 24 (82.8) 239 (71.3)   
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Table II. (Continued) 
Patient’s characteristics N = 364 
 Non response 
N = 29 
Response  
N = 335 
OR (CI 95%) P value 
Disease behaviour (%)     
Complicated 9 (31.0) 47 (14.0) 2.75 (1.18 - 6.41) 0.019 
Inflammatory 20 (69.0) 288 (86.0)   
Family history of IBD* (%)     
Yes 4 (13.8) 39 (11.6) 1.20 (0.40 - 3.7) 0.731 
No 25 (86.2) 296 (88.4)   
EIM† (%)     
Yes 9 (31.0) 79 (23.6) 0.80 (0.32 - 2.04) 0.648 
No 20 (69.0) 256 (76.4)   
Concomitant medication (%)     
None 6 (20.7) 50 (14.9) Reference  
Immunomodulators 16 (55.2)  122 (36.4) 1.09 (0.40 - 2.9) 0.861 
ASA 7 (24.1) 163 (48.7 ) 0.36 (0.11 - 1.11) 0.076 
Surgery (%)     
Yes 5 (17.2) 12 (3.6) 5.6 (1.82 - 17.23) 0.003 
No 24 (82.8) 323 (96.4)   
Disease severity (%)     
Mild-moderate 10 (34.5) 188 (56.1)   
Severe 19 (65.5) 147 (43.9) 2.43 (1.10 - 5.38) 0.029 
Growth retardation‡ (%)     
Yes 4 (16.7) 68 (26.8) 0.55 (0.21 - 1.86) 0.286 
No 20 (83.3) 186 (73.2)   
* IBD in first-degree relatives.  
† Extra intestinal manifestations.  
‡ Data available for Montreal cohort only. 
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Table III: Univariate and multivariate analyses of long term response to corticosteroids in CD patients. 
 
Patient’s characteristics  
N = 313 
Univariate analysis  
 
Multivariate analysis 
 
Dependence Prolonged    
N = 149 N = 164 OR (CI 95%) Adjusted OR P value 
Age at diagnosis (%)      
1st Q  48 (32.2) 34 (20.7)  1.82 (1.10 - 3.03) ‡ 1.34* (1.03 – 3.01) 0.040 
2nd 3rd and 4t h Q 101 (67.8) 130 (79.3)    
Year of diagnosis (%)      
<2000 54 (36.2) 52 (31.7)    
>2000 95 (63.8) 112 (68.3) 0.82 (0.51 - 1.30) 1.44 (0.80 - 2.60) 0.227 
Study centre (%)      
Montreal 116 (77.8) 122 (74.4)  1.21 (0.72 - 2.04) 1.13 (0.58 - 2.21) 0.579 
Ottawa 33 (22.15) 42 (25.6)    
Gender (%)      
Females 70 (47.0) 69 (42.1) 1.22 (0.78 - 1.90) 1.36 (0.83 - 2.21)  0.217 
Males  79 (53.0) 95(57.9)    
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Table III (Continued)  
 
Patient’s characteristics  
N = 313 
 
Univariate analysis  
 
Multivariate analysis 
 
 Dependence Prolonged    
 N = 149 N = 164 OR (CI 95%) Adjusted OR P value 
European ancestry (%)      
Yes 143 (96.0) 156 (95.1) 1.22 (0.41 - 3.60) 1.34 (0.43- 4.21) 0.611  
No 6 (4.0) 8 (4.9)    
Disease behaviour (%)       
Complicated 18 (12.1) 20 (12.2) 0.99 (0.50 - 1.95) 1.10 (0.51 - 2.38) 0.806 
Inflammatory  131 (87.9) 144 (87.8)    
Disease localization (%)      
L1±L4 24 (16.1) 36 (21.9) Reference Reference  
L2±L4 44 (29.5) 48 (29.3) 1.37 (0.71 - 2.65) 1.46 (0.72 - 2.95) 0.295 
L3±L4  81 (54.4) 80 (48.8) 1.52 (0.83 - 2.77) 1.63 (0.84 - 3.16) 0.150 
Coexisting L4 (%)      
Yes 51 (34.2) 38 (23.2) 1.72 (1.05 - 2.83)** 1.35* (1.06 - 3.07) 0.031 
No 98 (65.8)  126 (76.8)    
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Table III ( Continued) 
 
Patient’s characteristics  
N = 313 
  
Univariate analysis  
 
Multivariate 
analysis 
 
 
 Dependence Prolonged    
 N = 149 N = 164 OR (CI 95%) Adjusted OR P value 
Family history of IBD (%)      
Yes 16 (10.7)  21 (12.8) 0.82 (0.41 - 1.64) 0.94 (0.45 - 1.96) 0.877 
No 133 (89.3)  143 (87.2)    
EIM (%)†      
Yes 39 (26.2) 38 (23.2) 1.17 (0.70 - 1.97) 1.21 (0.70 - 2.09) 0.489 
No 110 (73.8) 126 (76.8)    
Concomitant medication (%)      
None 27 (18.1) 19 (11.6) Reference Reference  
Immunomodulators 41 (27.5) 75 (45.7) 0.38 (0.19 - 0.77) ††  0.35 (0.16 - 0.75) 0.007 
ASA 81 (54.4) 70 (42.7) 0.81 (0.42-1.59) 0.94 (0.45 - 1.96) 0.871 
Disease severity (%)       
Mild- moderate  78 (52.4) 95 (57.9)    
Severe  71(47.6) 69 (42.1) 1.25 (0.80 - 1.96) 1.45 (0.89 – 2.35) 0.136 
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Table III (Continued) 
 
Patient’s characteristics  
N = 313 
Univariate analysis  
 
Multivariate analysis  
 Dependence Prolonged    
 N = 149 N = 164 OR (CI 95%) Adjusted OR P value 
Growth retardation (%)      
Yes 34 (22.8) 28 (17.1) 1.39 (0.78 - 2.49) - - 
No 115 (77.2) 136 (82.9)    
*Bias corrected estimates26 
† Extra intestinal manifestations.   
‡ p-value = 0.022.  
** p-value = 0.031.  
††p-value = 0.007  
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Figure 1. Proportion of patients on continuous corticosteroid therapy during the year 
following initiation. 
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Figure 2. Short- and long-term responses in CD patients after the first course of 
corticosteroids
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3.2.1 Abstract  
Background 
Corticosteroids (CS) effectively induce remission in patients with moderate to 
severe Crohn’s disease (CD). However, CS dependence in children is a significant 
clinical problem associated with numerous side-effects. Identification of molecular 
markers of CS dependence is of paramount importance. The ABCB1 gene codes for P-
glycoprotein a transporter involved in the metabolism of CS. We examined whether 
DNA variation in the ABCB1 gene was associated with CS dependency in children with 
CD. 
Methods 
A retrospective study was carried out in two Canadian tertiary paediatric 
gastroenterology centers. Clinical information was abstracted from medical charts of CD 
patients (N=260) diagnosed with CD prior to age 18 and administered a first course of 
CS during the one year since diagnosis. Patients were classified as CS dependent if they 
relapsed during drug tapering or after the end of therapy. DNA was extracted from blood 
or saliva. Thirteen tagging single nucleotide polymorphisms (tag-SNPs) and a 
synonymous variation (C3435T) in ABCB1 gene were genotyped. Allelic, genotype and 
haplotype associations were examined using logistic regression and HAPLOVIEW. 
Results 
Tag-SNP rs2032583 was statistically significantly associated with CS 
dependency. The rare C allele of this SNP (OR=0.56, 95% CI: 0.34-0.95, p=0.029) and 
heterozygous genotype TC (OR=0.52, 95% CI: 0.28-0.95, p=0.035) conferred protection 
from CS dependency. A 3-marker haplotype was significantly associated with CS 
dependence (multiple comparison corrected p-value=0.004). 
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Conclusion 
Our results suggest that the ABCB1 gene may be associated with CS dependence 
in paediatric CD patients.  
 
Keywords: Pharmacogenetics; steroids in IBD; Gene/Drug response; ABCB1; Crohn’s 
disease; paediatric 
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3.2.2 Introduction 
Inter-individual variability in response to corticosteroid (CS) therapy is 
widespread in patients with various diseases treated with this medication.1-4 In moderate 
and severe Crohn’s disease (CD) management, CS are the mainstay of therapy. 
Although effective in inducing remission in the majority of patients, some of patients 
experience a flare of disease during dose tapering or shortly after an initial response and 
require reintroduction of CS (dependent). Patients treated with CS for long duration 
experience numerous side effects many of which are serious and irreversible.5-10 The 
consequences of these side effects are even more significant in children potentially 
affecting their psychological & physical wellbeing and development. We and others 
have shown that CS dependence is a frequent outcome (ranging from 30 to 40%)11-13 in 
children with CD, presenting a serious clinical dilemma. Some studies have attempted to 
identify clinical and demographical markers of CS dependence, but results have been 
inconsistent. Researching such markers is nonetheless paramount as they would 
potentially enable the early identification of patients most susceptible for becoming CS 
dependent. Susceptible children could then benefit from alternative therapeutic 
strategies. 
The steroid metabolic pathway is under genetic control. An individual’s ability to 
metabolize steroids is intimately related to the kind of genetic variation he or she 
harbours in key proteins within the pathway. We have recently observed that variation in 
the glucocorticoid receptor gene (NR3C1) was associated with steroid dependence in 
children with CD.14 Another candidate gene of interest is the MDR1 (ABCB1) gene that 
codes for P-glycoprotein (Pg) a trans-membrane transporter. The gene is involved in the 
metabolism of various xenobiotics (including steroids) and has been the subject of study 
for susceptibility for CD. Most studies focused on two single nucleotide polymorphisms 
(SNPs) in the gene, a synonymous SNP C3435T (rs1045642) and a non-synonymous 
triallelic variation SNP G2677T/A. Some studies have found associations between these 
variants and CD 15-17, however others have not.18-26  Using a gene-wide approach in 
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Canadian children, we did not observe overall associations with the gene and CD, 
although some evidence for associations with colonic disease were evident.26  None of 
the genome-wide association studies (GWAS) have reported associations between the 
gene and CD 27-30, as well. Although intimately associated with steroid metabolism, 
previous studies on whether variations in MDR1 gene are associated with steroid 
response have however been unclear.16,20,24,31  Much of the inconsistency is probably 
related to the examination of few markers in small sample sizes and differing definitions 
of steroid response. In order to further clarify the role of the MDR1 gene vis-à-vis 
steroid dependency in children we comprehensively examined variation across the gene 
in a large cohort of Canadian children who were administered steroids for CD. 
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3.2.3 Methods 
3.2.3.1 Study design and population  
A retrospective cohort study was carried out, including patients recruited from 
two tertiary paediatric gastroenterology clinics in Canada (Montreal and Ottawa). This 
cohort have been recently described.11 Briefly, patients diagnosed with CD according to 
established criteria32,33 prior to age 18 and treated with an initial course of CS, were 
identified and their follow-up information covering the period of 1 year was abstracted 
from the medical charts. CS treatment consisted of prednisone (1 mg/kg/day) for 2–4 
weeks and subsequent dose tapering by 5 mg/week or budesonide (9 mg) for 1 month 
with subsequent dose tapering by 3 mg/month. Previously reported criteria4,34 were 
adapted to define response to corticosteroid therapy. Patients were classified as CS 
dependent if after an initial response they experienced clinical relapses during drug 
tapering or after the end of therapy resulting in reintroduction of CS. Patients that 
maintained partial or total remission after the end of corticosteroid therapy were 
classified as responders to CS. Information on clinical and socio-demographic 
parameters such as disease localization & behaviour at diagnosis, disease activity at 
steroid initiation, family history of inflammatory bowel disease (IBD) and ethnicity was 
also acquired. Disease localization and behaviour were classified according to Montreal 
classification.35 A total of 364 CD patients diagnosed between 1980 and 2008 and 
administered a first course of CS were identified. Of these 313 (86%) patients could be 
classified according to the definition set for CS dependency or CS responsiveness. The 
mean (± SD) age at diagnosis was 12.3 (± 3.2) years. The majority of patients were male 
(54.0 %), of Caucasian ancestry (96.9%) (Table I on page 121) and had ileocolonic 
disease (54.2 %) and inflammatory behaviour (88.8%). Blood and/or saliva samples 
were available for 260 patients (83.1%).  
The institutional ethical boards of the two study centers approved the study and 
informed consent was acquired from the patients. 
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3.2.3.2 Selection of SNPs and genotyping 
Blood or saliva was obtained as a source of DNA. We used an established 
approach36 to select tagging single nucleotide polymorphisms (tag-SNPs) for 
genotyping. Tag-SNPs across the ABCB1 gene were identified from publicly available 
databases (http://pga.gs.washington.edu). A linkage disequilibrium (LD) threshold of r2 
≥ 0.8 and minor allele frequency of >10% was utilized to select the tag-SNPs. In 
addition to 13 selected tag-SNPs, SNP C3435T, a synonymous SNP known to influence 
MDR1 expression was included. Genotyping was carried out at the McGill University & 
Genome Quebec Innovation Center using the GenomeLab Sequenom technology which 
is based on a newly developed genotyping assay termed iPLEX for use with the Mass 
ARRAY platform. Personnel performing genotyping were unaware of the phenotype of 
interest.  
3.2.3.3 Statistical analyses 
Data were checked for missing genotypes and Hardy-Weinberg Equilibrium 
(HWE). Single marker associations between selected SNPs and CS dependence were 
examined using logistic regression analysis (STATA). Associations were examined 
under additive, recessive and dominant models after adjusting for potential confounding 
variables such as disease localization and behaviour, disease severity, age at diagnosis 
and gender. Odds ratios (ORs) along with 95% confidence intervals (95% CI) were 
estimated. LD between tag-SNPs was visualized and haplotype analysis carried out 
using HAPLOVIEW.37 Ungenotyped SNPs were imputed  using the Hapmap release 22, 
CEU population as reference based on procedures implemented in the MACH 
software.38 Association p-values were corrected for multiple testing using Bonferroni 
correction (for single marker analysis) and permutation methods (for haplotype 
associations, implemented in HAPLOVIEW).   
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3.2.3.4 Study power estimation 
Study power was determined using QUANTO software 
(http://hydra.usc.edu/gxe.). Based on the expected sample size and assuming a range of 
allele frequencies (0.10 to 0.50), an alpha level of=0.05, and a case-control ratio of ~1.0 
to 1.1, the range of risks (OR) that could be detected with adequate power (≥ 80%) was 
estimated. 
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3.2.4 Results 
The overall genotyping rate for the 14 SNPs (Table II on page 122, Figure 1 on 
page 133) was 99%. All SNPs were in HWE. Of these 14 SNPs, a minor allele (C) of 
SNP rs2032583 showed a statistically significant association with CS dependence 
(Table III on page 123) when an additive model was fit (OR=0.56; 95% CI: 0.34 - 0.95, 
p= 0.029). Individuals heterozygous (TC) for the SNP were less likely to become CS 
dependent (OR=0.52, 95%CI: 0.28-0.95, p=0.035). Associations with this SNP were 
also evident under a dominant model (OR=0.51; 95% CI: 0.20-0.92, p = 0.026). There 
were suggestions for associations with SNP rs3789243 under an additive model (OR 
=0.71, 95%CI: 0.49-1.02, p = 0.07) and with rare homozygous genotype (OR=0.51, 
95%CI: 0.24-1.06, p=0.07), but these were borderline non-significant. Haplotype 
analysis was carried out to examine associations between SNPs that showed evidence 
for association in the single SNP analysis (rs2032583 and rs3789243) and SNP 
rs1045642 that is known to alter MDR1 expression. The 3 marker combination resulted 
in 6 haplotypes (Table IV on page 130) of which haplotype C-T-C was significantly 
associated with CS dependency (p = 0.0014) and this association remained significant 
after correction for multiple testing (p = 0.004). 
On imputation, among 111 SNPs that met the quality requirements (r2 >0.3), 24 
SNPs in addition to one genotyped SNP (rs2032583) were statistically significantly (p < 
0.05) associated with CS dependence at the allelic level (Table V on page 131). These 
significant associations did not withstand adjustment for multiple testing. Haplotype 
analysis of non-genotyped SNPs showed that six haplotypes belonging to nine blocks 
(defined according to the “four gamete rule” implemented in HAPLOVIEW) were 
statistically significantly associated with CS dependence. None of these however 
maintained significance after corrections for multiple comparisons (data not shown). 
Assuming the frequency of CS dependence about 40 % and expecting a cohort 
size of ~260 our study had > 80% power to detect risks > 1.6 for the markers with minor 
allele frequencies of ~0.50. For the alleles frequencies between 0.30 and 0.40 power was 
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sufficient to detect the effects > 1.7, for allele’s frequencies of 0.20 – > 1.8, and for 
alleles frequencies less than 0.20 the study was powered to detect effects > 2.0. 
3.2.5 Discussion 
We carried out a comprehensive gene-wide study to examine associations 
between the MDR1 gene and CS dependence in children with CD. Of the 14 markers 
studied, associations with 1 marker were evident whereas associations with another 
marker were borderline non-significant. Haplotype analysis suggested multi-marker 
variation in the gene may be associated with CS dependence. Analysis of non-genotyped 
SNPs revealed associations but these did not persist after accounting for multiple 
comparisons. 
The Pg system is an efflux pump that protects cells from foreign molecules 
including CS 39 by moving them from the intracellular to the extracellular 
compartments.40 It is well known that the ABCB1 gene is involved in the response to 
various drugs administered for several medical conditions.41,42 The gene is highly 
expressed in various tissues exposed to foreign substances, such as the kidneys, liver and 
intestines43-45, highlighting its protective role against harmful influences. In the 
gastrointestinal tract the gene is variably expressed, with the highest expression 
observed in the colon.45 Of interest, Farrel et al.46 demonstrated that the expression of P-
glycoprotein was higher in peripheral lymphocites of CD and UC patients not 
responding to medication suggesting that genetic variation may underlie the variability 
in observed responses to steroid treatment. Indeed three polymorphisms in the gene, 
C3435T (rs1045642), T1236C (rs1128503) and triallelic SNP G2677T/A, have been 
shown to affect the expression of the P-glycoprotein.47  
Epidemiological evidence however for association between MDR1 variants and 
steroid response in CD have been inconsistent. Two Italian studies20,24 did not find 
associations between the C3435T and G2677T/A variants and response to CS in CD. A 
Slovenian study16 examined 10 SNPs in the gene and also did not observe associations 
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with any SNP including the C3435T SNP. However associations between haplotypes 
comprised of two intronic SNPs (rs2235035 and rs1922242) were found with refractory 
CD (defined as the failure to respond to corticosteroids and immunomodulators and 
subsequent treatment with anti-TNF medication). Although interesting, these findings, 
however, were based on only 24 patients. A study on North Indian ulcerative colitis 
patients31 did not find associations between MDR1 SNPs and CS dependence, however 
some associations with partial response to CS were evident.  
Similar to previous reports, we did not observe associations between SNPs 
rs1045642 and rs1128503 and CS dependence in our study in single marker analysis.  
However, haplotype analysis suggested that a haplotype encompassing one previously 
studied SNP (rs1045642) was associated with CS dependence. Both decreased and 
increased P-glycoprotein function has been shown to be associated with this 
polymorphism.48-53 Moreover, rs1045642 has been shown to affect serum cortisol level54 
in healthy women. It is intriguing that intronic SNP (rs3789243) that was a part of the 
haplotype significantly associated with CS dependence in our study, was previously 
shown by Ho et al.22 to be associated with susceptibility to UC and as a part of 
haplotypes, with differences in response to CS in Chinese epilepsy patients.55 It is also 
of interest that another SNP (rs2032583), that was a part of the haplotype significantly 
associated with CS dependence in our study, has been shown to influence remission in 
depressive patients treated with antidepressants.56,57 Taken together these observations 
support the notion47 that haplotypes, rather than individual SNPs, were likely to affect 
the function of P-glycoprotein and thus likely to modify response to steroids. Our results 
however should be interpreted with caution considering the modest sample size. Noted 
associations (both single SNP and haplotype) although withstanding corrections for 
multiple comparisons, could nonetheless be false positive. Similarly lack of associations 
noted for many SNPs may be the result of low power of the study to detect associations 
<1.5. Studies to replicate the findings in larger cohorts are required.  
In our recent study14 examining the role of NR3C1 genetic variations in CS 
dependence we have shown statistically significant haplotype associations with CS 
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dependence considering both genotyped and imputed SNPs. Altogether these findings 
suggest that both genes (ABCB1 and NR3C1) are implicated and CS dependence appears 
to be complex phenotype. In the context of a lack of reliable clinical markers that could 
predict the response to CS in IBD our findings are of interest and need to be confirmed 
in larger patients’ cohorts. Further studies to explore functional mechanisms and 
potential interactions with other candidate genes such as the GR gene will be also 
needed. 
In conclusion, the ABCB1 gene appears to be relevant to CS dependency in 
paediatric CD.  
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3.2.7 Tables 
Table I: Demographic and clinical characteristics of studied patients.  
 
Clinical characteristics 
CS dependent patients 
N=127 
CS responsive patients 
N=133 
Age at diagnosis, mean (SD) 11.6 (±3.5) 13.0 (±2.8)  
Gender, n (%)   
Females 60 (47.2) 59 (44.4) 
Males 67 (52.8) 74 (55.6) 
Ethnicity, Caucasians, n (%) 124 (97.6) 128 (96.2) 
Intestinal localization a, n (%)   
L1±L4 16 (12.6) 28 (21.1) 
L2±L4 38 (29.9) 37 (27.8) 
L3±L4 73 (57.5) 68 (51.1) 
Disease behaviour a, n (%)   
Inflammatory disease B1±p 113 (89.0) 118 (88.7) 
B2±p and B3±p 14 (11.0) 15 (11.3) 
Disease severity, n (%)   
Mild-to-moderate 68 (53.5) 77 (57.9) 
Moderate-severe 59 (46.5) 56 (42.1) 
CD, Crohn’s disease; CS, corticosteroids;L1±L4, Ileum with or without upper digestive 
tract involvement; L2±L4, Colon with or without upper digestive tract involvement; 
L3±L4,Ileocolon with or without upper digestive tract involvement;B1±p, Inflammatory 
disease with or without perianal involvement; B2±p, Stricturing disease with or without 
perianal involvement; B3±p, Penetrating disease with or without perianal involvement. 
a Defined according to Montreal classification. 
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Table II: Characteristics of the SNPs in the ABCB1 gene selected for study. 
 
db SNP id Genomic 
location 
Position, Bp Alleles Type  MAF 
rs1128503 Exon 12 86824252 C/T CS;T1236C  0.41 
rs1202186 Intron  86857909 A/G NC 0.32 
rs1045642 Exon 26 86976581 T/C CS;C3435T 0.50 
rs2032583 Intron 21 86998497 C/T NC 0.14 
rs10248420 Intron 20 87002922 A/G NC 0.18 
rs2235046 Intron 16 87012002 G/A NC 0.43 
rs2091766 Intron 15 87012440 C/T NC 0.39 
rs2235035 Intron 13 87017022 C/T NC 0.33 
rs6950978 Intron 5 87038403 A/T NC 0.42 
rs10264990 Intron 5 87040551 T/C NC 0.35 
rs17327442 Intron 5 87050926 T/A NC 0.16 
rs1202184 Intron 5 87051837 A/G NC 0.48 
rs17327624 Intron 4 87054753 G/T NC 0.21 
rs3789243 Intron 3 87058822 C/T NC 0.49 
Bp, Base pairs; CS, Coding - Synonymous; NC, Non-Coding; MAF, Minor Allele 
Frequency. 
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Table III: Associations between ABCB1 gene SNPs and CS dependence in paediatric 
CD patients. 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
value
a 
 
rs1128503       
C 143 (57.2) 157 (60.4)     
T 107 (42.8) 103 (39.6) 1.14 (0.80-1.62) 0.465 1.17 (0.81-1.68) 0.412 
CC 40 (32.0) 48 (36.9)     
CT 63 (50.4) 61 (46.9) 1.24 (0.72-2.14) 0.443 1.33 (0.76-2.35) 0.310 
TT 22 (17.6) 21 (16.2) 1.26 (0.60-2.61) 0.539 1.28 (0.60-2.73) 0.519 
Dom   1.24 (0.74-2.09) 0.409 1.32 (0.78-2.26) 0.303 
Rec   1.11 (0.58-2.13) 0.760 1.07 (0.55-2.11) 0.834 
HWE    1.00   
rs1202186       
A 170 (67.7) 170 (63.9)     
G 81 (32.3) 96 (36.1) 0.86 (0.57-1.20) 0.335 0.82 (0.55-1.20) 0.299  
AA 57 (45.24) 53 (39.9)     
AG 57 (45.24) 64 (48.1) 0.83 (0.49-1.38) 0.475 0.85 (0.49-1.44) 0.551 
GG 12 (9.52) 16 (12.0) 0.69 (0.30-1.61) 0.398 0.63 (0.26-1.51) 0.305 
Dom   0.80 (0.48-1.35) 0.381 0.81 (0.48-1.34) 0.409 
Rec   0.77 (0.32-1.82) 0.516 0.69 (0.31-1.57) 0.380 
HWE    1.00   
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Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs1045642       
T 124 (48.8) 135 (54.4)     
C 130 (51.2) 113 (45.6) 1.07 (0.77-1.50) 0.668 1.01 (0.77-1.53) 0.647 
TT 32 (25.2) 36 (27.0)     
TC 60 (47.2) 63 (47.4) 1.10 (0.60-1.93) 0.820 1.12 (0.60-2.08) 0.716 
CC 35 (27.6) 34 (25.6) 1.16 (0.60-2.26) 0.668  1.18 (0.59-2.35) 0.645 
Dom   1.10 (0.61-1.99) 0.732 1.14 (0.64-2.03) 0.654 
Rec   1.11 (0.62-1.99) 0.716 1.09 (0.62-1.92) 0.759 
HWE    0.387   
rs2032583       
T 223 (89.2) 217 (82.2)     
C 27 (10.8) 47 (17.8) 0.56 (0.34-0.94) 0.027 0.56 (0.33-0.94) 0.029 
TT 100 (80.0) 89 (67.4)     
TC 23 (18.4) 39 (29.6) 0.52 (0.29-0.94) 0.032 0.52 (0.28-0.95) 0.035 
CC 2 (1.6) 4 (3.0) 0.44 (0.80-2.49) 0.357 0.43(0.07-2.56) 0.354 
Dom   0.52 (0.28-0.95) 0.022 0.51 (0.29-0.92) 0.026 
Rec   0.52 (0.05-3.71) 0.448 0.51 (0.09-2.99) 0.455 
HWE    0.799   
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Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs10248420       
A 204 (84.3) 183 (78.9)     
G 38 (15.7) 49 (21.2) 0.70 (0.44-1.12) 0.135 0.71 (0.44-1.14) 0.158  
AA 86 (71.1) 73 (62.9)     
AG 32 (26.4) 37 (31.9) 0.73 (0.42-1.29) 0.285 0.75 (0.42-1.34) 0.337 
GG 3 (2.5) 6 (5.2) 0.42 (0.10-1.76) 0.237 0.41 (0.09-1.78) 0.235 
Dom   0.69 (0.39-1.23) 0.182 0.70 (0.40-1.23) 0.220 
Rec   0.47 (0.07-2.25) 0.229 0.45 (0.10-1.92) 0.281 
HWE    0.665   
rs2235046       
G 144 (56.7) 154 (57.9)     
A 110 (43.3) 112 (42.1) 1.05 (0.74-1.49) 0.779 1.01(0.75- 1.55) 0.695 
GG 39 (30.7) 45 (33.8)     
GA 66 (52.0) 64 (48.1) 1.19 (069-2.10) 0.535 1.32 (0.75-2.33) 0.335 
AA 22 (17.3) 24 (18.1) 1.06 (0.48-2.17) 0.879 1.07 (0.51-2.27) 0.849 
Dom   1.15 (0.66-2.01) 0.590 1.25 (0.73-2.15) 0.411 
Rec   0.87 (0.44-1.72) 0.664 0.90 (0.47-1.74) 0.765 
HWE    0.800   
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Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs2091766       
C 150 (59.1) 164 (62.1)     
T 104 (40.9) 100 (37.9) 1.13 (0.80-1.60) 0.482 1.10(0.76-1.56) 0.631 
CC 44 (34.7) 53 (40.2)     
CT 62 (48.8) 58 (43.9) 1.28 (0.75-2.20) 0.356 1.38(0.80-2.39) 0.245 
TT 21 (16.5) 21 (15.9) 1.20 (0.58-2.49) 0.615 1.04(0.49-2.22) 0.917 
Dom   1.26 (0.74-2.16) 0.360 1.29 (.77-2.16) 0.334 
Rec   1.05 (0.51-2.14) 0.891 0.87(0.43-1.76) 0.705 
HWE    0.696   
rs2235035       
C 166 (65.4) 178 (67.4)     
T 88 (34.6) 86 (32.6) 1.10 (0.77-1.58) 0.582 1.01(0.72-1.53) 0.781 
CC 54 (42.5) 63 (47.4)     
CT 58 (45.7) 54 (40.6) 1.25(0.75-2.11) 0.394 1.33 (0.78-2.27) 0.298 
TT 15 (11.8) 16 (12.0) 1.10 (0.50-2.42) 0.825 0.88 (0.38-2.06) 0.771 
Dom   1.22 (0.72-2.04) 0.432 1.22 (0.74-2.02) 0.437 
Rec   0.98 (0.43-2.23) 0.957 0.77 (0.34-1.72) 0.522 
HWE    0.580   
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Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs6950978       
A 145 (57.1) 156 (58.6)     
T 109 (42.9) 110 (41.4) 1.06 (0.76-1.46) 0.738 1.00(0.74-1.45) 0.825  
AA 45 (35.4) 52 (39.1)     
AT 55 (43.3) 52 (39.1) 1.22 (0.70-2.12) 0.475 1.24 (0.70-2.19) 0.454 
TT 27 (21.3) 29 (21.8) 1.1 (0.56-2.08) 0.828 1.03 (.52-2.04) 0.929 
Dom   1.19 (0.71-1.94) 0.541 1.17 (0.69-1.96) 0.562 
Rec   0.97 (0.51-1.83) 0.915 0.92 (0.50-1.69) 0.781 
HWE    0.015   
rs10264990       
T 158 (62.2) 180 (67.7)     
C 96 (37.8) 86 (32.3) 1.26 (0.88-1.79) 0.204 1.24(0.86-1.78) 0.250 
TT 51 (40.2) 62 (46.6)     
TC 56 (44.1) 56 (42.1) 1.22 (0.72-2.05) 0.465 1.23 (0.72-2.09) 0.454 
CC 20 (15.7) 15 (11.3) 1.62 (0.75-3.48) 0.216 1.54 (0.70-3.39) 0.280 
Dom   1.30 (0.77-2.19) 0.294 1.29 (0.78-2.14) 0.317 
Rec   1.47 (0.72-3.02) 0.291 1.39 (0.66-2.91) 0.381 
HWE    0.414   
 
  
128 
Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs17327442       
T 216 (85.0) 220 (82.7)     
A 38 (15.0) 46 (17.3) 0.84 (0.53-1.34) 0.472 0.80 (0.49-1.29) 0.362 
TT 91 (71.6) 92 (69.2)     
TA 34 (26.8) 36 (27.1) 0.95(0.55-1.66) 0.869 1.0 (0.57-1.79) 0.976 
AA 2 (1.6) 5 (3.7) 0.40 (0.08-2.14) 0.287 0.23 (0.04-1.3) 0.102 
Dom   0.88 (0.50-1.56) 0.661 0.88 (0.51-1.53) 0.654 
Rec   0.41 (0.08-2.15) 0.291 0.23 (.034-1.34) 0.101 
HWE    0.822   
rs1202184       
A 126 (49.6) 144 (54.1)     
G 128 (50.4) 122 (45.9) 0.95 (0.61-1.48) 0.811 1.26 (0.88-0.81) 0.20 
AA 32 (25.2) 39 (29.3)     
AG 62 (48.8) 66 (49.6) 1.14 (0.64-2.05) 0.649 1.29 (0.71-2.36) 0.401 
GG 33 (26.0) 28 (21.1) 1.44 (0.72-2.85) 0.302 1.59 (0.78-3.27) 0.203 
Dom   1.23(0.71-2.13) 0.456 1.38 (0.78-2.44) 0.268 
Rec   1.32 (0.74-2.30) 0.349 1.35 (0.74-2.44) 0.330 
HWE    0.805   
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Table III (Continued) 
db SNP id CS 
dependent 
N (%) 
CS 
responsive 
N (%) 
Odds ratio 
(95% CI) 
P 
value  
Adjusted 
Odds ratio 
(95% CI)  
P 
valuea 
 
rs17327624       
G 205 (80.7) 207 (77.8)     
T 49 (19.3) 59 (22.2) 0.84 (0.55-1.28) 0.422 0.80 (0.52-1.24) 0.328 
GG 83 (65.4) 81 (60.9)     
GT 39 (30.7) 45 (33.8) 0.85 (0.50-1.43) 0.533 0.87 (0.51-1.49) 0.609 
TT 5 (3.9) 7 (5.3) 0.70 (0.21-2.29) 0.552 0.53 (.15-1.83) 0.314 
Dom   0.83 (0.50-1.37) 0.457 0.82 (0.49-1.37) 0.446 
Rec   0.74 (0.23-2.39) 0.612 0.55 (0.16-1.90) 0.345 
HWE    0.710   
rs3789243       
T 133 (52.4) 122 (45.9)     
C 121 (47.6) 144 (54.1) 0.77 (0.54-1.08) 0.138 0.71 (0.49-1.02)  0.070 
TT  35 (27.6) 27 (20.3)     
TC 63 (49.6) 68 (51.1) 0.71 (0.39-1.31) 0.279 0.70 (0.38-1.32) 0.275 
CC 29 (22.8) 38 (28.6) 0.59 (0.29-1.18) 0.136 0.51 (0.24-1.06) 0.070 
Dom   0.66 (0.38-1.17) 0.091 0.64 (0.35-1.16) 0.138 
Rec   0.74 (0.41-1.34) 0.291 0.65 (0.36-1.17) 0.147 
HWE    1.00   
HWE, Hardy-Weinberg Equilibrium; CI, Confidence interval; Dom, Dominant; Rec, 
Recessive. 
a Adjusted for demographic and clinical variables. 
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Table IV: Haplotype associations between variations in ABCB1 gene and CS 
dependence. 
SNPs 
Frequencies  
rs
10
45
64
2 
rs
20
32
58
3 
rs
37
89
24
3 Overall 
Freq 
Cases/ 
Controls 
Chi2 P value 
T T C 0.396 0.392, 0.400 0.035 0.8525 
C T T 0.279 0.286, 0.273 0.098 0.754 
C C T 0.129 0.095, 0.161 5.04 0.0248 
T T T 0.102 0.096, 0.107 0.183 0.6685 
C T C 0.078 0.117, 0.041 10.251 0.0014a 
C C C 0.016 0.014, 0.017 0.052 0.8199 
a Empiric P value = 0.004 
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Table V: Single marker associations between imputed SNPs in ABCB1 gene and CS 
dependence. 
 
SNP id 
Type of SNP Imputation 
Quality, r2 
Frequencies, 
Case, Control 
Chi2 P value 
rs6979885 Intr 0.91 0.339, 0.263 3.52 0.061 
rs2235067 Intr 0.99 0.886, 0.820 4.524 0.033 
rs11979702 Intr 0.99 0.886, 0.820 4.524 0.033 
rs10280101 Intr 0.99 0.886, 0.820 4.524 0.033 
rs10225473 Intr 0.99 0.886, 0.820 4.524 0.033 
rs7787082 Intr 0.93 0.886, 0.820 4.524 0.033 
rs2032583 Intr 0.99 0.886, 0.820 4.524 0.033 
rs4148739 Intr 0.99 0.886, 0.820 4.524 0.033 
rs11983225 Intr 0.99 0.886, 0.820 4.524 0.033 
rs11760837 Intr 0.99 0.886, 0.820 4.524 0.033 
rs10274587 Intr 0.99 0.886, 0.820 4.524 0.033 
rs2235040 Intr 0.99 0.886, 0.823 4.069 0.044 
rs12720067 Intr 0.99 0.886, 0.823 4.069 0.044 
rs10268314 Intr 0.99 0.886, 0.823 4.069 0.044 
rs10276603 Intr 0.93 0.886, 0.823 4.069 0.044 
rs11772987 Intr 0.98 0.886, 0.823 4.069 0.044 
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Table V (Continued) 
SNP id 
Type of SNP Imputation 
Quality, r2 
Frequencies, 
Case, Control 
Chi2 P value 
rs10244266 Intr 0.94 0.886, 0.823 4.069 0.044 
rs1882479 Intr 0.98. 0.886, 0.823 4.069 0.044 
rs2188525 Intr 0.90 0.063, 0.026 4.134 0.042 
rs2214103 Intr 0.90 0.063, 0.026 4.134 0.042 
rs2235074 Intr 0.90 0.063, 0.026 4.134 0.042 
rs2888599 Intr 0.90 0.063, 0.026 4.134 0.042 
rs3213619 5` UTR 0.83 0.063, 0.026 4.134 0.042 
rs10486996 Intr 0.74 0.063, 0.026 4.134 0.042 
rs12539395 Intr 0.57 0.063, 0.030 3.198 0.074 
rs7790722 Intr 0.62 0.067, 0.030 3.856 0.05 
rs17149864 Intr 0.56 0.063, 0.030 3.198 0.074 
rs2188528 Intr 0.72 0.063, 0.026 4.134 0.042 
Intr, Intronic; 5` UTR, Five Prime Untranslated Region. 
Only statistically significantly (p< 0.1) associated SNPs are presented.  
Genotyped marker highlighted in bold. 
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Figure 1. LD (r2 x 100) between genotyped SNPS in ABCB1 gene. 
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3.3.1 Abstract  
Objectives 
In pediatric-onset of Crohn’s disease (CD) corticosteroids (CS) dependency 
(~40%) is a significant clinical problem associated with numerous side-effects. Given 
the known effects of the glucocorticoid receptor (NR3C1) gene in CS metabolism, we 
investigated whether variation in the gene was associated with CS-dependency.  
Methods  
A retrospective cohort study was carried out including CD patients diagnosed 
before 18 years and treated with a first course of CS in two Canadian tertiary pediatric 
gastroenterology clinics. DNA was obtained from blood or saliva. Tagging single 
nucleotide polymorphisms (Tag-SNPs) and functionally important SNPs were 
genotyped. Ungenotyped SNPs were imputed using the HAPMAP CEU reference panel. 
Allelic, genotype and haplotype associations between the GR SNPs and CS-dependency 
were examined.  
Results  
A total of 255 CS-dependent and CS-responsive CD patients were studied. Of the 
12 SNPs examined, 3 SNPs rs10482682 (OR=1.43, 95% CI:0.99-2.08, P=0.047), rs6196 
(OR=0.55, 95% CI:0.31-0.95, P=0.024), and rs2963155 (OR=0.64, 95% CI:0.42-0.98, 
P=0.039), showed associations under an additive model whereas rs4912911 (OR=0.37, 
95% CI:0.13-1.00, P=0.03) and rs2963156 (OR=0.32, 95% CI:0.07-1.12, P=0.047) 
showed significant associations under a recessive model. Haplotype analysis of 5 
associated markers revealed significant associations between two haplotypes and CS-
dependence (P-values 0.002 and 0.004). On imputation, a further 19 SNPs were 
associated with CS-dependency. Two multi-marker haplotypes (P-values=0.001 each) 
including genotyped and imputed SNPs conferred susceptibility for CS-dependency.  
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Conclusion 
Our results suggest that variations in the GR/NR3C1 gene are associated with 
CS-dependency in paediatric-onset CD. Studies to replicate these findings and identify 
the potentially relevant variants are required. 
 
Keywords: GR-receptor; NR3C1; pharmacogenetics; corticosteroids; paediatric; 
Crohn’s disease 
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3.3.2 Introduction 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) 
characterized by a progressive course and various complications. The incidence of CD is 
on the rise among younger individuals particularly in Canada [1-5]. Corticosteroids (CS) 
are the mainstay of therapy used to induce remission in patients with moderate to severe 
CD. However, inter-individual variability in the response to these agents is frequently 
observed. About 30 % to 40% of initially responsive patient’s experience disease flares 
during drug tapering or after drug discontinuation (become CS dependent) [6-11]. Most 
of these patients require either surgery or reintroduction of steroids. Long-term 
administration of CS is frequently associated with harmful side-effects in children [12-
14]. Determination of predictors that will enable identification of paediatric-CD patients 
most likely to become CS dependent is thus paramount. Demographic (younger age at 
diagnosis) and/or clinical [6-9, 11, 15-17] markers (colonic localization, coexisting 
upper tract disease localization, and growth impairment) [17] have been examined but 
associations have not been consistently replicated. Given their stability genetic markers 
are likely to complement clinical and/or demographic predictors. Few studies have 
however investigated such markers [18, 19].  
A potential genetic marker is the glucocorticoid receptor (NR3C1) gene, 
spanning ≈150 kb and located on chromosome 5. This gene is intimately involved in the 
metabolism of natural substrates - steroid hormones and exogenous steroids, its action 
being mediated via its regulation of glucocorticoid-responsive genes [20]. DNA 
variations in the gene are known to be associated with inter-individual variation in 
steroid metabolism. Although NR3C1 variation has been shown to influence steroid 
response in some conditions, it is not known whether such variation can determine 
response to CS in paediatric-onset CD. We investigated the latter in a well-characterized 
cohort of Canadian children diagnosed with CD and who were administered CS for 
treatment. 
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3.3.3 Material and Methods  
3.3.3.1 Study design and patients 
A retrospective cohort study was carried out, including patients recruited from 
two tertiary paediatric gastroenterology clinics in Canada (Montreal and Ottawa). 
Details on this cohort have been recently reported [21]. In brief, patients diagnosed with 
CD according to established criteria [22, 23] prior to age 18 and treated with an initial 
course of CS, were identified and their follow-up information covering the period of 1 
year was abstracted from the medical charts. CS treatment consisted of prednisone (1 
mg/kg/day) for 2–4 weeks and subsequent dose tapering by 5 mg/week. Some patients 
(11.8%) were receiving budesonide (9 mg) for 1 month with subsequent dose tapering 
by 3 mg/month. Previously reported criteria were adapted to define response to 
corticosteroid therapy [7, 10]. Patients were classified as steroid dependent if after an 
initial response, clinical relapse either during drug tapering or shortly after the end of 
treatment was experienced resulting in reintroduction of CS. Patients that maintained 
partial or total remission since the end of corticosteroid therapy were classified as 
responders to CS. Information on clinical and socio-demographic parameters such as 
disease localization and behaviour (at diagnosis), disease activity at steroid initiation, 
family history of inflammatory bowel disease (IBD), ethnicity etc. was also acquired.  
The institutional ethical boards of the two study centers approved the study and 
consent was acquired from the patients. 
 
3.3.3.2 Selection of SNPs and genotyping 
Blood or saliva was obtained as a source of DNA. Fourteen tag-SNPs (single 
nucleotide polymorphisms) across the NR3C1 gene were identified using the methods 
described by Carlson et al [24]. A linkage disequilibrium (LD) threshold of r2 ≥ 0.8 and 
minor allele frequency of >10% was utilized to select the tag- SNPs. In addition to the 
tag-SNPs, three SNPs (rs6190, rs6195, rs258751) were added to set of markers based on 
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their functional/clinical significance. Genotyping was carried out at McGill University’s 
Genomics Innovation Center using high throughput genotyping technology. Personnel 
performing genotyping were unaware of the phenotype of interest.  
3.3.3.3 Statistical analyses 
Genotyped SNPs  
Each genetic marker was tested for Hardy-Weinberg equilibrium in the cohort. 
Single marker associations between the SNPs and CS-dependency were initially 
examined using univariate logistic regression analysis. Subsequently multivariate 
logistic regression adjusting for demographic and clinical variables (gender, age at 
diagnosis, disease localization and behavior, disease severity, family history of IBD) 
was carried out. Various models of inheritance including additive, dominant and 
recessive were fit. Odds ratios (OR) and respective 95% confidence intervals (95% CI) 
were estimated. The STATA statistical package (Stata Statistical Software: Release 10. 
College Station, TX: StataCorp) was used to carry out these analyses. Association 
between specific haplotypes comprising the selected markers were investigated using 
HAPLOVIEW (v.4.2 http://www.broad.mit.edu/mpg/haploview/) [25].  
Imputation  
Ungenotyped SNPs in and around the NR3C1 gene were imputed using the 
HapMap reference panel (Release 22). SNPs with MAF ≥ 0.01 and genotyping 
frequency > 0.95 in the 60 CEU founders were utilized. Imputation analysis was carried 
out using procedures implemented in MACH 
(http://www.sph.umich.edu/csg/abecasis/mach/) [26] and validated using BEAGLE [27]. 
Only SNPs with r2 values > 0.3 (indicator of imputation quality) were considered for 
further association analysis. Single marker and haplotype analysis was carried out as 
described above for the genotyped SNPs. 
Adjustment for multiple comparisons 
P values were corrected using Bonferroni method for single marker analyses and 
permutation (n=10000) for haplotype analyses (implemented in HAPLOVIEW). 
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3.3.4 Results  
A total of 364 CD patients diagnosed between 1980 and 2008 and administered a 
first course of CS were identified. Of these 313 (86%) patients could be classified 
according to the definition set for CS dependency or CS responsiveness. Blood and/or 
saliva samples were available for 255 patients (81.5%). The mean age (±SD) at 
diagnosis was 12.4 (±3.2) years (Table I on page 151). Most patients were male (53.7%) 
and Caucasian (96.9%). Most patients had ileo-colonic disease (54.5%) and 
inflammatory behaviour (89 %) at diagnosis. A total of 125 (49 %) patients became CS 
dependent.   
From 14 tag-SNPs we were able to successfully genotype 10 SNPs. One of 
functionally significant SNP (rs258751) was not in HWE, so our final set of analyzed 
markers included 12 SNPs (Table II on page 152). The overall genotyping rate in 
individuals and markers was high (97.0 % and 96.8 % respectively). Single SNP 
analysis showed that of the 12 markers, three markers (rs10482682, rs6196 and 
rs2963155) were associated at the allelic level (unadjusted for multiple comparisons, P 
values of 0.05; 0.02 and 0.036 respectively) with corticosteroid dependency (Table III 
on page 153; Figure 1 on page 162). For two other markers (rs2963156 and rs4912911) 
associations were evident when a recessive model was fit. Adjusting for demographic 
and clinical variables did not change the effect of the allelic associations with CS-
dependency for the majority of SNPs (excepting rs4912911). For this SNP allelic 
association became significant (P value 0.039) after adjustment for demographic and 
clinical variables (Table IV on page 157). Haplotype analysis based on these 5 
significantly associated SNPs showed that two haplotypes (AAACA and GGGCG) were 
significantly associated with the corticosteroid-dependent phenotype (Table V on page 
158). Haplotype AAACA was risk conferring whereas haplotype GGGCG was 
protective. These associations remained significant (respective empirical P values 0.006 
and 0.01) after permutation testing (10000).  
Imputation results acquired using MACH were retained given the similarity with 
those obtained using BEAGLE. Imputation of ungenotyped SNPs revealed that from 
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among the 74 SNPs that passed the quality control criteria (r2 >0.3), in addition to the 3 
genotyped SNPs, 19 SNPs were statistically significantly associated with CS dependent 
phenotype at the allelic level (Table VI on page 159). Five of these markers remained 
significantly associated with CS dependence after adjusting for multiple testing. The LD 
pattern of genotyped and imputed SNPs revealed the presence of 6 haplotype blocks 
(based on implementing the “four gamete rule” algorithm in HAPLOVIEW). Haplotype 
association analysis showed that one haplotype in each of two blocks (Block 1 and 2) 
(Figure 2 on page 163) were associated with CS dependency and remained statistically 
significantly associated after accounting for multiple comparisons (respective permuted 
P values 0.03 and 0.02) (Table VII-A on page 160 and Table VII-B on page 161).  
3.3.5 Discussion 
Using tag-SNP approach, we examined whether variants in the NR3C1 gene were 
associated with the development of CS dependency in paediatric patients with CD. In 
single-marker analysis, we observed that 5 SNPs were potentially associated with CS 
dependency. Haplotype analysis of associated SNPs provided evidence for associations 
as well. Analysis of imputed and genotyped SNPs showed potential associations with 
haplotypes within 2 distinct LD blocks in the gene.  
CS dependency is a serious clinical challenge during the management of 
pediatric-onset CD. We [21] and others have shown that ≈40% of children administered 
steroids can become CS dependent. CS dependency is known to be associated with 
serious side-effects and investigating markers to enable identification of susceptible 
children is an important priority. However many studies that searched for clinical or 
socio-demographical markers have not produced consistent results. Based on the 
intimate relationship between the NR3C1 gene and steroid metabolism and the large 
inter-individual variability in the NR3C1 gene, we hypothesized that DNA variation in 
the gene may predispose children to susceptibility for steroid dependency. Our findings 
suggest that indeed the NR3C1 gene may be an important predictor of CS dependency in 
children diagnosed with CD. To our knowledge, this is the first study that has 
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comprehensively explored the role of genetic variations across the NR3C1 gene with 
respect to corticosteroid-dependence in either children or adults diagnosed with CD.  
The GR protein is expressed in the cytoplasm until it binds to a ligand, which 
induces transport into the nucleus. There are several isoforms of GR: GRα, GRβ and 
GRγ, arising from alternative splicing and translational events [28, 29]. The alpha form 
of GR is a ligand-activated transcription factor that modulates the expression of 
glucocorticoid-responsive genes. The beta form of GR is not transcriptionnally active 
but is able to inhibit the effect of glucocorticoid activated GRα and therefore may be 
physiologically and pathophysiologically relevant to tissue sensitivity to glucocorticoids. 
Various lines of evidence indicate that variation in the NR3C1 gene can influence 
sensitivity to glucocorticoids in normal and diseased conditions and modify response to 
CS [30-33]. Two non-synonymous coding polymorphisms (rs6195, rs6190) and an 
intronic SNP rs41423247) in the gene have been most investigated. For example, the 
BclI (rs41423247), ER22/23EK (rs6189/6190), and N363S (rs6195) polymorphisms 
have been shown to be associated with a variation in sensitivity to exogenous 
glucocorticoids [31, 33] in patients with rheumatoid arthritis and in healthy individuals.  
Although we did not detect significant associations with SNPs rs6195 and rs6190 
[probably due to low power, given the lower frequency (≈2%)], there were suggestions 
that they could be potentially associated with CS dependency (ORs of 1.65 and 2.4 
respectively). We did not genotype SNP rs41423247, however, it is in high LD (D` 0.95) 
with the coding synonymous SNP rs6196 [34], which was significantly associated with 
CS dependency in our study. The rs6196 polymorphism resides in exon 9α which codes 
for transcriptionally active form of GR [35, 36]. Another SNP found to be associated 
with CS dependency in our study (rs33389) was previously shown to be associated with 
sensitivity to CS by Stevens et al. [37].  
With regards to IBD, De Iudicibus et al. [18], reported that the homozygous rare 
genotype of the BclI polymorphism was significantly more frequent in responders to 
corticosteroids than in CS-dependent patients. It is interesting to note that in our study 
rare homozygotes for SNP rs6196 that is in high LD with the BclI polymorphism, were 
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absent among children with CS dependency and that carriage of the minor allele was 
protective (OR=0.55, 95% CI=0.13-0.95), indirectly supporting the findings of De 
Iudicibus et al. [18]. In another study, [38] the authors found a higher frequency of the 
BclI polymorphism in CD patients versus healthy controls, but stratification based on 
steroid response was not carried out. Other studies have reported an increased expression 
of GRβ isoform in CS resistant ulcerative colitis (UC) patients [39, 40], but did not 
studied associations with CS dependence.  
The NR3C1 gene is located in a genomic region characterized by high LD and 
the identification of causal variants is therefore hampered by numerous mutually 
associated SNPs. Our results suggest that NR3C1 haplotypes are likely to play role in CS 
dependent phenotype. Two haplotypes comprising 5 markers that were individually 
nominally associated with CS dependence were associated with CS dependence even 
after adjustment for multiple comparisons, suggesting that multi-marker variation in the 
gene were responsible for the observed associations. At least two SNPs that were 
associated with CS dependency in our study (one encompassed in the associated 
haplotypes) have been previously shown to influence various glucocorticoid-mediated 
phenotypes [34, 37, 41], further supporting the role of the gene in determining CS 
response in CD. A more comprehensive analysis that examined imputed and genotyped 
SNPs further revealed that variation across two distinct haplotype blocks could be 
potentially associated with CS dependency. 
In conclusion, our findings suggest that variations across the NR3C1 gene play 
role in response to CS in paediatric CD. These associations need to be investigated 
further in larger cohorts. Furthermore, functional studies to assess the implications of 
these associations for therapeutic modulation of steroid administration need to be carried 
out.  
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3.3.7 Tables  
Table I: Demographic and clinical characteristics of the CD patients. 
Clinical characteristics 
CS dependent patients 
N=125 
CS responsive patients 
N=130 
Age at diagnosis, mean (SD) 11.6 (±3.5) 13.0 (±2.8) 
Gender, n (%)   
Females 60 (48.0) 58 (44.6) 
Males 65 (52.0) 72 (55.4) 
Ethnicity, Caucasians, n (%) 122 (97.6) 125 (96.2) 
Intestinal location, n (%)   
L1±L4 16 (12.8) 27 (20.8) 
L2±L4 37 (29.6) 36 (27.7) 
L3±L4 72 (57.6) 67 (51.5) 
Disease behaviour a, n (%)   
Inflammatory disease B1±p 111 (88.8) 116 (89.2) 
B2±p and B3±p 14 (11.2) 14 (10.8) 
Disease severity, n (%)   
Mild-to-moderate 68 (54.4) 75 (57.7) 
Moderate-severe 57 (45.6) 55 (42.3) 
CD, Crohn’s disease; CS, corticosteroids; L1±L4, Ileum with or without upper digestive 
tract involvement; L2±L4, Colon with or without upper digestive tract 
involvement;L3±L4, Ileocolon with or without upper digestive tract involvement; B1±p, 
Inflammatory disease with or without perianal involvement; B2±p, Stricturing disease 
with or without perianal involvement; B3±p, Penetrating disease with or without perianal 
involvement.   
a Defined according to Montreal classification. 
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Table II: Characteristics of studied markers in NR3C1 gene. 
 
SNP id Location in the gene Position, Bp Alleles  MAF Type 
rs6196 Exon 9 142641683 A/G 0.14 CS 
rs10482682 Intron 5 142659590 G/A 0.40 NC 
rs860457 Intron 4 142668516 T/C 0.29 NC 
rs4912905 Intron 2 142710569 G/C 0.22 NC 
rs2963155 Intron 2 142736197 A/G 0.22 NC 
rs2963156  Intron 2 142738689 C/T 0.24 NC 
rs6195 Exon 2 142759510 A/G 0.026  CNS 
rs6190 Exon 2 142760530 G/A 0.025 CNS 
rs10482616 Intron 1 142761760 G/A 0.14 NC 
rs7701443 Intron 1 142772843 A/G 0.44 NC 
rs4244032 Intron 1 142774918 A/G 0.22 NC 
rs4912911 Intron 1 142787225 A/G 0.33 NC 
CS, Coding synonymous; CNS, Coding non-synonymous; Bp, Base pairs; MAF, Minor 
allele frequency; NC, Non-coding; SNP, Single nucleotide polymorphism.  
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Table III: Allelic and genotypic associations between NR3C1 gene variants and 
response to CS in children with CD.  
SNP id CS dependent  
n (%) 
CS responsive 
 n (%) 
Odds ratios 
(95% CI) 
P values  
rs6196     
A 223 (89.9) 216 (83.1)   
G 25 (10.1) 44 (16.9) 0.55 (0.31 - 0.95) 0.024a 
AA 99 (79.8) 89 (68.5) ref  
AG 25 (20.2) 38 (29.2) 0.59 (0.33 - 1.06) 0.076 
GG 0 3 (2.3) -  -  
Dominant   0.55 (0.29 - 1.01) 0.039a 
Recessive   -  -  
rs10482682     
G 140 (56.0) 168 (64.6)   
A 110 (44.0) 92 (35.4) 1.43 (0.99 - 2.08) 0.047 a 
GG 36 (28.8) 59 (45.4)  ref  
GA 68 (54.4) 50 (38.5) 2.23 (1.28 - 3.87) 0.004a 
AA 21 (16.8) 21 (16.1) 1.64 (0.79 - 3.41) 0.187 
Dominant   2.05 (1.18 - 3.57) 0.006 a 
Recessive   1.05 (0.51 - 2.14) 0.890 
rs860457     
T 170 (68.5) 188 (72.9)   
C 78 (31.5) 70 (27.1) 1.23 (0.82 - 1.84) 0.285 
TT 55 ( 44.3) 65 (50.4) ref  
TC 60 (48.4) 58 (45.0) 1.22 (0.73 - 2.03) 0.439 
CC 9 (7.3) 6 (4.6) 1.77 (0.59 - 5.29) 0.305 
Dominant   1.27( 0.75 - 2.15) 0.337 
Recessive   1.60 (0.49 - 5.65) 0.380 
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Table III (Continued) 
SNP id CS dependent  
n (%) 
CS responsive 
 n (%) 
Odds ratios 
(95% CI) 
P values  
rs4912905     
G 192 (78.7) 201 (77.9)   
C 52 (21.3) 57 (22.1) 0.95 (0.61 - 1.49) 0.832 
GG 75(61.5) 75 (58.2) ref  
GC 42 (34.4) 51 (39.5) 0.82 (0.49 - 1.38) 0.463 
CC 5 (4.1) 3 (2.3) 1.67 (0.38 - 7.22) 0.495 
Dominant   0.87 (0.51 - 1.49) 0.590 
Recessive   1.79 (0.34 - 11.78) 0.424 
rs2963155     
A 206 (82.4) 194 (74.6)   
G 44 (17.6) 66 (25.4) 0.64 (0.42 - 0.98) 0.039 a 
AA 85 (68.0) 74 (56.9) ref  
AG 36 (28.8) 46 (35.4) 1.47 (0.86 - 2.51) 0.161 
GG 4 (3.2) 10 (7.7) 0.51 (0.15 - 1.76) 0.288 
Dominant   0.62 (0.36 - 1.07) 0.068 
Recessive   0.40 (0.09 - 1.43) 0.115 
rs2963156      
C 193 (77.2) 196 (75.4)   
T 57 (22.8) 64 (24.6) 0.90 (0.59 - 1.39) 0.630 
CC 72 (57.6) 78 (60.0) ref  
CT 49 (39.2) 40 (30.8) 1.33 ( 0.78 - 2.25) 0.292 
TT 4 (3.2) 12 (9.2) 0.36 (0.11 - 1.17) 0.090 
Dominant   1.10 (0.65 - 1.87) 0.697 
Recessive   0.32 (0.07 - 1.12) 0.047 a 
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Table III (Continued) 
SNP id CS dependent  
n (%) 
CS responsive 
 n (%) 
Odds ratios 
(95% CI) 
P values  
rs6195     
A 180 (96.8) 198 (98.0)   
G 6 (3.2) 4 (2.0) 1.65 (0.38 - 8.07) 0.439 
AA 87 (93.5) 97 (96.0) ref  
AG 6 (6.5) 4 (4.0) 1.67 (0.46 - 6.12) 0.437 
GG 0 0 - _ 
Dominant   1.67 (0.46 - 6.12) 0.433 
Recessive   - - 
rs6190     
G 241 (96.4) 256 (98.5)   
A 9 (3.6) 4 (1.5) 2.39 (0.65 - 10.74) 0.139 
GG 116 (92.8) 126 (96.9) ref  
GA 9 (7.2) 4 (3.1) 2.44 (0.73 - 8.15) 0.146 
AA 0 0 - - 
Dominant   - - 
Recessive   - - 
rs10482616     
G 217 (86.8) 222 (85.4)   
A 33 (13.2) 38 (14.6) 0.89 (0.52 - 1.51) 0.644 
GG 94 (75.2) 95 (73.1) ref  
GA 29 (23.2) 32 (24.6) 0.92 (0.51 - 1.63) 0.766 
AA 2 (1.6) 3 (2.3) 0.67 (0.11 - 4.12) 0.669 
Dominant   0.89 (0.49 - 1.63) 0.698 
Recessive   0.69 (0.06 - 6.12) 0.683 
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Table III (Continued) 
SNP id CS dependent  
n (%) 
CS responsive 
 n (%) 
Odds ratios 
(95% CI) 
P values  
rs7701443     
A 137 (54.8) 148 (56.9)   
G 113 (45.2) 112 (43.1) 0.92 (0.76 - 1.57) 0.629 
AA 43 (34.4) 41 (31.5)   
AG 51 (40.8) 66 (50.8) 0.74 (0.42 - 1.30) 0.287 
GG 31 (24.8) 23 (17.7) 1.28 (0.64 - 2.56) 0.475 
Dominant   0.88 (0.50 - 1.53) 0.627 
Recessive   1.53 (0.80 - 2.96) 0.164 
rs4244032     
A 185 (77.1) 185 (79.1)    
G 55 (22.9) 49 (20.9) 1.12 (0.71 - 1.78) 0.603 
AA 70 (58.3)   74 (63.3) ref  
AG 45 (37.5) 37 (31.6) 1.28 (0.75 - 2.21) 0.365 
GG 5 (4.2) 6 (5.1) 0.88 (0.26 - 3.02) 0.840 
Dominant   1.22 (0.70 - 2.14) 0.438 
Recessive   0.80 (0.19 - 3.27) 0.725 
rs4912911     
A 168 (70.0) 151 (62.9)   
G 72 (30.0) 89 (37.1) 0.73 (0.49 - 1.08) 0.100 
AA 55 (45.8) 48 (40.0) ref  
AG 58 (48.4) 55 (45.8) 0.92 (0.54 - 1.57) 0.761 
GG 7 (5.8) 17 (14.2)  0.36 (0.14 - 0.94) 0.037 a 
Dominant   0.79 (0.46 - 1.36) 0.361 
Recessive   0.37 (0.13 - 1.00) 0.031 a 
CS, corticosteroid; SNP, Single nucleotide polymorphism. 
-  Counts were not sufficient to permit calculation. 
a P values < 0.05 unadjusted for multiple comparisons. 
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Table IV: Allelic associations between tag-SNPs in NR3C1 gene and response to CS 
before and after adjustment for patient’s demographic and clinical characteristics. 
SNP id OR (95% CI) P value Adjusted a  
OR (95% CI) 
Adjusted a 
P value 
rs6196 0.55 (0.31 - 0.95) 0.024 0.52 (0.29 - 0.91) 0.021 
rs10482682 1.43 (0.99 - 2.08) 0.047 1.37 (0.96 - 1.97) 0.091 
rs860457 1.23 (0.82 - 1.84) 0.285 1.20 (0.79 - 1.83) 0.390 
rs4912905 0.95 (0.61 - 1.49) 0.832 0.98 (0.61 - 1.55) 0.918   
rs2963155  0.64 (0.42 - 0.98) 0.039  0.62 (0.40 - 0.96) 0.033 
rs2963156  0.90 (0.59 - 1.39) 0.630 0.88 (0.58 - 1.34) 0.559 
rs6195 1.65 (0.38 - 8.07) 0.439 1.93 (0.50 -7.36) 0.336 
rs6190 2.39 (0.65 -10.74) 0.139 2.41 (0.71 - 8.20) 0.160 
rs10482616 0.89 (0.52 - 1.51) 0.644 0.86 (0.52 - 1.45) 0.577 
rs7701443 0.92 (0.76 - 1.57) 0.629 1.12 (0.79 - 1.59) 0.514 
rs4244032 1.12 (0.71 - 1.78) 0.603 1.12 (0.72 - 1.75) 0.614 
rs4912911  0.73 (0.49 - 1.08) 0.100 0.65 (0.43 - 0.99) 0.039 
a Adjusted for age at diagnosis, gender, disease localization, disease behaviour,family 
history of IBD & disease severity in multivariate models. 
Statistically significant (<0.05) P values are highlighted in bold. 
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Table V: Associations between haplotypes in GR NR3C1 gene and response to CS in 
paediatric CD patients. 
SNPs Frequency   
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A G A C A 0.253 0.240  0.265 0.515 
A A A T A 0.180 0.176  0.184 0.818 
A A A C A 0.152 0.202  0.105 0.002a 
A G A C G 0.136 0.150  0.122 0.347 
G G G C G 0.101 0.062  0.139 0.004b 
A A A T G 0.057 0.052  0.062 0.616 
A G G C A 0.048 0.044  0.051 0.685 
A G G C G 0.031 0.024  0.039 0.324 
G G G C A 0.029 0.036  0.022 0.343 
CS, corticosteroid.  
a Empiric P value = 0.006.  
b Empiric P value = 0.01. 
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Table VI: Allelic associations between imputed SNPs and CS dependence in children 
with CD. 
SNP id Association Allele Imputation 
Quality, r2 
Frequencies, 
 Case, Control  
Chi square P value 
rs10482689 T 0.740 0.212, 0.108 10.379 0.001a 
rs10482682 A 1.00 0.440, 0.354 3.955 0.048 
rs17287758 A 0.628 0.208, 0.108 9.696 0.002a 
rs6196 A 0.997 0.896, 0.831 4.58 0.032 
rs10482642 C 0.813 0.204, 0.108 9.030 0.003a 
rs10515521 A 0.830 0.192, 0.104 7.896 0.005a 
rs17339831 C 0.845 0.192, 0.104 7.896 0.005a 
rs2963155 A 1.00 0.824, 0.746 4.566 0.033 
rs11740792 G 0.856 0.192, 0.108 7.144 0.007 
rs10482633 G 0.867 0.184, 0.108 5.983 0.014 
rs4128428 C 0.875 0.184, 0.108 5.983 0.014 
rs1438732 G 0.913 0.900, 0.838 4.23 0.040 
rs10515522 T 0.937 0.900, 0.838 4.23 0.040 
rs9324918 T 0.891 0.900, 0.838 4.23 0.040 
rs4912903 T 0.697 0.440, 0.354 3.955 0.050 
rs17287745 G 0.754 0.440, 0.354 3.955 0.050 
rs33389 C 0.925 0.900, 0.842 3.765 0.050 
rs2918419 T 0.922 0.900, 0.842 3.765 0.050 
rs2918418 G 0.867 0.900, 0.842 3.765 0.050 
rs2963151 T 0.929 0.900, 0.842 3.765 0.050 
rs2963154 T 0.880 0.900, 0.842 3.765 0.050 
rs2918415 A 0.942 0.900, 0.842 3.765 0.050 
a Empiric P values. 
Only significantly (P ≤ 0.05) associated markers are shown. 
Genotyped markers are highlighted in bold.  
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Table VII-A: Association between haplotypes in the NR3C1 gene with response to CS in paediatric CD using genotyped and 
imputed SNPs data, block 1. 
SNPs Frequencies  
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Freq. 
Freq.  
C/Ctr. 
Chi2 
P 
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G C C C C T T A C A G A A 0.404 0.384/0.423 0.81 0.369 
G C C T C T A G C G A A A 0.155 0.208/0.104 10.56 0.001a 
A C C T C T A G C G G G A 0.143 0.140/0.146 0.04 0.843 
G A T C C C A A G G G A G 0.131 0.104/0.158 3.22 0.073 
G C C T C T A G C G G G A 0.094 0.088/0.100 0.21 0.643 
G C C C T T T A C A G A A 0.065 0.072/0.058 0.43 0.511 
C, Cases; Ctr., Controls. 
a Empiric P value = 0.03. 
Genotyped marker highlighted in bold. 
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Table VII-B: Association between haplotypes in the NR3C1 gene with response to CS in paediatric CD using genotyped and 
imputed SNPs data, block 2. 
SNPs 
Frequencies  
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Freq 
Freq C/Ctr. Chi2 P value 
A A T C A G C 0.467 0.456/0.477 0.22 0.636 
A G T G G G C 0.237 0.228/0.246 0.23 0.630 
G A G C A A T 0.157 0.208/0.108 9.69 0.0018 a 
G A G C A A C 0.131 0.104/0.158 3.22 0.073 
C, Cases; Ctr., Controls. 
a Empiric P value = 0.025. 
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Figure 1. LD (r2 x 100) between genotyped Tag-SNPS in NR3C1 gene.  
Legend: The line at top of the figure represents association between the SNPs and CS 
dependence (P-values). The markers significantly associated (P<0.05) with CS dependence under 
an additive model are boxed. Under a recessive model they are in rounded boxes. 
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Figure 2. LD between genotyped and imputed SNPs, and haplotype blocks.  
Legend: The line on the top designates P values of single marker association analysis for 
genotyped and imputed SNPs. The markers significantly (P value <0.05) associated with CS 
dependence are in boxes and in rounded boxes are the markers marginally significantly (P<0.10) 
associated with CS dependence.  rs6196 is a genotyped SNP. 
 
    
 
 
 
 
 
 
 
 
 
 
CHAPTER 4  
DISCUSSION OF THE RESULTS 
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4.1 Summary of the results  
This study confirms that CS dependence is very common among children 
diagnosed with CD. The high rates of ~40% suggest that approximately 1 in 2 children 
treated with CS are likely to become dependent. These high rates are particularly 
challenging and make the search for the identification of clinical and molecular 
predictors that much more urgent. Concerning clinical and demographic markers, our 
study has shown that children diagnosed with CD at a very young age (<10.7) are more 
likely to become CS dependent. Similarly, those children who had co-existing upper 
digestive tract disease were also more likely to be susceptible. Findings related to a 
younger age at diagnosis and susceptibility for CS dependence have been reported 
previously. Associations with upper digestive tract disease, however, are novel. 
Concerning genetic markers, we found some evidence that the MDR1 gene was 
associated with CS dependency. Associations appear to be confined to 1-2 markers 
within the gene, although haplotype combinations with SNP C3435T (Exon 26), which 
is known to alter MDR1 expression, seem important as well. As for the GR gene, 
multiple markers individually and at the haplotype level were found to be related to CS 
dependence.  
The rate of CS resistance that we report (8%) is consistent with the majority of 
previous paediatric studies but is substantially lower than those in adult studies. This 
difference in rates between paediatric and adult patients may be related to the age-
dependent expression of GR receptor [302]. Moreover, a lesser extent of the previous 
exposure to various environmental influences, including CS, in a paediatric IBD 
population could possibly explain the difference, given that a sensitizing effect of CS on 
the development of the sub-population of T cells, which contributes to CS resistance, has 
been suggested [303]. We also observed a higher incidence of CS resistance in girls than 
in boys (11, 6% vs. 5%). This finding may reflect more severe disease in girls in 
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accordance with USA based study [304]. However in our study disease severity was not 
different between boys and girls. Another explanation could be related to differences in 
hormonal background between girls and boys or to use of contraceptives. Although 
interesting these differences were based on small number of patients and need to be 
further examined in larger samples.  
The rates of CS dependence that we report are comparable to rates reported in 
some paediatric studies and are slightly higher than those reported in adult patients. This 
difference could be attributed to the differential expression of studied genes in children 
and adults. Indeed, the association of younger age at diagnosis and upper digestive tract 
involvement reported by this study suggests that the CS dependent phenotype may be 
heterogeneous. It is of interest that an experimental animal study [302] suggested that 
the loss and gain of glucocorticoid responsiveness in the proximal and distal small 
intestine, respectively, were related to age- and segment-dependent expression of GR. It 
could thus be speculated that variations in the GR gene may be related to CS dependence 
via its influence on GR expression in different parts of the intestinal tract.  
LD among some tag-SNPs (rs1202184 and rs37789243) exceeds the selected 
threshold of 0.80 in our population as it shown in Figure 1 (page 133). Higher LD in our 
population than in the HAPMAP data could be explained by composition of our 
population that comprise CD patients as opposed to the healthy individuals in the 
HAPMAP. With respect to associations between the ABCB1 gene and CS dependence, 
from among the 14 SNPs investigated we observed associations only with SNP 
rs2032583 (Intron 21). In our study, he minor allele (C) of rs2032583 was inversely 
associated with CS dependence (OR=0.56; 95% CI: 0.34 - 0.95, p=0.029). The 
comparison of our findings with other similar studies in the paediatric population is not 
possible as none of the earlier studies examined associations between this SNP (or a 
proxy) and CS dependence in CD. However, consistent with our findings in CD, in 
German [305] and USA based [306] studies, the C allele of SNP rs2032583 has been 
shown to be associated with a higher probability of remission from depression after 4 
weeks in carriers treated with antidepressants. Nevertheless, these comparisons should 
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be interpreted with caution because of the different Pgp substrates (CS versus anti-
depressants) and the different phenotypes involved. It is also notable that in our earlier 
study [307] the same SNP (rs2032583) was associated with colonic CD. It is possible 
that the same variant contributes to the CS dependent phenotype and colonic disease. 
However, no association was found between colonic disease and CS dependence in our 
present study. It is therefore possible that, the link between the MDR1 gene and colonic 
CD may be independent from that between the MDR1 gene and CS response and that 
different pathways may be implicated in these associations. 
In addition to the single SNP association, we found a haplotype, comprising the 
functionally relevant SNP C3435T (rs1045642) in exon 26, to be associated with CS 
dependence. Gene-wide haplotype analysis carried out as well revealed that haplotypes 
in one of blocks were associated with CS-dependence, but did not withstand permutation 
test. The association appeared to be driven by C3435T and rs2032583 variants, so 
further analysis strategy focused on theses SNPs with addition of marginally significant 
one (rs3789243) in single marker analysis. The association of haplotype CTC, 
comprising two intronic (rs3789243 and rs2032583) in intron 2 and intron 21 and one 
coding synonymous (rs1045642) variant, was significant after correction for multiple 
testing. In our study, the C allele of rs1045642 was part of the haplotype that was more 
frequent in CS-dependent patients than in responders to CS. This finding supports the 
hypothesis that a decrease in intracellular concentration of the drug due to the over-
expression of Pgp may be involved in CS dependence, given that the C allele has been 
shown to be associated with increased activity of the Pgp pump in expression studies 
[203, 204]. Our results nonetheless differ from some previous association studies that 
have explored ABCB1 variants and CS response. For example, in contrast to our study, 
Potocnik et al. [220] observed positive associations between a haplotype encompassing 
the T allele of rs1045642, and refractory CD. This study was however based on a small 
sample, used a comparison group different from our study and had a broader definition 
for refractory CD (it included all patients not responding to various drugs used to treat 
IBD). In the Belgium [223] study, observations of positive associations between the TT 
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genotype and complete tapering of CS are however consistent with those in our study. 
As also noted by the authors of this study, observed associations of the T allele with CS 
response may be related to the T allele being associated with more extensive and severe 
disease [227]. In our cohort however, disease severity was not correlated with CS 
dependence, indicating that associations between the SNP and CS dependence may be 
independent of disease severity. Two other SNPs (rs3789243 and rs2032583) 
comprising the haplotype associated with CS dependence in our study have also been 
shown to influence response to treatment in other medical conditions. Particularly, the C 
allele of rs3789243 (Intron 2) was shown to be more frequent in responders to 
antiepileptic drugs [308], and the C allele of rs2032583 (Intron 21) was shown to be 
more frequent in patients responding to antidepressants [305, 306], implying that 
associations between variants in the MDR1 gene may not be specific to CD. This is not 
surprising given that the MDR1 gene has multiple substrate specificity and influences 
the metabolism of a variety of drugs besides steroids.  
With regard to known haplotype comprising SNPs at the positions 1236, 2677 
and 3435, we were not able to explore its association with CS dependence, because 
marker 2677 could not be typed due to technological limitations. The haplotype 
comprising two other markers of interest (1236 and 3435) was not significantly 
associated with outcome of interest.  
One of known SNPs in NR3C1 gene (rs41423247), shown by Mill et al.[309] to 
be in high LD (D` 0.95) with the coding synonymous SNP rs6196 that was significantly 
associated with CS dependency in our study. Although there appears to be high D` 
between these two markers, their allele frequencies are quite disparate (50% versus 
14%) and hence r2 is likely to be quite low. Therefore, given potentially low LD, the 
rs41423247 SNP may require specific investigation. We observed associations between 
multiple SNPs across the NR3C1 gene (both single marker and haplotype) and CS 
dependency implicating the gene in CS response. The haplotype associations noted were 
of particular interest. Both, gene-wide and 5-marker haplotype associations comprising 
SNPs significant in single marker analysis, withstood adjustment for multiple 
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comparisons. A 6-marker haplotype AACGAC (defined using solid spine of LD), that 
included the coding-synonymous variant rs6196 (Exon 9) in gene-wide analysis was 
positively associated with CS-dependence (p-value 0.0013). A 5-marker haplotype 
AAACA that also comprised allele A of rs6196, was positively associated with CS 
dependence. These observations are consistent with the inverse associations between the 
G-allele of SNP rs6196 and CS dependence noted in the single-SNP analysis in our 
study. Our findings, however, differ from the only other study that examined 
associations between the rs6196 variant and CS response in IBD. In a Swiss study [264], 
in 181 IBD patients, no associations were noted either at the single SNP or haplotype 
level with SNP rs6196. The Swiss study was however potentially underpowered to 
detect associations, did not analyse CD separately and used different definitions for 
steroid response, making comparisons between studies difficult.   
Recently it has become clear that multiple isoforms of the GR protein are 
generated endogenously as a result of alternative RNA splicing and alternative 
translation initiation [245]. In addition, each isoform is subject to a variety of post-
translational modifications. Consequently, the potential existence of numerous receptor 
variants, each having differential characteristics in expression, localization, 
transcriptional activity, and degradation, contributes substantially to unique biological 
responses. In our study, the haplotype associated with CS-dependency contained rs6196, 
a coding-synonymous SNP located in exon 9α, encoding the transcriptionally active 
form of a GR receptor, consequently supporting the role of α isoform in variability to 
drug response. Since GRα can also undergo a variety of other post-translational modifications 
[310], leading to other isomers such as the β isoforms, the variants coding for this 
isoform may also be related to CS dependency. It was suggested previously that the 
variability of GC sensitivity could depend on the ratio of GR alternative splicing and 
therefore on imbalance in α and β isoforms. However, as our study did not include 
variations in exon 9β encoding for the β isomer we were unable to examine its 
associations with CS response. Certainly, additional studies will be required to further 
differentiate associations between the various GR isomers and CS response.  
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Our examination of both the MDR1 and GR genes, by-and-large, suggested that 
synonymous coding variations were likely to be associated with CS response. This is in 
line with recent evidence indicating that synonymous sites are not neutral or non-
functional [219, 311]. Incidentally, synonymous variations have been shown to affect 
gene function by altering the stability, splicing or localisation of m-RNA [312-314], thus 
affecting the expression and activity of the coded protein.  
4.2 Alternate pathways mediating variation in response to CS  
The mechanism of CS refractoriness is likely complex and unlikely to be 
associated with a single pathway. Although CS refractoriness may be a primary 
phenomenon related to abnormalities in the proteins in the upstream pathway of steroid 
metabolism, it is also likely that the anti-inflammatory capacity of CS is overwhelmed 
by inflammation-driven excessive synthesis and the activity of intracellular transcription 
factors that may reduce the affinity of GR for its intracellular substrate (CS). For 
instance, an excessive constitutive activation of the pro-inflammatory molecule NF- B, 
and IL-10 cannot be ruled out. It has been recently shown that [315] in CD patients who 
are resistant to CS, there is an increase in activity and level of NF- B in the epithelial 
cells of the intestinal mucosa and reporter gene assays indicate that these higher levels 
inhibit the activity of GRα preventing its transcriptional activity. Similarly, associations 
between the IL-10 gene and CS response have been reported [316]. It is quite plausible 
that an excess of inflammatory cytokines accumulated locally during relapses cannot be 
efficiently down-regulated in response to CS because of an insufficient up-regulation of 
IL-10 synthesis in IBD patient in particular in carriers of the low IL-10 producer 
genotype. In addition to IL-10, variation in the IL-2 and CYP3AA genes may also be of 
interest. Lee et al. [303] have reported an increased proliferation of CD4+ T cells 
expressing the interleukin receptor (IL-2) after exposure to dexamethasone in adult 
patients with UC. A higher prevalence of these cells was observed in subjects with a 
history of CS resistance. A higher resistance of lymphocytes to steroids has also been 
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reported in healthy subjects [317] with suggestions that up to 30% of the healthy 
population would fail to respond to CS therapy for severe inflammatory conditions [317, 
318] as a consequence. As for the CYP3A4 gene, it is known to catalyze the 6-
hydroxylation of a number of steroids, including dexamethasone and prednisone [213, 
214], implying that variations in this gene may also underlie susceptibility for CS 
dependence. It is therefore clear that CS-dependency is apparently a multi-factorial 
phenotype involving perhaps the contribution of several genes and unknown 
environmental influences. These potential influences need to be further explored.   
4.3 Strengths and limitations of the study 
The studies undertaken had some strengths and limitations as well. A major 
strength in comparison to previous studies was that that our studies were based on a 
relatively large cohort of well-characterized CD patients. Another strength was the 
inclusion of only CS-naïve patients so that the possible influence of previous CS 
exposure could be limited. A comprehensive investigation of the target genes was 
carried out by: (1) selecting tag-SNPs that provided adequate coverage of variation 
across the genes and (2) using imputation methods to allow us to infer the associations 
with other markers possibly not captured by the SNP-tagging approach. This approach 
ensured that any associations between the target genes and CS response would not be 
missed.  
The studies also had some limitations. They were based on a cohort for whom 
data was acquired retrospectively. They were thus susceptible to the different biases 
inherent in such designs. The potential for such biases, the methods utilized to reduce 
them and their impact on the study findings are summarized below. 
In the context of retrospective cohort studies, selection bias may arise when the 
selected study population is not representative of the target population, limiting the 
generalisation of findings [319]. For our studies, we have used two sources to identify 
patients diagnosed with CD: a patient list maintained at the gastroenterology clinics and 
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the medical archives’ databases at the main study hospital, which is one of the largest 
paediatric hospitals in Canada. From within this cohort, the study cohort (patients with 
moderate-severe disease who were administered steroids during the first year after 
diagnosis) was established. This comprehensive approach would have limited the 
potential for selection bias, if any. It is nonetheless possible that many patients with 
moderate-severe CD who visited the other paediatric IBD center in Montreal (Montreal 
Children’s Hospital) and who were administered steroids, may differ in some ways from 
our study cohort. Similarly, a minority of patients with mild CD are also at times 
administered steroids. Such patients are more likely to be treated by their family 
physicians and hence would not have been eligible for selection in our cohort. Therefore, 
the potential for selection bias remains but is likely to be limited. 
Another potential for selection bias in a cohort study may be due to the rates of 
participation and/or follow-up that differ according to the exposure or the outcome under 
study. Among the ~ (n=450) patients that were eligible for selection, participation and 
follow-up, in our clinical and/or genetic studies, 86% were finally included. Thus 
complete data was available for 82% to 86% of patients. These participation rates can be 
considered high (and therefore acceptable) and unlikely to have resulted in major 
selection bias, if any. Among those patients who were eligible for inclusion it is 
nonetheless possible that patients who responded to CS versus those who became CS 
dependent had different propensities to attrition or to provide the biomaterial. However, 
the main reason for the missing samples of biomaterial was the impossibility to retrace 
patients’ addresses with only few refusals to provide samples. It has to be noted however 
that the follow-up period in our study was quite short (1 year since diagnosis) and that 
the majority of patients continued to visit the hospitals for this time period, ensuring that 
follow-up was near-complete for all included patients. We also believe that the 
distribution of alleles was unlikely to be different in patients who either did not 
participate or did not have complete clinical data or did not provide DNA samples, as a 
result ensuring that selection bias was also likely to be limited. Nevertheless, in order to 
verify potential bias, we compared main characteristics of patients (such as age, sex, 
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clinical characteristics at diagnosis) that were lost to follow-up (i.e. patients who did not 
have complete clinical information for the follow-up duration) with those with complete 
follow-up. Similarly, in order to identify the occurrence of analogous bias due to the 
refusal to provide samples of biomaterial, patients’ baseline characteristics and the 
response to CS were compared between those who contributed DNA material and those 
who did not. No meaningful differences were evident, suggesting that selection bias was 
limited. We also believe that possibility of survival bias is very limited given that firstly, 
mortality during 1-2 years since diagnosis in early onset of CD is quite low and secondly 
none of the examined genes are known to be associated with survival. 
We have considered a possibility of the presence of information bias resulting 
from potential genotyping errors. Aiming to decrease the possibility of such bias and the 
extent of random errors, which may lead to reduced power to detect true associations, 
the genotyping process involved a stringent protocol for maintaining the quality of the 
acquired results. Each of the SNPs was tested for genotyping reproducibility in 5 % of 
samples. We observed >98% concordance in results in the duplicate samples. The 
samples of biological material of all subjects were handled in a similar way adhering to 
stringent protocols during DNA extraction process, so possible contamination, which 
may lead to low quality of DNA, is likely to be equally distributed among the 
comparison groups. Moreover, laboratory personnel that performed genotyping were 
unaware of patients’ outcome status. Consequently, if genotyping errors due to the 
“human factor” have occurred, they should be equally distributed among comparison 
groups as well. Most of the tested SNPs, barring 1, were in HWE. Although this test 
may have limited power to detect genotyping errors in conjunction with the quality 
control methods implemented, we believe that information bias with regards to 
genotyping was likely to be limited. In any case, if present, it would be expected, on 
average, to be non-differential and have resulted in an underestimation of the true 
associations.  
With respect to majority of clinical and demographic predictors of CS 
dependence, information bias was unlikely to occur, since characteristics such as age at 
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diagnosis, gender, CD phenotypes and other clinical characteristics were well-
documented in the medical charts and were not susceptible to misinterpretation. 
Nevertheless, some misclassification in the assignment of patients to the studied 
outcomes was possible. This is because the assessment of study outcomes was based on 
inscriptions in medical charts. The description of some symptoms required in particular 
for classifying individual short term outcomes (response and partial response to CS) was 
not complete. For these patients, classification was based on the physician’s assessment 
of the patients’ profile. If misclassification was present, it may have resulted in 
lower/higher estimates of the true prevalence rates. It was however unlikely to influence 
comparisons between groups as it was unlikely to be related to the socio-demographic, 
clinical variables and genotypes of the patient. With respect to long-term study outcomes 
(CS-dependence and CS response) the possibility of such misclassification is minimal 
because of the nature of the definitions used. The definition of CS-dependency was 
based on the occurrence of clinical relapse of disease, which was in turn well-
documented in the medical charts by the treating physicians. In doubtful instances, the 
outcome was validated after consulting with the treating physician. Moreover, inter- rater 
reliability assessed for long-term outcomes on the subset of patients was satisfactory. 
Nevertheless, the potential for misclassification remains, but was likely to be non-
differential as well and may have lead to the underestimation of the true effects.  
Confounding refers to the mixing of the estimated effect with other risk factors 
[319]. .In our study, some patients’ characteristics were considered as potential 
confounders given that they could be associated with response to CS and the studied 
genes. These include variables such as concomitant medication, age at diagnosis and 
disease localization or behaviour. In order to assess the true effects of the genetic 
variants of interest on the occurrence of CS dependence, we have applied an adjustment 
in analysis using the multivariate models. The anti-TNF medication was introduced in 
Quebec in about 2000 and a little earlier in Ontario. This medication however according 
to recent practice was used only in cases of non-response or dependence to CS, thus 
after the study outcomes were developed. Therefore, the possibility of confounding by 
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these therapeutic agents is not likely. The same procedure, control in analysis, was 
applied to the assessment of the effects of potential clinical and demographic markers of 
a response to CS, based on the knowledge that many of them may be associated each 
with another and with CS resistance or/and CS dependence. 
Confounding by ethnicity, also called population stratification, is an inherent 
limitation of genetic association studies, occurring when both the frequencies of genetic 
variations and the proportions of outcome differ in the ethnic subgroups of the study 
population. In the context of our study, ethnicity could have potentially confounded 
genetic associations if the gene frequencies varied according to ethnicity and CS 
response was different between ethnic groups. The majority of the studied cohort was 
Caucasian (>90%). An analysis excluding non-Caucasians did not alter the findings, 
indicating that ethnicity was unlikely to have played a major role.  
Although by-and-large our studies were adequately powered to examine genetic 
markers for CS dependence, power was limited for comprehensively examining 
associations with CS resistance. Also, the power to detect associations between some 
low frequency functional SNPs such as rs6195 and rs6190 in NR3C1 gene and CS 
dependence was potentially limited as well. Furthermore, our study did not have 
adequate power to investigate gene-gene interactions, that could potentially influence CS 
response.  
4.4 Clinical and public health implications 
Advances in pharmacogenetics and genomics can improve the overall results of 
patients’ care and thus contribute to the improvement of health services. The prevention 
of disease outcomes based on the risk stratification approach has long been proposed 
[320]. It has been maintained, that the clarification of the role of genes and environment 
could lead to new combined approaches towards prevention based on risk stratification. 
Personalized medicine and personalized genomics approaches have recently emerged in 
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clinical medicine [321], promising the improvement of efficiency of treatment strategies 
by adjusting drug choices according to genetic patient’s profile.  
In the context of our study, the identification of molecular markers could permit 
the timely introduction of appropriate alternate therapies to patients potentially 
susceptible to develop CS-dependence. Ultimately, such alternate strategies can  result in 
the improvement of the quality of life of patients and would decrease the burden 
imposed on health services due to disease flares and complications requiring 
hospitalization. The observed associations between the NR3C1 and ABCB1 genes and 
the CS dependent phenotype among paediatric patients, if confirmed, could potentially 
aid clinicians in pursuing individualized treatments and researchers in pursuing the 
search for mechanisms underlying variability in response to CS. 
The clinical relevance of potential markers of drug response largely depends on 
the frequency of a variant in patients’ population. The characteristic of a good clinical 
marker depends on its prevalence in a population of interest, its specificity and 
sensitivity. The proportion of children’ under 11 years of age in our population is about 
25%, and those with upper digestive disease is about 26%. These two potential markers 
for CS dependency (young age at diagnosis and upper digestive disease) would not 
represent all CS-dependent patients. Moreover, the two mentioned potential markers do 
not appear to explain all variations related to the CS-dependent phenotype, highlighting 
the importance of studying the role of genetic variations, including those in other 
putative genes. Given that the overall frequencies of markers associated with CS 
dependency in our study were from 10 to 50% and the frequencies of associated 
haplotypes range from 10 to 15.5 %, it is unlikely that the results of this study could be 
translated into clinical practice presently. Future exploration would be necessary in order 
to delineate the simultaneous contribution of the two studied genes, the role of other 
putative genes and other potentially clinical predictors. Nonetheless, our findings do 
provide clues to possible pathogenesis of CS dependence that could be investigated using 
functional studies.  
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Although pharmacogenetics is a promising field that already contributes to a 
better understanding of some of the underlying mechanisms of action of drugs used in 
IBD, until now the only discovery translated into daily practice is the relation between 
the thiopurine S-methyltransferase (TPMT) gene polymorphisms and the hematological 
toxicity of thiopurine treatment. In reality, the majority of currently established genetic 
polymorphisms that influence drug therapy are mono-genic traits, such as those found in 
TPMT. As CS dependence is very likely to be a complex phenotype, on a cautious note, 
the translation of findings of genetic associations into clinical practice may be more 
complicated and require extensive study. 
These findings are of relevance to other inflammatory and auto-immune medical 
conditions where CS are commonly used. The magnitude of the problem related to 
altered response to CS depends on prevalence of given disease and the extent of inter-
individual variability of response to CS. Childhood ALL is the most common 
malignancy in children below age of 15 years [322] with an annual incidence in Europe 
and the United States of 3.5 cases per 100,000 children 0 to 14.9 years of age [323]. 
Notably, in ALL CS are widely used as a part of induction therapy according to current 
protocols. About 10-30% of ALL patients do not respond well to CS therapy [324]. In 
childhood asthma despite the relatively small fraction (5%) of CS dependent/resistant 
patients, this problem presents significant clinical challenge due to the difficulties of 
disease management and is associated with 2-fold increase of health costs [325, 326].  
Given that other inflammatory and autoimmune conditions share common 
pathways related to CS action and CS metabolism, the results of this thesis could help 
future investigations. 
4.5 Future directions 
Our findings of associations between the variations in NR3C1 and ABCB1 genes 
and CS dependency have to be replicated in larger prospective cohorts of paediatric or 
adult CD patients. Furthermore, expression studies examining the relationship between 
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CS dependent phenotype and haplotypes in two studied genes would be of relevance. 
The role of the GR isoform α and β should also be further explored. Regarding the 
clinical predictors of CS dependency, the mechanisms underlying the association with 
younger age at diagnosis need exploration as well.  The studies of the interaction 
between the two investigated genes and the CS dependent phenotype would be of 
interest. Another focus of interest could be the exploration of the underlying 
mechanisms that differentiate between the resistance and dependence to CS, as well as 
the mechanisms involved in secondary resistance and dependence to CS. In our study, 
the patients were not previously exposed to CS, precluding the examination of secondary 
CS dependence. As some patients change from a CS resistant (with an increased dose of 
CS) to a CS dependent phenotype, studying the mechanisms underlying these changing 
phenotypes would be of interest as well.  
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QUESTIONNAIRE 
_________________________________________________________________________
__________ 
Date d'achèvement du questionnaire : _______________(J/M/A) 
 
A. ID DU SUJET:      ____________________________________ 
 
Sexe: Garçon _____  Fille _____ 
 
Diagnostic : ________ Crohn     ________ Colite ulcéreuse _______ Indéterminée 
        _________Contrôle  
 
Pour les questions suivantes, veuillez cocher la case si nécessaire (NR = ne souhaite pas 
ou ne connaît pas la réponse). 
 
 
Quel est le rang de l’individu dans la famille? (ordre de 
naissance) 
(mettez 1 s’il est né le premier, 2 s’il est né le second etc.) 
______ 
 
NR 
 Combien de frères et/ou soeurs a votre enfant? ______ 
 
NR 
 Taille actuelle de l’individu (pieds/pouce) 
___ pieds 
___ pouce 
 
NR  
 Poids actuel de l’individu (kg/grammes) 
___kg 
___gm 
 
NR 
 
 
Pour chaque frère/sœur, veuillez indiquer l’âge et le sexe (M pour garçon, F pour 
fille) : 
 
 
 
 
  
iv 
 
Frère/sœur 1     Prénom : _______    Age : _______      Sexe : _______              
Frère/sœur 2     Prénom : _______    Age : _______      Sexe : _______              
Frère/sœur 3     Prénom : _______    Age : _______      Sexe : _______              
Frère/sœur 4     Prénom : _______    Age : _______      Sexe : _______              
Frère/sœur 5     Prénom : _______    Age : _______      Sexe : _______              
 
(Vous pouvez ajouter ci-dessous d’autres frères/sœurs si nécessaire) 
 
 
 
B. HISTOIRE MÉDICALE ANTÉRIEURE 
Les questions suivantes portent sur les maladies affectant ou ayant affecté un membre 
de la famille. Lorsque nécessaire, veuillez cocher les cases correspondantes. (NA = ne 
s’applique pas, NR = ne souhaite pas répondre ou ne connaît pas la réponse) 
 
Maladie de Crohn Colite ulcéreuse 
Père ____Oui ___ Non ___ NR ___ NA 
Age au moment du diagnostic: _____ ans 
Mère ____Oui ___ Non ___ NR ___ NA 
Age au moment du diagnostic: _____ ans 
Grand-père ____Oui ___ Non ___ NR ___ 
NA 
Age au moment du diagnostic: _____ ans 
Grand-mère ____Oui ___ Non ___ NR ___ 
NA 
Age au moment du diagnostic: _____ ans 
Oncle(s): maternel(s) ou paternel(s) 
 1. ____Oui ___ Non ___ NR ___ NA 
Père ____Oui ___ Non ___ NR ___ NA 
Age au moment du diagnostic: _____ ans 
Mère ____Oui ___ Non ___ NR ___ NA 
Age au moment du diagnostic: _____ ans 
Grand-père ____Oui ___ Non ___ NR ___ 
NA 
Age au moment du diagnostic: _____ ans 
Grand-mère ____Oui ___ Non ___ NR ___ 
NA 
Age au moment du diagnostic: _____ ans 
Oncle(s): maternel(s) ou paternel(s) 
 1. ____Oui ___ Non ___ NR ___ 
  
v 
             Age au moment du diagnostic: _____ 
ans 
 2. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 3. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
Tante(s):maternel(s) ou paternel(s) 
 1. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 2. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 3. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
Premier(s) cousin(s) : maternel(s) ou 
paternel(s) 
 1. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 2. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 3. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
NA 
             Age au moment du diagnostic: 
_____ ans 
 2. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 3. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
Tante(s): maternel(s) ou paternel(s) 
 1. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 2. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 3. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
Premier(s) cousin(s) : maternel(s) ou 
paternel(s) 
 1. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
  
vi 
Frère(s)/sœur(s) 
            1. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 2. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 3. ____Oui ___ Non ___ NR ___ NA 
            Age au moment du diagnostic: _____ 
ans 
 
 
_____ ans 
 2. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 3. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
Frère(s)/sœur(s) 
            1. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 2. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 3. ____Oui ___ Non ___ NR ___ 
NA 
            Age au moment du diagnostic: 
_____ ans 
 
  
vii 
 
C. Les questions suivantes portent sur les maladies affectant ou ayant affecté certains 
membres de la famille.  Lorsque nécessaire, veuillez cocher les cases correspondantes. 
(NA = ne s’applique pas, NR = ne souhaite pas répondre ou ne connaît pas la réponse) 
 
Asthme 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Arthrite rhumatoïde 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Scléroses multiples 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Diabète 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Lupus Erythémateux aigu 
Oui 
Non 
NR 
Quel(s) membre (s):___________________ 
Colon irritable 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Infection Hélicobacter Pylori 
Oui  
Non 
NR 
Quel(s) membre (s):___________________ 
Autre(s) (spécifiez): 
Oui 
Non 
NR 
Quel(s) membre (s):___________________ 
 
  
viii 
 
D. GROUPE ETHNIQUE 
Auquel des groupes suivants appartenez-vous ? (il s’agit ici de la provenance du sujet-cas 
ou sujet témoin). Si plus d'un groupe, sélectionnez les groupes pertinents. 
Blanc  
Noir, Africain Américain  
Amérindien ou natif d’Alaska 
 
Asiatique Indien  
Japonais  
Natif d’Hawaii  
Chinois  
Coréen  
Guamanien ou Chamorro 
 
Philippin  
Vietnamien  
Samoan  
Autre Asiatique (préciser): 
________________________________ 
 
Autre insulaire du Pacifique (préciser): 
______________________ 
 
Autre (préciser) : 
________________________________________ 
 
NR  
Ce questionnaire est maintenant terminé, nous vous remercions pour le temps que vous y 
avez consacré.  
  
ix 
 
Appendix 2 
List of selected tag-SNPs in ABCB1/MDR1 gene 
  
x 
Gene Name: ABCB1 
Gene ID: 5243 
Chromosome 7: 86970884 - 87180500 (-) 
Genes in this region: ABCB1 RUNDC3B  
Allele Frequency Cutoff (%): 10, monomorphic sites included  
R2 Threshold for Clusters: 0.8 
Minimal Genotype Coverage (%) of Snps to Be TagSnps: 85 
Minimal Genotype Coverage (%) of Snps to Be Clustered: 80 
Data Merging: common samples with combined variations 
Population: AFD_EUR_PANEL, Submitter: PERLEGEN 
Bin Total 
Number 
of Sites 
Average 
Minor Allele 
Frequency 
Tag SNPs Other SNPs 
1 14 47 % rs2235046 
rs10276036 
rs1202167 
rs1202168 
rs1202170 
rs2235013 
rs2520464 
rs3789244 
rs4148738 
rs6949448 
rs6961665 
rs6969155 
rs10808072 
rs12539098 
2 9 13 % rs1882479 
rs2032583 
 
  
xi 
Bin Total 
Number 
of Sites 
Average 
Minor Allele 
Frequency 
Tag SNPs Other SNPs 
rs2235067 
rs4148739 
rs4148740 
rs10276603 
rs10280101 
rs11983225 
rs12720067 
3 8 28 % rs1202171 
rs1202172 
rs1202179 
rs1202181 
rs1202182 
rs1202185 
rs1202186 
rs1989830 
 
4 6 31 % rs2091766 rs956825 
rs1922240 
rs4148735 
rs4148736 
rs4148737 
5 3 21 % rs6950978 
rs10256836 
rs10259849 
 
6 2 38 % rs1045642  
  
xii 
Bin Total 
Number 
of Sites 
Average 
Minor Allele 
Frequency 
Tag SNPs Other SNPs 
rs2235048 
7 2 15 % rs4148733 
rs17327442 
 
8 2 21 % rs7787082 
rs10248420 
 
9 1 48 % rs1128503  
10 1 48 % rs1202184  
11 1 33 % rs2235035  
12 1 46 % rs3789243  
13 1 29 % rs10264990  
14 1 25 % rs17327624  
Legend:   
Variation Color code 
splice-site 
coding-nonsynonymous 
coding-synonymous 
coding 
mrna-utr 
SNPs that were included in panel to genotype are underlined  
 
    
 
 
 
 
 
 
 
 
Appendix 3 
List of selected tag-SNPs in NR3C1/GR gene 
  
xiv 
Gene Name: NR3C1 
Gene ID: 2908 
Chromosome 5: 142637689 - 142795270 (-) 
Total chromosome span: 142635689 - 142797270 
Allele Frequency Cutoff (%): 10, monomorphic sites included  
R2 Threshold for Clusters: 0.8 
Minimal Genotype Coverage (%) of Snps to Be TagSnps: 85 
Minimal Genotype Coverage (%) of Snps to Be Clustered: 80 
Data Merging: common samples with combined variations 
Population: AFD_EUR_PANEL, Submitter: PERLEGEN 
Bin 
Total 
Number 
of Sites 
Average 
Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
1 12 21 % 
rs2963156 
rs4986593 
rs9324916 
rs10482634 
rs10482655 
rs11750172 
rs17209237 
rs17209251 
rs17209258 
rs17339455 
rs17399352 
rs11745958 
2 11 18 % 
rs6196 
rs33389 
rs258748 
 
  
xv 
Bin 
Total 
Number 
of Sites 
Average 
Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
rs1438732 
rs2918415 
rs2918418 
rs2918419 
rs2963151 
rs2963154 
rs9324918 
rs10515522 
3 10 34 % 
rs190488 
rs258750 
rs258813 
rs852977 
rs852982 
rs860457 
rs1866388 
rs2918416 
rs2918417 
rs10052957 
 
4 8 16 % 
rs4128428 
rs10482633 
rs10482642 
rs10482689 
rs10515521 
 
  
xvi 
Bin 
Total 
Number 
of Sites 
Average 
Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
rs11740792 
rs17287758 
rs17339831 
5 7 45 % 
rs33383 
rs33388 
rs258747 
rs852980 
rs4634384 
rs6877893 
rs10041520 
 
6 5 27 % rs4912911 
rs4912910 
rs12655166 
rs12054797 
rs17100289 
7 3 14 % 
rs10482616 
rs10482672 
rs17100236 
 
8 2 20 % 
rs4244032 
rs13182800 
 
9 1 30 % rs2963155  
10 1 45 % rs4607376  
11 1 23 % rs4912905  
  
xvii 
Bin 
Total 
Number 
of Sites 
Average 
Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
12 1 29 % rs7701443  
13 1 32 % rs9324924  
14 1 37 % rs10482682  
 
Legend:  
Variation Color code 
splice-site 
coding-nonsynonymous 
coding-synonymous 
coding 
mrna-utr 
 
SNPs that were included in panel to genotype are underlined  
 
    
 
 
 
 
 
 
 
 
Appendix 4 
Study power estimation for article 1 
  
xix 
Model # 1 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.1000 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0588    0.000101 
      1.2000              0.0837    0.000102 
      1.3000              0.1232    0.000103 
      1.4000              0.1756    0.000104 
      1.5000              0.2388    0.000105 
      1.6000              0.3101    0.000106 
      1.7000              0.3862    0.000107 
  
xx 
      1.8000              0.4639    0.000108 
      1.9000              0.5400    0.000109 
      2.0000              0.6121    0.000110 
      2.1000              0.6782    0.000111 
      2.2000              0.7372    0.000112 
      2.3000              0.7885    0.000113 
      2.4000              0.8321    0.000114 
      2.5000              0.8684    0.000115 
-------------------------------------------- 
 
Model # 2 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.1500 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
  
xxi 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0624    0.000101 
      1.2000              0.0976    0.000103 
      1.3000              0.1532    0.000104 
      1.4000              0.2260    0.000106 
      1.5000              0.3118    0.000107 
      1.6000              0.4048    0.000109 
      1.7000              0.4992    0.000110 
      1.8000              0.5896    0.000112 
      1.9000              0.6722    0.000113 
      2.0000              0.7442    0.000115 
      2.1000              0.8048    0.000116 
      2.2000              0.8540    0.000118 
      2.3000              0.8928    0.000119 
      2.4000              0.9226    0.000121 
      2.5000              0.9450    0.000122 
-------------------------------------------- 
 
Model # 3 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.2000 
Disease model                   Summary parameters 
  
xxii 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0655    0.000102 
      1.2000              0.1095    0.000104 
      1.3000              0.1784    0.000106 
      1.4000              0.2675    0.000108 
      1.5000              0.3696    0.000110 
      1.6000              0.4762    0.000112 
      1.7000              0.5795    0.000114 
      1.8000              0.6731    0.000116 
      1.9000              0.7535    0.000118 
      2.0000              0.8191    0.000120 
      2.1000              0.8706    0.000122 
      2.2000              0.9095    0.000124 
      2.3000              0.9379    0.000126 
      2.4000              0.9582    0.000128 
      2.5000              0.9723    0.000130 
-------------------------------------------- 
  
xxiii 
 
Model # 4 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.2500 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0682    0.000102 
      1.2000              0.1193    0.000105 
      1.3000              0.1990    0.000107 
      1.4000              0.3003    0.000110 
      1.5000              0.4137    0.000112 
      1.6000              0.5282    0.000115 
  
xxiv 
      1.7000              0.6349    0.000117 
      1.8000              0.7274    0.000120 
      1.9000              0.8030    0.000122 
      2.0000              0.8618    0.000125 
      2.1000              0.9056    0.000127 
      2.2000              0.9369    0.000130 
      2.3000              0.9587    0.000132 
      2.4000              0.9735    0.000135 
      2.5000              0.9832    0.000137 
-------------------------------------------- 
 
Model # 5 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.3000 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                      
  
xxv 
Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0703    0.000103 
      1.2000              0.1271    0.000106 
      1.3000              0.2150    0.000109 
      1.4000              0.3251    0.000112 
      1.5000              0.4457    0.000115 
      1.6000              0.5645    0.000118 
      1.7000              0.6716    0.000121 
      1.8000              0.7616    0.000124 
      1.9000              0.8326    0.000127 
      2.0000              0.8859    0.000130 
      2.1000              0.9243    0.000133 
      2.2000              0.9508    0.000136 
      2.3000              0.9687    0.000139 
      2.4000              0.9804    0.000142 
      2.5000              0.9878    0.000145 
-------------------------------------------- 
 
Model # 6 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
  
xxvi 
   Prevalence:                  0.3500 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0719    0.000103 
      1.2000              0.1329    0.000107 
      1.3000              0.2265    0.000110 
      1.4000              0.3425    0.000114 
      1.5000              0.4673    0.000117 
      1.6000              0.5877    0.000121 
      1.7000              0.6942    0.000124 
      1.8000              0.7815    0.000128 
      1.9000              0.8490    0.000131 
      2.0000              0.8986    0.000135 
      2.1000              0.9336    0.000138 
      2.2000              0.9574    0.000142 
      2.3000              0.9731    0.000145 
      2.4000              0.9833    0.000149 
  
xxvii 
      2.5000              0.9897    0.000152 
-------------------------------------------- 
 
Model # 7 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Environment only 
Sample size:                    180 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Binary environmental factor 
   Prevalence:                  0.4000 
Disease model                   Summary parameters 
    P0      0.000100               *kP      0.000100 
    RE:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Environment     bE=0        bE        ---- 
-------------------------------------------------- 
 
                     Power 
              ------------------ 
          RE         Environment          kP 
-------------------------------------------- 
      1.0000              0.0500    0.000100 
      1.1000              0.0730    0.000104 
      1.2000              0.1368    0.000108 
      1.3000              0.2339    0.000112 
      1.4000              0.3530    0.000116 
  
xxviii 
      1.5000              0.4796    0.000120 
      1.6000              0.6002    0.000124 
      1.7000              0.7054    0.000128 
      1.8000              0.7907    0.000132 
      1.9000              0.8560    0.000136 
      2.0000              0.9036    0.000140 
      2.1000              0.9369    0.000144 
      2.2000              0.9594    0.000148 
      2.3000              0.9743    0.000152 
      2.4000              0.9840    0.000156 
      2.5000              0.9901    0.000160 
--------------------------------------------  
 
Legend:   
K
p
 Overall disease risk in the general population  
P
0
 Baseline disease risk: disease risk in 
unexposed (E=0 or Z=0) genetically normal 
(G=0, H=0) subjects  
R
e
 Environmental relative risk (or odds ratio): 
Risk relative to P
0 
when E=1 or Z=1, in 
genetically normal (G=0) subjects  
R
g
 Genetic relative risk (or odds ratio): Risk 
relative to P
0 
when G=1, in environmentally 
unexposed (E=0 or Z=0) subjects  
    
 
 
 
 
 
 
 
 
Appendix 5 
Study power estimation for articles 2 and 3 
  
xxx 
Model # 1 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1) 
Hypothesis:                     Gene only 
Sample size:                    150 cases, 1 control(s) per case are required 
Significance:                   0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.1000 to 0.5000 by 0.0500 
Disease model                   Summary parameters 
    P0      0.400000               *kP      0.400000 
    RG:       1.0000                (*indicates calculated value) 
 
Parameter       Null        Full      Reduced 
-------------------------------------------------- 
Gene            bG=0        bG        ---- 
-------------------------------------------------- 
                                 Power 
                          ------------------ 
   Frequency          RG                Gene          kP 
------------------------------------------------------- 
0.100000   1.0000              0.0500    0.400000 
                  1.1000              0.0643    0.404619 
                  1.2000              0.1033    0.408898 
                  1.3000              0.1625    0.412869 
                  1.4000              0.2369    0.416561 
                  1.5000              0.3209    0.420000 
                  1.6000              0.4085    0.423209 
                  1.7000              0.4947    0.426208 
                  1.8000              0.5755    0.429017 
                  1.9000              0.6484    0.431653 
                  2.0000              0.7123    0.434130 
                  2.1000              0.7668    0.436462 
  
xxxi 
                  2.2000              0.8124    0.438661 
                  2.3000              0.8501    0.440738 
                  2.4000              0.8807    0.442703 
                  2.5000              0.9054    0.444565 
0.150000   1.0000              0.0500    0.400000 
                  1.1000              0.0702    0.406931 
                  1.2000              0.1259    0.413354 
                  1.3000              0.2102    0.419313 
                  1.4000              0.3138    0.424849 
                  1.5000              0.4259    0.430000 
                  1.6000              0.5357    0.434800 
                  1.7000              0.6357    0.439281 
                  1.8000              0.7213    0.443471 
                  1.9000              0.7913    0.447395 
                  2.0000              0.8463    0.451078 
                  2.1000              0.8884    0.454539 
                  2.2000              0.9198    0.457798 
                  2.3000              0.9428    0.460872 
                  2.4000              0.9595    0.463774 
                  2.5000              0.9714    0.466520 
0.200000  1.0000              0.0500    0.400000 
                  1.1000              0.0754    0.409244 
                  1.2000              0.1457    0.417814 
                  1.3000              0.2512    0.425763 
                  1.4000              0.3776    0.433142 
                  1.5000              0.5083    0.440000 
                  1.6000              0.6288    0.446383 
                  1.7000              0.7306    0.452333 
                  1.8000              0.8108    0.457887 
                  1.9000              0.8707    0.463082 
                  2.0000              0.9134    0.467948 
                  2.1000              0.9430    0.472514 
                  2.2000              0.9629    0.476807 
  
xxxii 
                  2.3000              0.9761    0.480848 
                  2.4000              0.9847    0.484659 
                  2.5000              0.9902    0.488258 
0.250000   1.0000              0.0500    0.400000 
                  1.1000              0.0798    0.411560 
                  1.2000              0.1624    0.422279 
                  1.3000              0.2853    0.432218 
                  1.4000              0.4289    0.441439 
                  1.5000              0.5712    0.450000 
                  1.6000              0.6954    0.457957 
                  1.7000              0.7936    0.465363 
                  1.8000              0.8655    0.472267 
                  1.9000              0.9150    0.478712 
                  2.0000              0.9476    0.484740 
                  2.1000              0.9683    0.490387 
                  2.2000              0.9811    0.495686 
                  2.3000              0.9888    0.500667 
                  2.4000              0.9934    0.505356 
                  2.5000              0.9962    0.509778 
0.300000   1.0000              0.0500    0.400000 
                  1.1000              0.0834    0.413877 
                  1.2000              0.1760    0.426748 
                  1.3000              0.3127    0.438680 
                  1.4000              0.4688    0.449741 
                  1.5000              0.6179    0.460000 
                  1.6000              0.7421    0.469523 
                  1.7000              0.8350    0.478373 
                  1.8000              0.8990    0.486610 
                  1.9000              0.9403    0.494287 
                  2.0000              0.9656    0.501455 
                  2.1000              0.9806    0.508157 
                  2.2000              0.9892    0.514436 
                  2.3000              0.9941    0.520328 
  
xxxiii 
                  2.4000              0.9968    0.525866 
                  2.5000              0.9982    0.531081 
0.350000   1.0000              0.0500    0.400000 
                  1.1000              0.0862    0.416196 
                  1.2000              0.1866    0.431222 
                  1.3000              0.3336    0.445148 
                  1.4000              0.4984    0.458048 
                  1.5000              0.6513    0.470000 
                  1.6000              0.7740    0.481080 
                  1.7000              0.8619    0.491362 
                  1.8000              0.9196    0.500916 
                  1.9000              0.9549    0.509806 
                  2.0000              0.9754    0.518091 
                  2.1000              0.9869    0.525825 
                  2.2000              0.9931    0.533058 
                  2.3000              0.9964    0.539833 
                  2.4000              0.9982    0.546190 
                  2.5000              0.9991    0.552165 
0.400000  1.0000              0.0500    0.400000 
                  1.1000              0.0882    0.418516 
                  1.2000              0.1941    0.435701 
                  1.3000              0.3483    0.451622 
                  1.4000              0.5188    0.466360 
                  1.5000              0.6737    0.480000 
                  1.6000              0.7947    0.492629 
                  1.7000              0.8787    0.504330 
                  1.8000              0.9319    0.515185 
                  1.9000              0.9633    0.525269 
                  2.0000              0.9808    0.534649 
                  2.1000              0.9902    0.543391 
                  2.2000              0.9951    0.551551 
                  2.3000              0.9976    0.559180 
                  2.4000              0.9988    0.566327 
  
xxxiv 
                  2.5000              0.9994    0.573032 
0.450000   1.0000              0.0500    0.400000 
                  1.1000              0.0894    0.420838 
                  1.2000              0.1985    0.440184 
                  1.3000              0.3569    0.458102 
                  1.4000              0.5306    0.474676 
                  1.5000              0.6865    0.490000 
                  1.6000              0.8064    0.504169 
                  1.7000              0.8880    0.517277 
                  1.8000              0.9386    0.529418 
                  1.9000              0.9678    0.540675 
                  2.0000              0.9836    0.551130 
                  2.1000              0.9919    0.560854 
                  2.2000              0.9960    0.569914 
                  2.3000              0.9981    0.578370 
                  2.4000              0.9991    0.586277 
                  2.5000              0.9996    0.593681 
0.500000   1.0000              0.0500    0.400000 
                  1.1000              0.0898    0.423162 
                  1.2000              0.1999    0.444671 
                  1.3000              0.3595    0.464588 
                  1.4000              0.5343    0.482998 
                  1.5000              0.6907    0.500000 
                  1.6000              0.8103    0.515700 
                  1.7000              0.8913    0.530204 
                  1.8000              0.9411    0.543613 
                  1.9000              0.9694    0.556026 
                  2.0000              0.9847    0.567532 
                  2.1000              0.9925    0.578215 
                  2.2000              0.9964    0.588149 
                  2.3000              0.9983    0.597403 
                  2.4000              0.9992    0.606039 
                  2.5000              0.9996    0.614113 
  
xxxv 
Legend:  
K
p
 Overall disease risk in the general population  
P
0
 Baseline disease risk: disease risk in 
unexposed (E=0 or Z=0) genetically normal 
(G=0, H=0) subjects  
R
e
 Environmental relative risk (or odds ratio): 
Risk relative to P
0 
when E=1 or Z=1, in 
genetically normal (G=0) subjects  
R
g
 Genetic relative risk (or odds ratio): Risk 
relative to P
0 
when G=1, in environmentally 
unexposed (E=0 or Z=0) subjects  
R
ge
 Interaction effect (Relative-risk ratio, or Odds-
ratio ratio): Risk relative to to P
0 
when G=1 
and E=1 (or G=1 and Z=1), divided by the 
product R
e
×R
g 
 
eR  
 
Marginal environmental relative risk (or odds 
ratio): Risk relative to P
0 
when E=1 or Z=1, 
irrespective of genetic status  
gR  
 
Marginal genetic relative risk (or odds ratio): 
Risk relative to P
0 
when G=1, irrespective of 
environmental exposure status  
 
 
